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RÉSUMÉ 
Le microenvironnement hypoxique tumoral régule la signalisation du LPA pour 
favoriser l'invasion des cellules cancéreuses et le développement des métastases 
Par 
Kelly Harper 
Programme d’Immunologie 
 
Thèse présentée à la Faculté de médecine et des sciences de la santé en vue de l’obtention 
du diplôme de philosophiae doctor (Ph.D.) en immunologie, Faculté de médecine et des 
sciences de la santé, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
Le développement des métastases est la cause principale de mortalité des patients atteints de cancer, 
mais demeure un obstacle majeur aux traitements. L'hypoxie, une caractéristique commune des 
tumeurs solides, est fortement impliquée dans l'invasion cellulaire et le développement des 
métastases, mais les mécanismes sous-jacents demeurent méconnus. La signalisation du LPA joue 
un rôle important au cours de la tumorigenèse et du développement des métastases, les membres de 
cette voie étant souvent régulés à la hausse dans les cellules tumorales. La signalisation du LPA a 
également été impliquée dans la production de structures de dégradation, les invadopodes, qui sont 
nécessaires à la formation de métastases. Des études récentes indiquent que la formation 
d'invadopodes est également induite par l'hypoxie. Par conséquent, nous avons voulu élucider 
l'influence du microenvironnement hypoxique sur l'axe de signalisation du LPA et si celui-ci joue 
un rôle dans la production d'invadopodes et la formation de métastases. 
 
Nous avons découvert que le LPA1 est un récepteur utilisé de façon commune et majoritaire  pour 
la production d'invadopodes induite par l'hypoxie, et ce, dans diverses lignées cellulaires 
cancéreuses. Nous avons démontré que l'hypoxie favorise la formation d'invadopodes en utilisant 
une voie de signalisation distincte qui implique une communication croisée entre le récepteur LPA1 
et l'EGFR, médiée par la kinase Src, Dans ce contexte, l'inhibition combinée du LPA1 et de l'EGFR 
agit en synergie afin d’empêcher la formation de métastases spontanées. Étant donné que la toxicité 
et la résistance aux inhibiteurs de l'EGFR représentent un défi important pour les patients atteints de 
cancer, ce travail permet l’identification d’une cible potentielle, le LPA1, qui pourrait être inhibée 
conjointement avec l'EGFR dans le but d’améliorer la survie de ces  patients. D'autres études sur la 
régulation hypoxique de l'axe de signalisation du LPA ont démontré que l'hypoxie peut contrôler les 
niveaux d'expression des enzymes impliqués dans la production (ATX) et la dégradation (LPP1 / 
LPP3) du LPA, des évènements qui conduisent à une production accrue d'invadopodes. L'hypoxie 
permet également de modifier la localisation de ces protéines, ce qui pourrait constituer un 
mécanisme additionnel de régulation de l’axe de signalisation du LPA en hypoxie. 
 
Notre travail suggère que l'hypoxie est un régulateur important de l'axe de signalisation du LPA 
menant à l’invasion et à la formation de métastases. Par conséquent, les thérapies ciblant cet axe 
pourraient être bénéfiques pour contrer les effets néfastes de l'hypoxie tumorale sur la survie des 
patients atteints de cancer. De plus, un traitement combiné, ciblant le LPA1 et l’EGFR, pourrait être 
utile afin de réduire les effets secondaires et la résistance aux inhibiteurs de l'EGFR. Des études 
supplémentaires seront  nécessaires afin de valider le potentiel thérapeutique de ce type de 
traitement.   
Mots clés : [Autotaxin, LPA, Invadopodia, Hypoxia, Metastasis] 
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SUMMARY 
The hypoxic tumor microenvironment regulates the LPA signaling axis to promote 
cancer cell invasion and metastasis 
 
By 
Kelly Harper 
Immunology Program 
 
Thesis presented at the Faculty of Medicine and Health Sciences for the obtention of 
Doctor degree diploma philosophiae doctor (Ph.D.) in Immunology, Faculty of Medicine 
and Health Sciences, Université de Sherbrooke, Sherbrooke, Québec, Canada, J1H 5N4 
 
Metastasis is the leading cause of cancer patient mortality yet remains a major hurdle for 
treatment.  Hypoxia, a common feature of solid tumors, has been critically involved in cell 
invasion and metastasis but the underlying mechanisms remain poorly understood. The 
LPA signaling axis plays an important role during tumorigenesis and metastasis, with 
members of this pathway often being upregulated in tumor cells. LPA signaling has also 
been implicated in production of the degradative structures invadopodia, which are known 
to be required for metastasis. Interestingly, formation of invadopodia can also be induced 
by hypoxia. Therefore, we endeavoured to elucidate the influence of the hypoxic tumor 
microenvironment on the LPA signaling axis and whether this could play a role in 
invadopodia production and metastasis.  
 
We uncovered LPA1 as a common and major receptor used for hypoxia-induced 
invadopodia production in various cancer cell lines. We demonstrated that hypoxia 
promotes invadopodia formation through a distinct signaling pathway that involves Src-
mediated cross-communication between LPA1 and EGFR, and that combined inhibition of 
LPA1 and EGFR acts synergistically to impede spontaneous metastasis. Since EGFR 
inhibitor toxicity and resistance represents a current challenge for cancer patients, this work 
identifies a potential target, LPA1 that could be inhibited in conjunction with EGFR to 
improve patient outcomes.  Further studies into hypoxic regulation of the LPA signaling 
axis demonstrated that hypoxia can control the expression levels of LPA producing (ATX) 
and degrading (LPP1/LPP3) enzymes, events that lead to increased invadopodia 
production.  Hypoxia was also found to alter the localization of these proteins, uncovering 
an additional mechanism of hypoxic regulation. 
 
Our work suggests that hypoxia is a master regulator of the LPA signaling axis that leads to 
metastasis, therefore therapies targeting this axis could be beneficial to counteract the 
detrimental effects of tumor hypoxia on cancer patient survival.  Furthermore, LPA1-EGFR 
combination therapy could be a useful strategy to reduce EGFR inhibitor side effects and 
resistance and therefore warrants further studies to evaluate the potential of combination 
therapies in cancer patients. 
 
Keywords: [Autotaxin, LPA, Invadopodia, Hypoxia, Metastasis] 
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1. INTRODUCTION 
Cancer is the deadliest disease for Canadians, accounting for 30% of deaths in Canada in 
2012 (Canadian Cancer Society’s Advisory Committee on Cancer Statistics, 2017). Over 
90% of cancer patients end up dying from metastatic cancer rather than the growth of the 
primary tumor. However treatments specifically targeting metastasis are not in clinical use 
due, in part, to the complexity of this process (Gandalovičová et al., 2017).  For cancer cells 
to metastasize they must first acquire migratory and invasive capabilities in order to leave 
the site of the primary tumor by degrading their surrounding extracellular matrix (ECM) 
and/or underlying basement membrane. The cancer cells then eventually enter into 
lymphatic or blood vessels, allowing them to travel to distant sites in the body. At these 
distant sites, cancer cells will need to leave the blood vessels to form micrometastasis and 
eventually full-blown macrometastasis at the new site (Steeg and Theodorescu, 2008). The 
acquisition of cellular invasive capabilities is therefore an essential step for metastasis, 
which allows cancer cells to degrade ECM and leave the primary tumor, as well as 
intravasate into, and extravasate out of blood vessels. A better understanding of the 
mechanisms underlying the invasion-metastasis cascade should lead to the development of 
novel targeted therapeutics to inhibit this deadly aspect of tumor progression.  
1.1 The Tumor microenvironment promotes invasion and metastasis  
The tumor microenvironment has become acknowledged as a major player promoting 
tumorigenesis.  It has been increasingly recognized that tumor cell intrinsic properties, such 
as immortality and sustained proliferation, alone are not enough to drive tumor progression 
and metastasis. Rather, as tumor cells exist in complex tissue environments, the 
surrounding tumor microenvironment has an important role to play, interacting with, or 
being modified by, tumor cells to promote tumorigenesis. The tumor microenvironment 
consists of many factors such as stromal, immune, and endothelial cells, as well as non-
cellular components such as ECM, growth factors and cytokines (Sounni and Noel, 2013). 
Sites of chronic inflammation are often associated with the development of cancer, 
reinforcing the importance of the microenvironment during cancer development (Balkwill 
and Mantovani, 2001). For example, liver cirrhosis is associated with increased incidence 
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of hepatocellular carcinoma (Sangiovanni et al., 2004) and inflammatory bowel disease 
with increased risk of colorectal cancer (Beaugerie et al., 2013). The tumor 
microenvironment consequently contains many inflammatory cells, for example tumor-
associated macrophages (TAMs), which support tumor progression and drive tumor cell 
invasion by supplying promigratory factors like epidermal growth factor (EGF) and ECM 
degrading proteases (Condeelis and Segall, 2003; Qian and Pollard, 2010; Quail and Joyce, 
2013; Wyckoff et al., 2007). Other immune cell types in the microenvironment, such as 
regulatory T cells, act as immunosuppressants contributing to tumor immune evasion 
(Whiteside et al., 2012). Another important tumor microenvironment cell type are the 
cancer-associated fibroblasts (CAFs), which have been shown to affect tumorigenesis and 
metastasis by providing a major source of secreted growth factors such as vascular 
endothelial growth factor (VEGF), Transforming growth factor-β (TGF-β) and hepatocyte 
growth factor (HGF), pro-inflammatory factors such as monocyte chemoattractant protein-
1 (MCP-1) and Interleukin-1 (IL-1), and ECM degrading proteases such as matrix 
metalloproteinases (MMPs), particularly in breast cancer (Dumont et al., 2013; Kalluri and 
Zeisberg, 2006). Endothelial cells in the microenvironment can also aid tumor progression 
by forming new blood vessels to support the growth of the tumor (Du et al., 2008; 
Semenza, 2013; Weis and Cheresh, 2011). A major driver of angiogenesis is hypoxia, 
which is another important factor in the tumor microenvironment. Hypoxia promotes 
angiogenesis in part by inducing the expression of the major angiogenic factor, VEGF, to 
affect endothelial cells, pericytes and bone marrow-derived cells (BMDCs) to induce vessel 
growth (Chouaib et al., 2012; Du et al., 2008; Petrova et al., 2018; Semenza, 2013; Weis 
and Cheresh, 2011).  Hypoxia in the tumor microenvironment can also induce the 
recruitment of immune cells, such as macrophages, through endothelin-2 and VEGF 
secretion from tumor cells.    Hypoxia then promotes the switch of macrophages to a pro-
tumorigenic phenotype through upregulation of genes affecting tumor growth, invasion, 
angiogenesis and immune evasion such as HGF, platelet-derived growth factor (PDGF), 
MMP7, VEGF, and tumor necrosis factor-α (TNF-α) (Chouaib et al., 2012; Lewis and 
Murdoch, 2005; Petrova et al., 2018).  Hypoxic cancer cells also secrete paracrine signaling 
molecules like TGF-β and PDGF to promote the transformation of fibroblasts into CAFs, 
which subsequently secrete pro-tumorigenic factors like HGF and angiogenic factors such 
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as VEGF and angiopoietin (Murdoch et al., 2004; Petrova et al., 2018; Yan et al., 2015). In 
addition to these effects on the tumor cellular microenvironment, hypoxia has profound 
effects on the tumor cells themselves, which will be discussed in the following sections. It 
is therefore important to take into consideration the supportive role of the tumor 
microenvironment during cancer progression (Fang and Declerck, 2013). 
1.1.1 Hypoxia in the tumor microenvironment 
Hypoxia is a condition of low oxygen concentration, commonly found within solid tumors. 
While normal tissues have oxygen levels varying from 4% to 9.5%, depending on vascular 
networks and metabolic activity of the tissue in question, oxygen levels in various tumors 
have been shown to fall between 0.3% and 2% (Muz et al., 2015). However, the majority of 
these tumors have regions of hypoxia around 1% oxygen (Muz et al., 2015), which is the 
oxygen level commonly used in experimental settings to evaluate the effects of hypoxia.  
The level of oxygen within a tumor depends on many factors such as the initial oxygenation 
of the tissue as well as the size and stage of the tumor (Carreau et al., 2011; Höckel et al., 
1991; Müller et al., 1998; Vaupel et al., 2007). Hypoxia first arises in solid tumors due to 
their rapid proliferation resulting in a high demand for oxygen and nutrients, to sustain their 
metabolic needs, that quickly exceeds the supply available from normal vasculature. The 
rapid tumor growth also results in increased distance between the cells and blood vessels 
further limiting access to oxygen and nutrients (Muz et al., 2015; Semenza, 2000; 
Thomlinson and Gray, 1955).  This starts a vicious cycle as hypoxia then induces 
angiogenesis that is structurally and functionally abnormal, resulting in chaotic, immature 
and leaky blood vessels that are prone to collapse generating additional regions of hypoxia 
within the growing tumor mass (Vaupel and Harrison, 2004).  The exposure to hypoxia 
within tumors may be acute or chronic.  Acute hypoxia is a brief and abrupt exposure to 
low oxygen levels that could be due to a blood vessel occlusion and lasts several minutes.  
Acute hypoxia is therefore often reversible and may even be cycling, with several minutes 
of hypoxia followed by reoxygenation and then hypoxia again.  In vitro, acute hypoxia is 
considered to be several minutes up to 72hr of hypoxic exposure, compared to chronic 
hypoxia, which is considered to be a few hours up to several weeks. Chronic hypoxia is 
observed more often in larger tumors where changes in blood flow and decreased oxygen 
availability cause a sustained lack of oxygen to the cells (Bayer and Vaupel, 2012; Vaupel 
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and Harrison, 2004).  This tends to lead to more long-term effects on the cells, including 
increased DNA damage (Luoto et al., 2013).  
1.1.2 Mechanisms of hypoxia-induced effects in cells  
1.1.2.1 Gene expression  
Hypoxia activates a diverse array of transcription factors to profoundly affect cellular gene 
expression promoting long-term cell survival and adaptation to hypoxic conditions.  Some 
of the transcription factors activated in hypoxic cells are NF-κB, CREB, and AP-1, which 
regulate genes involved in cell proliferation, apoptosis, angiogenesis and inflammatory 
responses (Beitner-Johnson and Millhorn, 1998; Koong et al., 1994; Millhorn et al., 1997).  
For example, NF-κB reduces apoptosis through effects on Bcl-2 family members and 
induces angiogenesis by regulating the expression of important chemokines such as IL-8 
(D’Ignazio and Rocha, 2016). However, many of the transcriptional responses to hypoxia 
are orchestrated by the hypoxia-inducible factors (HIFs), with HIF-1 being the most well 
known and studied. HIFs are heterodimers composed of a HIFα and HIFβ subunit that 
together bind to hypoxia-responsive elements in the promotor region of many genes.  They 
are members of the basic helix-loop-helix (bHLH) family of transcription factors (Wang et 
al., 1995).  These transcription factors are sensitive to hypoxia because the HIFα subunit is 
normally degraded under normoxic conditions due to the effects of oxygen-dependent 
prolyl hydroxylase domain proteins (PHDs) (Epstein et al., 2001). The HIF1α subunit is 
therefore stabilized under hypoxic conditions due to the inactivity of these PHD proteins 
(Schofield and Ratcliffe, 2004).  HIF-1 regulates the transcription of 100s of genes 
affecting diverse physiological and pathological processes (Semenza, 2012). One of the 
most well-known effects of hypoxia is the induction of angiogenesis and HIF-1 can 
promote this effect through upregulation of pro-angiogenic factors such as VEGF and SDF-
1 (Siemeister et al., 1996; Zagzag et al., 2005).  Hypoxia is also known to alter cell 
metabolism by inducing anaerobic glycolysis.  This process is also affected by HIF-1-
mediated gene expression of GLUT-1 and GLUT-3, glucose transporters that help supply 
the hypoxic cells with sufficient glucose for energy production through glycolysis 
(Iliopoulos et al., 1996; Iyer et al., 1998).  Hypoxia modulates apoptosis and cell survival 
through HIF-1 regulation of p53, TGF-β and bFGF (An et al., 1998c; Semenza, 2000).  
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Hypoxia is a strong inducer of EMT in part through HIF-dependent regulation of E-
cadherin, Zeb1 and Zeb2, regulating EMT, adhesion and motility (Krishnamachary et al., 
2006). Finally, HIF-1 induces CXCR4, CAIX, LOX, MMP2 and MMP9 expression 
promoting migration and invasion (Erler et al., 2006; Grabmaier et al., 2004; Semenza, 
2012; Staller et al., 2003). Transcription factors of the HIF family can therefore drive many 
aspects of tumorigenesis increasing cell survival and angiogenesis while reducing cell-cell 
attachment allowing cancer cells to migrate and invade.  These slower transcriptional 
responses however are not responsible for all of the effects of hypoxia, especially not the 
acute responses. 
 
1.1.2.2 Metabolism and pH alterations  
One of the major and immediate adaptations to hypoxia is a change in metabolism to 
anaerobic glycolysis.  This results in production of lactic acid, which, along with a decrease 
in CO2 dispersion, contributes to the acidification of the tumor microenvironment 
(Cassavaugh and Lounsbury, 2011).  In hypoxic cells the pH gradient is altered (reversed) 
with an acidic extracellular environment and a more alkaline intracellular environment.  
This is due to the action of a variety of proton pumps and transporters that are responsible 
for regulating cellular pH, such as Na+/H+ exchangers (NHEs), vacuolar-type H+-ATPase 
(VATPases), monocarboxylate transporters (MCTs) and CAIX. NHE-1, which is found at 
the cell membrane, is responsible for expelling protons, by exchanging one intracellular 
proton for one extracellular sodium ion. VATPases, similarly remove protons from the 
cytosol, however they move these protons into intracellular vesicles such as endosomes and 
lysosomes. MCTs move lactic acid and protons, produced by glycolysis, out of the cell. 
Finally, CAIX has an extracellular catalytic domain that catalyses the hydration of carbon 
dioxide to bicarbonate and protons. Therefore, all of these proteins contribute to the 
reversed pH gradient found in cancer cells, by acidifying the extracellular environment, 
while increasing the pH in the cell cytosol and can in turn be regulated by hypoxia (Chiche 
et al., 2010).  The reversed pH gradient in hypoxia has profound effects on the cell.  First, 
increased intracellular pH promotes proliferation and cell survival (Pouysségur et al., 
1985).  Proliferation is promoted in part by the increased activity of CDK2 (cyclin-
dependent kinase 2), a major driver of cell cycle progression, under alkaline conditions. 
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This is due to reduced expression of the protein kinase Wee1 in alkaline conditions, 
resulting in a reduction of the inhibitory phosphorylation of CDK2 (Putney and Barber, 
2003). The increased cell survival is mediated in part by limiting apoptosis, as apoptosis is 
associated with a lower more acidic pH, which results in conformational changes in the 
pro-apoptotic BAX protein (Lagadic-Gossmann et al., 2004).  Increased intracellular pH 
also further promotes glycolysis, which will result in increased lactic acid production 
thereby sustaining the acidic microenvironment (Kuwata et al., 1991). The activity of 
several enzymes important for glycolysis is controlled by pH, such as phosphofructokinase 
(PFK) and lactate dehydrogenase (LDH), which are more active at slightly alkaline pH 
(Chiche et al., 2010; Halprin and Ohkawara, 1966). Finally, the alkaline intracellular pH 
also facilitates migration, as many actin-binding proteins including cofilin (Pope et al., 
2004), profilin (McLachlan et al., 2007), villin (Grey et al., 2006), and talin (Srivastava et 
al., 2008), are pH sensors. These proteins adapt to altered pH due to conserved histidines 
found within their structure.  Histidines are the only amino acid with a pKa close to 
physiological pH and can therefore be protonated or deprotonated by changes in pH. This 
can result in conformational changes in the histidine containing protein, which can affect 
their activity or binding partners (Webb et al., 2011).  Cofilin, for example, dissociates 
from membrane lipids at high pH with an associated increase in its activity (Frantz et al., 
2008).  Finally, the acidic extracellular environment induced under hypoxic conditions also 
greatly affects cells.  Most notably, lower extracellular pH promotes degradation of the 
ECM essential for cancer cell invasion by activating many proteases, such as MMP-3, 
urokinase-type plasminogen activator (uPAR) and cathepsins.  Low pH also facilitates the 
conversion of pro-MMPs to active MMPs and the secretion of certain proteases such as 
MMP-9 and cathepsin B and L (Rozhin et al., 1994; Stock and Schwab, 2009). 
 
1.1.2.3 Endocytosis regulation  
Many endocytosis-associated proteins, such as clathrin, Rab25 and caveolin 1, are 
deregulated in cancer cells, with an associated alteration in receptor trafficking, that has 
been implicated in malignant transformation (Mosesson et al., 2008).  Recent evidence 
demonstrates that hypoxia regulates endocytosis in several ways in order to mediate 
cellular effects. For example, while hypoxia is known to upregulate signaling through 
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EGFR and other receptor tyrosine kinases (RTKs), most notably by increasing their 
expression, hypoxia was also shown to increase EGFR signaling by prolonging the half-life 
of EGFR (Wang and Ohh, 2010). Endocytosis involves early and late endosomal fusion 
events that are controlled by Rabs, a group of Ras-like small guanosine triphosphatases 
(GTPases) (Wang et al., 2009). Under hypoxic conditions there is a decrease in Rab5-
mediated early endosome fusion due to HIF-dependent downregulation of rabaptin-5. The 
delay of early endosome fusion results in a delay in EGFR movement through the 
endocytic pathway and degradation. This retention of EGFR in internalized vesicles results 
in prolonged signaling. The authors suggest that the deceleration of the endocytic cycle in 
hypoxia could therefore affect many signaling events due to delayed endocytosis-mediated 
deactivation of receptors (Wang et al., 2009).  Hypoxia may also affect integrin recycling 
as it stimulated Rab11 recycling of integrin α6β4 to the plasma membrane (Yoon et al., 
2005).  This was associated with increased invasion and migration by maintaining integrins 
at the leading edge of cells (Caswell et al., 2007). Acute hypoxia induces endocytosis of N, 
K-ATPase thereby inhibiting its activity. Endocytosis and internalization of N, K-ATPase 
has been associated with metastasis in several cancers (Dada et al., 2003).  Hypoxia was 
also found to promote the relocalization of the proprotein convertase furin to the plasma 
membrane where it can process proproteins involved in tumorigenesis. Importantly, this 
relocalization was associated with increased cellular invasion (Arsenault et al., 2012).  
More recently hypoxia was found to change global protein endocytosis via caveolin-1-
dependent mechanisms. Acute hypoxia inhibited global endocytosis in a HIF-1 independent 
manner (Bourseau-Guilmain et al., 2016). However certain proteins were found to have 
enhanced internalization under hypoxic conditions, including several RTKs such as EGFR, 
DDR1, IGFR1 and ROR2, and several integrins such as ITGA1, 2, or 3 and ITGB1 and 5 
(Bourseau-Guilmain et al., 2016). Therefore, it seems that hypoxia can have differing 
effects on protein internalization and trafficking depending on the protein being studied so 
much remains to be discovered on this subject. 
 
1.1.2.4 Activation of signaling pathways  
Additionally, many important signaling pathways are activated in hypoxic cells, resulting in 
complex signaling networks that interact with each other to mediate the effects of hypoxia.  
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Two major pathways activated under hypoxic conditions are PI3K/AKT/mTOR and 
MAPK/ERK, which are the main pathways responsible for cell proliferation, survival, 
apoptosis, metabolism, migration and inflammation (Courtnay et al., 2015; Muz et al., 
2015; Sanchez et al., 2012). For example, the PI3K/AKT pathway plays an important role 
in hypoxia-induced changes to metabolism by regulating glucose uptake (Courtnay et al., 
2015).  Hypoxia also induces activation of PI3K/AKT/mTOR cell survival pathways 
resulting in protection against apoptosis (Alvarez-Tejado et al., 2001). Interestingly, the 
mTOR pathway can also be activated independently of HIF-1 under hypoxia.  In hypoxia, 
mTOR and its effectors were readily hypophosphorylated resulting in rapid inhibition of 
mRNA translation (Arsham et al., 2003). Activation of the MAPK/ERK pathway is 
probably most well-known for its major role in cell proliferation in part by increasing the 
expression of Myc and cyclin D (Zhang and Liu, 2002). The MAPK/ERK pathway was 
also found to be essential for hypoxia-induced effects on endothelial cells, potentially 
contributing to enhanced expression of PDGF, TGF-β and metalloproteinases by 
upregulating the gene expression of Egr-1 (Lo et al., 2001). The MAPK pathway is also a 
key regulator of hypoxia-induced effects on inflammation (Sanchez et al., 2012).  These 
pathways can of course be activated independently of hypoxia by cytokines, chemokines 
and growth factors binding to RTKs, GPCRs and Toll-like receptors.  Interestingly, 
activation of each of these pathways can in turn lead to activation of HIFs further 
complicating matters (Muz et al., 2015). For example, PI3K was shown to activate HIF 
under normoxic conditions (Agani and Jiang, 2013).  On the other hand, ERK kinases 
activated in hypoxia were found to be involved in HIF activation in hypoxia by directly 
phosphorylating HIF (Minet et al., 2000).   
 
1.1.3 Hypoxia as a driver of invasion and metastasis 
As mentioned above, many of the genes regulated by hypoxia as well as other effects of 
hypoxia on the cells are implicated in various aspects of cancer progression.  Hypoxic cells 
have repeatedly been demonstrated to be more aggressive, invasive and prone to recurrence 
(Hockel et al., 1996).  For example, cervical carcinoma cells exposed to hypoxia had 
increased metastasis to lymph nodes in an orthotopic murine model (Cairns and Hill, 2004) 
and acute hypoxia was also found to increase lung metastasis of sarcoma cells in mice 
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(Cairns et al., 2001).  Many studies have investigated the mechanisms responsible for 
hypoxia-induced cellular invasion and a multitude of pathways have been implicated so far, 
surely with many more to come, as hypoxia appears to be a master regulator of cell 
invasion through a diverse array of effects.  Several HIF-dependent mechanisms of 
hypoxia-induced invasion have been delineated.  These include increased melanoma 
invasion through PDGFR- and FAK-mediated activation of Src as well as increased ECM 
degradation via MT1-MMP and MMP-2 expression under hypoxia (Hanna et al., 2013).  
Another study found a role for the Rho-family activator β-Pix in matrix degradation 
dependent on HIF-1 (Md Hashim et al., 2013).  Hypoxia, via HIF-1, was also found to 
promote metastasis by regulating the expression of Twist1, a major promotor of EMT 
(Yang et al., 2008).  Other studies identified HIF-independent mechanisms of hypoxia-
induced invasion, including many that depend on the altered pH observed in hypoxia.  
Hypoxia was found to induce cellular invasion through enhanced activity of HDAC6, via 
EGFR, promoting TGF-β signaling (Arsenault et al., 2013). Under hypoxia, HIF-
independent activation of NHE-1 was found to induce cell invasion in fibrosarcoma cells 
(Lucien et al., 2011).  Furthermore, NHE-1 was found to promote cell invasion by 
regulating cortactin-cofilin binding (Magalhaes et al., 2011) and through acidification of 
the extracellular space (Busco et al., 2010). Interestingly, in these reports, the increase in 
cellular invasion was associated with production of invadopodia, which are specialized cell 
structures required for cancer cell dissemination that will be discussed in the next section. 
All of this suggests that hypoxia is a tumor promoting force driving cancer cell invasion 
that we need to overcome in order to treat solid tumors and specifically block invasion and 
metastasis. 
 
1.2 Invadopodia mediate cancer cell invasion 
As previously discussed, cancer cells acquire invasive capabilities in order to metastasize 
and invadopodia have been shown to be the main structures mediating cancer cell invasion. 
Invadopodia have been implicated in many important steps of metastasis including crossing 
the basement membrane, invading through ECM and entering blood vessels (Chen, 1989; 
Kelly et al., 1998; Wolf and Friedl, 2009).  Invadopodia can be defined as actin-rich 
protrusions formed at the ventral side of cells.  These cell structures possess proteolytic 
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activity directly associated with sites of matrix degradation (Mueller and Chen, 1991).  
Electron microscopy studies have revealed that invadopodia structures consist of many 
protrusions, from 100 nm to several µm, extending from a deep invagination of 
approximately 8 µm in width and 2 µm in depth (Baldassarre et al., 2003; Chen, 1989). 
Invadopodia structures are stable with a long half-life of two hours or more and are found 
in proximity to the Golgi, which is orientated toward invadopodial protrusions, suggesting 
a possible relationship between membrane/protein transport and proteolytic activity 
(Baldassarre et al., 2003).  The following sections will detail the stages of invadopodium 
production, including the important players involved, as well as the regulators of their 
formation and their in vivo relevance to metastasis. 
 
Figure 1 Schematic representation of an invadopodium 
The core structure of an invadopodium is composed of actin and cortactin along with the 
actin regulatory proteins Arp2/3, N-WASP and cofilin.  Upstream signals from 
RhoGTPases activate N-WASP to promote actin polymerization. Recruitement of Tks5 to 
the core structure during the stabalization phase tethers these proteins to the plasma 
membrane. During the maturation phase β1 integrins and Src activate Arg, which 
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phosphorylates cortactin, further promoting actin polymerization. MT1-MMP is recruited 
to the plasma membrane and activates a cascade of MMPs to promote matrix degradation.  
 
1.2.1 The stages of invadopodia formation  
As research has focused on delineating the underlying mechanisms involved in invadopodia 
formation and function, distinct stages in their production have come to light (Artym et al., 
2006; Beaty and Condeelis, 2014; Murphy and Courtneidge, 2011).  There are three 
recognized steps necessary for fully functioning invadopodia: precursor formation, 
stabilization, and maturation.  Invadopodia are initiated mainly by growth factors or ECM-
rigidity signals, which will be further discussed in section 1.2.2.  Similar to other cellular 
protrusions such as lamellipodia and filipodia, invadopodia require spatially and temporally 
regulated remodeling of actin, which constitutes the core of their structure (Alblazi and 
Siar, 2015). See Figure 1 for a schematic representation of an invadopodium and the 
important proteins involved in its formation and function. 
 
Invadopodia precursor structures are formed within seconds and are inherently unstable 
(Artym et al., 2006; Sharma et al., 2013).  As actin remodeling is essential for the formation 
of invadopodial protrusions, it is unsurprising that many essential actin regulatory proteins 
are recruited to the cell surface around an actin-cortactin complex during the formation of 
invadopodia precursor structures. These include Arp2/3 (Actin related proteins 2 and 3), N-
WASP (neural Wiskott-Aldrich syndrome protein) and cofilin.  These proteins have all 
been either localized to invadopodia or shown to be essential for invadopodia formation 
(Artym et al., 2006; Baldassarre et al., 2006; Yamaguchi et al., 2005a).  
 
As mentioned, the core of the precursor structure is composed of actin and cortactin, an 
actin-binding scaffolding protein (Ammer and Weed, 2008). Cortactin is an essential 
element of invadopodia and is often used as a prominent marker of invadopodia structures. 
Cortactin clusters, located at the basement membrane near the center of the cell, and not in 
the cell periphery, can identify invadopodia structures (Gimona and Buccione, 2006). 
Cortactin binds to or interacts with filamentous actin (F-actin), Arp2/3, N-WASP, 
dynamin2 and Src to coordinate cell migration, cytoskeletal remodeling, and intracellular 
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protein transport (Ammer and Weed, 2008; Daly, 2004; Lua and Low, 2005; Weaver et al., 
2001). It can act by stabilizing branched actin filaments and, therefore, regulates actin 
assembly mediated by Arp2/3 (Uruno et al., 2001). Cortactin is a substrate of Src and 
tyrosine phosphorylation of cortactin, driven by growth factor stimulation or integrin 
activation, has been implicated in motility and metastatic dissemination of breast cancer 
cells (Li et al., 2001) as well as being important for invadopodia function (Artym et al., 
2006). Along with its cytoskeletal remodeling functions, cortactin might also regulate 
MMP secretion at focal sites of degradation during invadopodia maturation discussed 
below (Clark et al., 2007). Additionally, cortactin is frequently upregulated in many 
cancers including breast, head and neck, and bladder cancers suggesting that cortactin must 
play an important role in tumor progression, possibly through its role in invadopodia 
production (Schuuring, 1995). 
 
Important actin regulatory proteins, Arp2/3 and N-WASP, are recruited to the actin-
cortacin core of invadopodia. Proteins of the WASP family, including N-WASP, are 
responsible for functional activation of the Arp2/3 complex, which explains why these two 
proteins are recruited to invadopodia together (Mullins et al., 1998; Welch et al., 1998). 
The Arp2/3 complex serves as a nucleation site on an existing filament to initiate the 
growth of a new actin filament at a distinctive 70-degree angle, creating branched actin 
polymerization (Mullins et al., 1998; Welch et al., 1998).  Therefore, Arp2/3 is responsible 
for actin rearrangement implicated in the formation of lamellipodia, filopodia, invadopodia 
and cell motility in general (Goley et al., 2004). Proteins of the WASP family integrate 
multiple upstream signals, from Rho GTPases such as Cdc42 and Rac1, to induce actin 
polymerization through the Arp2/3 complex (Eden et al., 2002; Millard et al., 2004). 
Besides affecting actin polymerization through Arp2/3, N-WASP is also implicated in 
endocytic and phagocytic processes and may promote internalization of degraded matrix 
components or recycling of invadopodia components (Innocenti et al., 2005; Lorenzi et al., 
2000).  Similar to cortactin, Arp2/3 and WASP family proteins are found to be up-regulated 
in some tumors and invasive cells (Otsubo et al., 2004; Semba et al., 2006; Yamaguchi and 
Condeelis, 2007).  
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Finally, another essential component for the assembly of nascent invadopodia is cofilin.  
Cofilin is a member of the actin depolymerizing factor (ADF)/cofilin family that binds 
monomeric and filamentous actin (Paavilainen et al., 2004).  It is an essential regulator of 
actin dynamics at the plasma membrane through its ability to sever actin filaments. This 
results in disassembly of F-actin from the rear of migrating cells and recycling of actin 
monomers to the leading edge for further polymerization (Paavilainen et al., 2004). 
Depletion of cofilin results in small, short-lived and, therefore, poorly degrading 
invadopodia (Yamaguchi et al., 2005a).  Cofilin is also implicated in tumor cell invasion 
and metastasis (Wang et al., 2007).    
 
The next step in invadopodia formation is the stabilization of the precursor structure. This 
is achieved by recruitment of the scaffold protein Tks5/FISH (tyrosine kinase substrate 
5/five sh3 domains), which tethers the proteins involved in the formation of nascent 
invadopodia structures to the lipid membrane via PI(3,4)P2 (Sharma et al., 2013). The 
adaptor protein Tks5 contains five SH3 domains and one Phox homology (PX) domain, 
bringing membrane and cellular components together (Saini and Courtneidge, 2018). 
Binding of Tks5 to N-WASP occurs via its SH3 domains (Oikawa et al., 2008), while its 
PX domain interacts with PI(3,4)P2 anchoring these proteins to the cell membrane.  These 
events result in its specific localization to the invadopodium core structure. Furthermore, 
Tks5 has been shown to be essential for invadopodia formation in many different cell types 
(Abram et al., 2003; Mader et al., 2011; Oikawa et al., 2008; Seals et al., 2005; Stylli et al., 
2009), and its colocalization with cortactin can identify invadopodia structures (Eddy et al., 
2017). Additionally, Tks5 is involved in the generation of reactive oxygen species (ROS) 
that are implicated in signaling promoting invadopodia production (Saini and Courtneidge, 
2018).  The PI(3,4)P2, that Tks5 binds to, has been shown to accumulate at invadopodia 
sites a few minutes after the core initiation, this correlates with the arrival of SHIP2 at the 
same site. The increase in PI(3,4)P2 at invadopodia sites therefore seems to be regulated by 
SHIP2, a 5’-inositol phosphatase that is known to regulate PI(3,4)P2 levels (Sharma et al., 
2013).  Inhibition of SHIP2 or Tks5 has no effect on invadopodia precursor formation 
while significantly reducing the formation of mature invadopodia and blocking subsequent 
degradation, confirming their role in the maturation of the precursor structure (Sharma et 
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al., 2013).   
 
The third and final stage of invadopodia production is maturation, which consists of further 
actin polymerization to elongate the protrusion as well as recruitment of MMPs and 
subsequent degradation of the ECM.  Recently, β1 integrins have been shown to be 
required for the formation of mature degradation-competent invadopodia. Integrins of the 
β1 family are localized to invadopodia structures and promote metastasis of numerous 
cancer types including breast, ovarian, pancreatic and skin cancers (Grzesiak et al., 2011; 
Huck et al., 2010; Lahlou and Muller, 2011; Mitra et al., 2011; Trikha et al., 1994). 
Integrins of the β1  family promote the maturation of invadopodia through activation of 
Arg (Abelson-related gene). Cortactin is phosphorylated by Arg, which subsequently 
promotes the actin-severing activity of cofilin, resulting in actin polymerization at 
invadopodia sites. Cortactin phosphorylation mediated by Arg, triggered by β1 integrins, is 
therefore a key switch for invadopodia maturation (Beaty et al., 2013).  
 
An equally important part of the maturation process is the recruitment and activation of 
proteases that degrade ECM proteins. Invadopodia have been shown to degrade multiple 
extracellular substrates such as collagen type I and IV, fibronectin and laminin (Kelly et al., 
1994). The majority of proteolysis at invadopodial structures is due to the metalloproteinase 
family members, which includes matrix metalloproteinases (MMPs) and ADAMs (a 
disintegrin and metalloproteinase). A key metalloproteinase that is enriched at the 
invadopodia-associated plasma membrane is MT1-MMP/MMP14 (membrane type-1 
matrix metalloproteinase), which plays an important role in activating many of the 
subsequently recruited and secreted MMPs. The metalloproteinase, MT1-MMP degrades 
collagen, fibronectin and laminins and is a master regulator of protease-mediated cell 
invasion through activation of a cascade of proteases including the gelatinase MMP-2 
(Holmbeck et al., 2004; Nakahara et al., 1997). Therefore, recruitment of MT1-MMP to 
invadopodia might establish a focal zone of MMP activation around this structure.  In fact, 
MT1-MMP over-expression or knockdown has been shown to increase or decrease 
invadopodia degrading ability (Artym et al., 2006; Nakahara et al., 1997). Two gelatinases 
MMP-2 and MMP-9 have also been localized to invadopodia and are known to degrade 
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type IV collagen, a major component of basement membrane (Redondo-Muñoz et al., 
2006).  Serine proteinases and the urokinase-type plasminogen activator (uPA) proteolytic 
system are also implicated in invadopodia-mediated matrix degradation.  Seprase and DPP4 
(dipeptidyl dipeptidase IV) are transmembrane serine proteinases implicated in ECM 
degradation, shown to localize at invadopodia through binding with β1 integrins (Artym et 
al., 2002; Ghersi et al., 2006; Kindzelskii et al., 2004; Monsky et al., 1994; Mueller et al., 
1999). Urokinase-type plasminogen activator receptor (uPAR) is found in a complex with 
seprase at sites of invadopodia formation and activates plasminogen which can 
subsequently activate various MMPs (Lijnen, 2001).   
 
Recruitment and docking of proteases to invadopodia structures can be mediated by β1 
integrins, adding another aspect to their role in invadopodia maturation (Jacob and Prekeris, 
2015). Integrins of the β1 family can also recruit NHE-1 to invadopodia sites, via talin and 
moesin, which contributes to invadopodia maturation in two ways.  By acidifying the 
extracellular space, NHE-1 activates proteases around the invadopodia structure.  The 
subsequent increase in intracellular pH, due to the extrusion of protons from the cytosol, 
results in cofilin activation that promotes actin polymerization (Beaty et al., 2014; Brisson 
et al., 2012).  Cortactin has also be implicated in the localized delivery of proteases to 
invadopodia, as the plasma membrane delivery of MT1-MMP was found to correlate with 
cortactin expression levels (Clark et al., 2007).  
1.2.2 Inducers of invadopodia 
Many stimuli have now been identified that initiate invadopodia formation, most of them 
being microenvironmental signals.  Several oncogenes have also been implicated in 
invadopodia initiation such as constitutively active mutants of Src or Ras.  In pancreatic 
cancer invadopodia production was dependent on K-Ras (Neel et al., 2012), while Src has 
been repeatedly demonstrated to be essential for invadopodia production by 
phosphorylating cortactin and Tks5  (Bailey et al., 2016; Burger et al., 2014; Pignatelli et 
al., 2012; Williams and Coppolino, 2014).  In certain contexts, such as hypoxia, Notch 
mediates cell contact-dependent signaling resulting in paracrine activation of EGFR to 
induce invadopodia (Díaz et al., 2013; Pignatelli et al., 2016). However, the most common 
stimuli are growth factors that activate receptor tyrosine kinases (RTK) or serine/threonine 
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receptors, such as TGF-βR. Numerous growth factors, including EGF (Mader et al., 2011), 
PDGF (Eckert et al., 2011), VEGF (Hoshino et al., 2013a), HGF (Rajadurai et al., 2012), 
HB-EGF (Díaz et al., 2013), TGF-β (Pignatelli et al., 2012), and SDF-1 (Hoshino et al., 
2013a) can induce invadopodia production.  For example, EGF activation of the EGFR was 
shown to induce invadopodia formation in breast cancer cells via Src- and Arg-induced 
phosphorylation of cortactin (Mader et al., 2011).  Finally, ECM proteins can also initiate 
invadopodia maturation through the activity of adhesion receptors such as integrins, CD44 
and discoidin domain receptors (DDRs) (Di Martino et al., 2016; Eddy et al., 2017).  For 
example, Di Martino et al. found type I collagen to be a potent inducer of invadopodia via 
its activation of the discoidin domain receptor DDR1 (Di Martino et al., 2015). In another 
study, dense fibrillar collagen was found to induce invadopodia in human breast cancer 
cells through activation of α2β1 integrin, while alternative integrin α5β1 were necessary 
for invadopodia production in a fibronectin rich environment (Artym et al., 2015). 
Additionally, α6β1 activation promotes Src-dependent Tyr phosphorylation of 
p190RhoGAP, a key regulator of Rho GTPase signaling, affecting the actin cytoskeleton.  
This event activates membrane-protrusive and proteolytic activity leading to invadopodia 
formation and cell invasion (Nakahara et al., 1998). Matrix rigidity also promotes 
invadopodia production (Alexander et al., 2008; Parekh and Weaver, 2016; Parekh et al., 
2011).  
 
Activation of these integrins and RTKs induce many intracellular cascades involving PKC, 
Src, Rho GTPases and tyrosine kinases for invadopodia generation. In fact, increased total 
tyrosine phosphorylation is a marker of invadopodia (Mueller et al., 1992).  
Serine/threonine kinases, such as ERK1/2 and PAK, have also been implicated in 
invadopodia biogenesis, possibly through their involvement in cortactin phosphorylation 
(Ayala et al., 2008; Tague et al., 2004). Cell shape, morphology, polarization, motility and 
metastasis formation is influenced by RhoGTPases through their activation of protein 
kinases and actin nucleators (Hall, 2005). For example, Rac1 and Cdc42 can both activate 
Arp2/3 through their effectors Sra-1 and N-WASP, respectively (Caldieri et al., 2009). In 
particular, Cdc42 has been shown to act upstream of invadopodia formation, with 
constitutively active mutants of Cdc42 inducing dot-like degradation (Nakahara et al., 
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2003).  Also, RhoA has been suggested to play a role due to the fact that p190Rho-GAP 
activates membrane protrusive activity (Nakahara et al., 1998). Additionally, Rac1 can also 
promote invadopodia formation, possibly through activation of Arp2/3, inducing actin 
polymerization, or recruitment of cortactin, both essential to invadopodia formation (Fung 
et al., 2008; Revach et al., 2016). The Rho GTPase effector, ROCK, as well as Rac1 and 
Cdc42 also activate PAKs, which phosphorylate and activate LIMKs, which then 
phosphorylate cofilin to permit its role in actin dynamics at invadopodia (Ayala et al., 
2008; Caldieri et al., 2009).  In summary, microenvironment signals from growth factors, 
the ECM and also tumor hypoxia, discussed in the previous section (Arsenault et al., 2013; 
Díaz et al., 2013; Lucien et al., 2011; Md Hashim et al., 2013), promote the initiation of 
invadopodia in cancer cells under different cellular contexts.  
1.2.3 Implication of invadopodia in the metastatic process  
Recent progress suggests an essential role for invadopodia in tumor invasion and metastasis 
(Paz et al., 2014). Invadopodia biogenesis has previously been shown to correlate closely 
with well-established assays for invasive capability such as invasion through matrigel-
coated transwell chambers and xenograft metastasis models (Bowden et al., 1999; 
Coopman et al., 1998; Thompson et al., 1992).  Enrichment of invadopodia markers such as 
cortactin and Tks5 have also been found at the invading front of human tumors in tissue 
samples, consistent with invadopodia-mediated invasion (Seals et al., 2005; Zhang et al., 
2006). Invadopodia-like structures have been imaged in migrating cancer cells undergoing 
intravasion, while intravital imaging has allowed real-time visualization of invadopodia-
like protrusions in tumor cells invading through connective tissues (Condeelis and Segall, 
2003; Yamaguchi et al., 2005b). The visualization and characterization of invadopodia in 
breast cancer models suggest that invadopodia are key mediators of intravasation (Eckert et 
al., 2011; Gligorijevic et al., 2012; Kedrin et al., 2008; Roh-Johnson et al., 2014). For 
example, 3D time-lapse imaging of breast cancer cells showed formation of protrusions that 
were positive for cortactin and proteolytic activity (Gligorijevic et al., 2012). Furthermore, 
invadopodia were recently found to be required for cancer cell extravasation (Leong et al., 
2014). In this study by Leong et al, cancer cells were shown to extend invadopodia into the 
extravascular space prior to extravasation of the cells.  This was dependent on essential 
invadopodia components such as Tks5 and cortactin, as their genetic or pharmacological 
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inhibition blocked cancer cell extravasation and metastatic colony formation in vivo (Leong 
et al., 2014). Therefore the ability to form invadopodia correlates with the invasive and 
metastatic potential of tumor cells making them ideal targets for anti-metastasis therapy 
(Yamaguchi, 2012). Also, these structures are not important for cell viability and their 
disruption may, therefore, have less side effects than some of the current treatments 
(Weaver, 2006). 
1.3 The LPA signaling axis 
Lysophosphatidic acid (LPA; 1 or 2-acyl-sn-glycerol-3-phosphate) is a bioactive lipid 
implicated in a plethora of biological activities and processes including cancer (van 
Meeteren and Moolenaar, 2007). It was the first lysophospholipid found to exert growth 
factor-like activities, at submicromolar concentrations, and is an important lipid mediator 
(Tokumura et al., 1978). In this section we will examine the major aspects of the LPA 
signaling axis including the enzymes controlling the production and degradation of LPA. 
LPA acts on cell surface GPCRs to mediate intracellular signaling (Shimizu, 2009) 
therefore this aspect will be addressed to provide an understanding of the biological effects 
of LPA.  Finally, LPA has been found to promote many of the hallmarks of cancer through 
activation of its various LPA GPCRs (Houben and Moolenaar, 2011), therefore the 
implication of members of the LPA signaling axis during tumorigenesis will also be 
examined in this section.  
1.3.1 LPA structure and sources 
A glycerol backbone, a single carbon chain, and a polar headgroup compose the structure of 
LPA (Figure 2) (Meyer zu Heringdorf and Jakobs, 2007). Multiple different species of LPA 
with varying carbon chain lengths and degrees of unsaturation have been identified.  
Additionally, their carbon chains may be either acyl- or ether-linked with the acyl chain 
esterified at either the sn-1 or sn-2 position of the glycerol backbone (1-acyl-LPA or 2-
acyl-LPA) while ether-linked LPAs carry an alkyl or alkenyl linkage at the sn-1 position 
(1-alkyl-LPA or 1-alkenyl-LPA). All of these factors contribute to the differing biological 
activities of individual LPA species (Meyer zu Heringdorf and Jakobs, 2007). The 
concentration of LPA is approximately 154 pmol in cells, 0.1-6.3 µM in blood and 80-
100nM in plasma (Hosogaya et al., 2008; Kishimoto et al., 2003).  This lipid has been 
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detected in many biological fluids including serum, plasma, saliva, follicular fluid, seminal 
fluid, and malignant effusions (Hama et al., 2002; Sugiura et al., 2002; Tokumura et al., 
1999; Westermann et al., 1998).  The major cellular sources of LPA include platelets and 
adipocytes (Eichholtz et al., 1993; Valet et al., 1998), while postmitotic neurons, lymphoid 
cells, endometrial cells, erythrocytes and cancer cells are also reported to produce LPA 
(Aoki et al., 2008; Smyth et al., 2008; Ye, 2008).  Therefore, LPA may act as a circulating 
as well as a locally produced paracrine mediator (Takuwa et al., 2002).  
   
        
Figure 2 Structure of LPC and LPA 
Representation of the structures of LPC and LPA, each composed of a glycerol backbone, 
phosphate group, and fatty acyl chains. LPC has an additional choline headgroup. The 
lysophospholipase D activity of ATX is responsible for hydrolyzing the bond between 
choline and the phosphate group of LPC to produce LPA. Adapted from: (Mills and 
Moolenaar, 2003) with permission from Springer Nature, license # 4382541352781. 
 
1.3.2 Production and degradation of LPA 
Various enzymes are involved in the production and degradation of LPA as detailed in 
Figure 3. Intracellular LPA can be produced by de novo LPA biosynthesis through 
intermediate lipid metabolism (Goetzl and An, 1998). Extracellular LPA can be produced 
from precursor glycerophospholipids by the action of many different enzymes including 
phospholipase A1 or A2 (PLA1 or 2), monoacylglycerol kinase or glycerol-3-phosphate 
acyltransferase (Pébay et al., 2007). For example, PLA1/2 produces LPA by deacylating 
phosphatidic acid (PA) that is first generated intracellularly from phospholipids or 
diacylglycerol (Aoki et al., 2008).  However, the majority of LPA produced in vivo depends 
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on the lysophospholipase D activity of autotaxin, which will be discussed in the next 
subsection, 1.3.2.1 (Umezu-Goto et al., 2002).  Additionally, two families of proteins, lipid 
phosphate phosphatases (LPP) and acyl transferases, are responsible for the rapid 
degradation of LPA resulting in a short half-life for this lipid mediator. The LPA Acyl 
transferase (LPAAT) family mediates the acylation of LPA to PA (Yamashita et al., 2001). 
The LPPs, integral membrane proteins, that dephosphorylate LPA to monoacylglycerol 
(MAG), are the major LPA degrading enzymes that terminate LPA signaling (see section 
1.3.2.2) (Brindley et al., 2002). To counteract these degradative effects, extracellular LPA 
is normally bound to proteins such as albumin, fatty acid binding protein, or gelsolin which 
act to increase the stability and facilitate transport of LPA (Aoki, 2004; Gaits et al., 1997; 
Mills and Moolenaar, 2003; Pagès et al., 2001).  Another mechanism regulating LPA levels 
in the blood is the rapid trans-cellular uptake of LPA into the liver, which therefore acts as 
an important buffering system controlling LPA bioavailability (Salous et al., 2013). 
  
      
Figure 3 Mechanisms of LPA production and degradation 
The major producer of LPA in vivo is secreted ATX which converts LPC to LPA.  Other 
enzymes can also produce LPA such as PLA1/2, which can produce LPA from PA.  LPA 
may be degraded to PA by the action of LPAAT, or to MAG by the action of LPPs. 
Adapted from:(Meyer zu Heringdorf and Jakobs, 2007) with permission from Elsevier, 
license # 4382550417670. 
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1.3.2.1 Autotaxin as the main producer of LPA 
Autotaxin (ATX), also known as ENPP2 (ectonucleotide pyrophosphatase/ 
phosphodiesterase 2), was originally identified as a novel 125-kDa autocrine motility 
stimulating factor after its isolation from the culture medium of human melanoma cells 
(A2058) in 1991 (Stracke et al., 1992). It was subsequently found to be present in the 
culture medium of several other cancer cell types including glioblastoma and breast cancer 
(Gaetano et al., 2009; Jansen et al., 2005; Kishi et al., 2006). The ATX protein is a secreted 
protein that is synthesized as a pre-pro-protein and processed by a signal peptidase and pro-
protein convertase (such as furin) to remove the pre, N-terminal 27-residue hydrophobic 
domain, and pro domain of ATX, respectively (Jansen et al., 2005; Koike et al., 2006).  The 
ATX pro-protein follows the classical secretory pathway, where proteins are transported 
outside the cell from the E.R via the Golgi apparatus (Jansen et al., 2005). Four ATX 
isoforms have been identified, ATX α, β, γ, and δ with differing tissue distributions 
(Giganti et al., 2008; Hashimoto et al., 2012). High expression of ATXβ mRNA is found in 
peripheral tissues, ATXγ mRNA is expressed mostly in brain, ATXα mRNA has lower 
expression levels in all tissues, and ATXδ is highly expressed in the small intestine and 
spleen (Giganti et al., 2008; Hashimoto et al., 2012). Originally discovered in A2058 cells, 
ATXα lacks exon 21, while ATXβ, a splice variant reported in human teratocarcinoma (Lee 
et al., 1996) lacks exons 12 and 21 and is the major isoform of ATX. ATXγ (PD-1α) was 
isolated from the brain and lacks exon 12 and ATXδ is identical to ATXβ except for a 
deletion of four amino acids in the linker region and is the second most common isoform 
(Giganti et al., 2008; Hashimoto et al., 2012). All isoforms, except ATXα, were found to be 
fully active with no differences in catalytic efficiency or substrate specificity.  The ATXα 
isoform is cleaved in exon 12, which is unique to this isoform, resulting in a less active 
cleaved 55-66kDa form (Giganti et al., 2008; Hashimoto et al., 2012).  
1.3.2.1.1 Structure and activity of ATX  
The ATX protein contains several structural domains illustrated in Figure 4. These include 
a Modulator of Oligodendrocyte Remodeling and Focal adhesion Organization (MORFO) 
domain, implicated in oligodendroglial process network formation and focal adhesion 
organization (Dennis et al., 2008), an EF-hand-like motif that contributes to the function of 
the MORFO domain, an inactive nuclease-like domain, and two cysteine-rich somatomedin 
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B domains (Yuelling and Fuss, 2008). The somatomedin B domain (SMB), which is 
derived from the amino terminus of vitronectin, forms a presumed binding site for type 1 
plasminogen activator inhibitor (PAI-1), and uPAR (Seiffert and Loskutoff, 1991; Seiffert 
et al., 1994). The N-terminal SMB-2 domain has also been shown to bind to β1 and β3 
integrins thereby localizing ATX to platelets and cells including lymphocytes (Fulkerson et 
al., 2011; Hausmann et al., 2011).  Additionally, the ATXα isoform can bind to heparin 
sulfate proteoglycans, due to the arginine/lysine rich clusters in its 53 amino acid polybasic 
insertion. This isoform was therefore found to bind abundantly to cultured mammalian cells 
(Houben et al., 2013; Perrakis and Moolenaar, 2014). Finally, ATX has a catalytic domain 
which has lysophospholipase D (lysoPLD) activity, producing LPA from LPC (Umezu-
Goto et al., 2002).  The crystal structure of ATX has been solved and reveals a central 
catalytic domain interacting with the SMB domains on one side and the nuclease domain 
on the other side (Nishimasu et al., 2011).   
  
 
Figure 4 Structural domains of ATX 
ATX is processed by a signal peptidase and pro-protein convertase to remove pre and pro 
N-terminal domains. ATX contains a MORFO domain implicated in oligodendrocyte 
remodeling, an EF hand-like motif, an inactive nuclease-like domain and a putative ATP 
binding site. ATX also has two somatomedin B domains implicated in binding to integrins. 
Finally there is a catalytic domain which functions as a lysophospholipase D to produce 
LPA. 
 
 
The main physiological substrate for ATX/lysoPLD is LPC, which subsequently produces 
LPA from LPC by hydrolysis removing the choline head group (Figure 2) (Umezu-Goto et 
al., 2002). Cyclic phosphatidic acid (cPA), an analog of LPA and intermediate in LPA 
formation, may also be produced by ATX from LPC (TSUDA et al., 2006). Furthermore, 
ATX/LysoPLD has a higher affinity for unsaturated acyl-LPCs as compared to saturated or 
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ether-linked species (Tokumura et al., 1999). Interestingly, ATX does not contain the HKD 
motifs critical for the catalytic activity of the phospholipase D (PLD) superfamily (Xie and 
Meier, 2004).  The hydrolysis of lysophospholipids by ATX is instead a metal-assisted 
reaction that occurs via a nucleotidylated threonine requiring a metal ion such as Co2+ 
(Gijsbers et al., 2003). Calcium and Magnesium could also enhance ATX activity by 
stabilizing the structure of ATX, by protecting it from thermal denaturation and proteolysis, 
or by directly regulating the catalytic activity of ATX (Tokumura et al., 1998). Plasma 
ATX is constitutively active (Yuelling and Fuss, 2008), however, its catalytic activity 
depends on an essential disulfide bridge between the catalytic and nuclease-like domains 
(Jansen et al., 2009) as well as glycosylation of Asn-524 (Jansen et al., 2007).  Human 
ATX activity can be inhibited by EDTA, phenanthroline and ATP as well as by its products 
LPA, cPA and S1P (Baker et al., 2006; van Meeteren et al., 2005). 
 
1.3.2.1.2 Regulation of ATX expression 
Although ATX is ubiquitously expressed and is, therefore, synthesized by a variety of 
normal cells and tissues, there are several stimulators and inhibitors of its expression. 
Expression of ATX can be induced by cell differentiation mediators such as retinoic acid, 
in a neuroblastoma cell line with N-myc amplification (Dufner-Beattie et al., 2001), and 
Bmp-2, during mesenchymal development (Bächner et al., 1998). Ligands of TLRs, 
including Lipopolysaccharide (LPS) induce ATX expression via JNK and p38MAPK or 
IFN-β or α resulting in enhanced immune cell migration (Li and Zhang, 2009; Song et al., 
2015).  Growth factors such as EGF and bFGF have been shown to stimulate ATX in 
thyroid carcinomas (Kehlen et al., 2004), while anti-inflammatory cytokines such as IL-4, 
IL-1β, IFN-γ and TGF-β reduce ATX expression in auto-immune and cancer cells (Kehlen 
et al., 2004; Santos et al., 1996). Therefore, pro-inflammatory stimuli seem to increase 
ATX expression while anti-inflammatory cytokines have the opposite effect.  Furthermore 
it seems that molecular cues associated with cancer progression can induce ATX expression 
while tumor suppressors seem to reduce its expression. During cancer progression ATX can 
be upregulated by α6β4 integrin, via NFAT, which correlates with an invasive and 
migratory phenotype in advanced breast carcinomas, (Chen and O’Connor, 2005), and by 
the viral oncoprotein v-Jun (Black et al., 2004) or the oncogenic Epstein-Barr virus (EBV) 
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in different cancer cell lines (Baumforth et al., 2005). In neuroblastoma cells, ATX is 
upregulated by Ap1 and Sp transcription factors (Farina et al., 2012). In contrast, a 
candidate tumor suppressor gene for breast cancer, CST6, when expressed in breast cancer 
cells, down-regulated the expression of ATX (Song et al., 2006).  Interestingly, 
radiotherapy has been shown to increase ATX production in the adipose tissue of breast 
cancer patients (Meng et al., 2017). Finally, ATX expression and secretion can be regulated 
by its own product, LPA.  However this feedback regulation can be overcome by 
inflammatory cytokines such as TNF-α or IL-1β (Benesch et al., 2015).  Each of the above 
mentioned stimuli have been investigated in very few cell types. Therefore, more studies 
are needed to define exactly how ATX expression is regulated in most cell types. 
 
1.3.2.1.3 ATX role in physiology and pathology 
Many normal development processes such as adipogenesis (Simon et al., 2005) and central 
nervous system development show involvement of ATX (Dennis et al., 2005). A major role 
in vascular development is played by ATX (Khurana et al., 2008; Sato et al., 2005).  In fact, 
ATX knockout mice are embryonic lethal due to impaired vessel formation in the yolk sac 
and embryo (van Meeteren et al., 2006).  The vascular defects in atx-deficient mice 
resemble those in mice lacking genes involved in cell migration and adhesion such as the 
fibronectin and focal adhesion kinase genes.  Results of such study indicated that the loss of 
LPA production and downstream GPCR signaling is responsible for the phenotype 
observed in atx knockout mice (van Meeteren et al., 2006). Furthermore, ATX stimulates 
cytoskeletal reorganization in different cell types including intestinal cells, 
oligodendrocytes and lymphocytes, to regulate cell motility, myelination, and immune 
functions (Fox et al., 2004; Kanda et al., 2008; Khurana et al., 2008; Mori et al., 2007). 
Interestingly, ATX plays an important role in inflammation increasing cytokine production 
and lymphocyte infiltration, thereby aggravating many inflammatory conditions including 
asthma, pulmonary fibrosis and rheumatoid arthritis (Knowlden and Georas, 2014; Valdés-
Rives and González-Arenas, 2017). Furthermore, ATX is involved in the wound healing 
response where it induces platelet aggregation and keratinocyte proliferation, migration and 
differentiation (Benesch et al., 2016). Additionally, ATX has been implicated in numerous 
pathologies including Alzheimer’s disease, chronic hepatitis C, multiple sclerosis, 
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neuropathic pain, and obesity, but its most investigated and presumably most important role 
is in tumorigenesis, which will be discussed in section 1.3.4 (Ferry et al., 2003; Hammack 
et al., 2004; Inoue et al., 2008a, 2008b; Umemura et al., 2006; Watanabe et al., 2007; Zhao 
et al., 2008). 
1.3.2.2 Lipid phosphate phosphatases 
Lipid phosphate phosphatases were first characterized in 1991, by Jamal et al. (Jamal et al., 
1991). They were found to be magnesium independent, N-ethylmaleidimide-insensitive 
members of the phosphatidic acid phosphatase (PAP) family and were named type 2 PAPs 
(PAP2s) but were later renamed lipid phosphate phosphatases (LPPs) due to the fact that 
they dephosphorylate a wide variety of lipid phosphates.  These characteristics separate 
them from the magnesium dependent class I PAPs, which are responsible for 
dephosphorylating phosphatidic acid specifically (Donkor et al., 2007).  In contrast, LPPs 
can dephosphorylate LPA, S1P, C1P and PA to produce monoacyl glycerol, sphingosine, 
ceramide or diacyglycerol, respectively (Dillon et al., 1997; Waggoner et al., 1996). There 
are three members of the mammalian LPP family each coded by a separate gene PPAP2A, 
PPAP2B and PPAP2C, which correspond to LPP1 (and splice variant LPP1a), LPP3 and 
LPP2 respectively. The first in this family to be cloned was LPP1 in 1996 (Kai et al., 1996), 
followed shortly thereafter by LPP3 (Kai et al., 1997).  The 3 LPP proteins have differing 
catalytic efficiencies with LPP1 being most efficient at degrading LPA species with less 
activity at degrading S1P and C1P (LPA > PA > S1P > C1P).  LPP2 prefers PA as a 
substrate (PA > C1P > LPA > S1P) and LPP3 mostly degrades LPA and PA (LPA=PA > 
C1P > S1P) (Brindley and Waggoner, 1998).   
1.3.2.2.1 Structure and function of LPPs 
The LPPs are transmembrane proteins with 6 transmembrane alpha helices and 3 
extracellular catalytic domains, whose C and N terminal domains are cytoplasmic (Figure 
5) (Zhang et al., 2000b).  The catalytic domains, C1, C2 and C3 work together to 
dephosphorylate lipid phosphates.  C1 is responsible for substrate recognition while both 
C2 and C3 are involved in the phosphotransferase reaction (Sigal et al., 2005). Various 
residues are essential for the functioning of these catalytic domains.  A conserved histidine 
in C3 acts as a nucleophile important for the formation of a phospho-histidine intermediate.  
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Another conserved histidine in C2 is responsible for breaking the phosphate bond to release 
the dephosphorylated lipid product.  Specific arginine and lysine residues in C1 are 
involved in stabilizing the transition state (Sigal et al., 2005).  The main function of LPPs is 
the dephosphorylation of LPA and S1P resulting in attenuation of their downstream 
signaling, although the sphingosine produced from this reaction can reenter the cell and be 
converted to S1P again. The degradation of C1P by LPPs produces ceramide that may also 
be recycled by the cell. The degradation of extracellular PA may increase the uptake of 
diacylglycerol by the cells (Roberts and Morris, 2000).   
 
 
Figure 5 Lipid phosphate phosphatase structure and catalytic domains 
Illustration of the structure and orientation of the LPPs in the plasma membrane.  LPPs 
have six transmembrane domains (I-VI) and their C- and N-terminal domains are located 
intracellularly. Three conserved catalytic domains (blue circles) are located in the 
extracellular loops and work together to dephosphorylate lipid phosphates. Adapted from: 
(Tang et al., 2015)  
 
The LPPs are mainly responsible for degrading lipid phosphates found in the extracellular 
space due to the location of their catalytic domains but may also have some intracellular 
actions. Besides being found at the plasma membrane LPPs are localized to the 
endoplasmic reticulum (Barilà et al., 1996) and Golgi (Kai et al., 1997) where their 
catalytic domains presumably face into the lumen.  The LPPs seem to regulate some 
signaling pathways, including ERK and mobilization of calcium. This later pathway was 
found to be independent of LPP catalytic activity. The mechanisms used by LPPs to 
regulate these intracellular signaling pathways have not yet been elucidated, but may 
involve dephosphorylation of intracellular substrates (Pyne et al., 2004; Samadi et al., 
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2011). Intracellular PA may be an intracellular target of LPPs and when hydrolyzed 
produces DAG which can activate PKCs. In support of this theory, depletion of LPP3 was 
found to decrease levels of de novo DAG resulting in impaired protein trafficking 
(Gutiérrez-Martínez et al., 2013).  Intracellular LPPs may also degrade the C1P and S1P 
found within the cell that are both involved in inflammation and apoptotic signaling 
(Maceyka et al., 2002; Pettus et al., 2005).  Additionally, intracellular S1P can affect gene 
transcription through interactions with histone deacetylases (Hait et al., 2009), and TNF-α 
signaling (Alvarez et al., 2010), processes that may therefore be regulated by LPP activity.  
The LPPs have also been shown to have some non-catalytic functions.  Interestingly, LPP3 
can interact with integrins at the plasma membrane via its RGD domain.  Specifically, 
LPP3 has been shown to interact with αVβ3 and α5β1 to promote endothelial cell-cell 
adhesion (Humtsoe et al., 2003).  
1.3.2.2.2 Regulation of LPPs 
Importantly, LPP1 and LPP3 are downregulated in many tumor cells, however, little is 
known about the regulation of expression of the different LPPs (Samadi et al., 2011).  One 
study found that gonadotropin-releasing hormone could increase LPP3 expression in 
ovarian cancer cells (Imai et al., 2000).  Subsequently, tetracyclines were also found to 
increase the protein levels and plasma membrane expression of all three LPP members 
(Tang et al., 2016). Another form of regulation of LPPs appears to be in their subcellular 
localization. The LPPs may form homo- and heterodimers that can be found in different 
subcellular locations in the cell, therefore differences in dimerization might regulate the 
subcellular distribution of the LPPs and therefore result in spatial regulation of LPA and 
S1P signaling (Long et al., 2008).  Furthermore, LPP1 and LPP3 were found to localize to 
distinct lipid raft domains, which may provide unique environments for each LPP (Kai et 
al., 2006). 
1.3.2.2.3 Role of LPPs in physiology and pathology 
Some insight into the roles of LPPs in physiology and pathology has been attained through 
knockout mice or mice overexpressing the various LPPs, which suggest non-redundant 
roles for each LPP.  Mice overexpressing LPP1 were found to have a 50% decrease in birth 
weight as well and some abnormalities related to fur growth, such as decreased numbers of 
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hair follicles and disrupted hair structure.  Furthermore, LPP1 seems to be implicated in 
fertility as mice overexpressing LPP1 had reduced fertility associated with impaired 
spermatogenesis for males and decreased litter sizes for females.  Interestingly, these mice 
had no significant changes in their plasma LPA concentration (Yue et al., 2004).  In 
contrast, mice with LPP1 knockdown had increased levels of LPA but no obvious 
phenotypic effects (Tomsig et al., 2009). Tumor progression can be regulated by LPP1 due 
to its effects on LPA-induced signaling, which will be further discussed in section 1.3.4.  
The LPP2 knockout mice are fertile and viable (Zhang et al., 2000a) however increased 
expression of LPP2 caused premature entry into the S-phase of the cell cycle. This is 
opposite to the effects of LPP1 and LPP3 whose overexpression inhibits cell growth and 
migration (Morris et al., 2006).  Consistent with its cell cycle-promoting activity, LPP2 
expression is increased in carcinomas and sarcomas (Flanagan et al., 2009). Finally LPP3 
knockout mice have the most drastic defects with embryonic death at gestational day 9.5.  
This is due mainly to its important role in vascular development as LPP3 knockout mice do 
not form chorioallantoic placenta or yolk sac vessels. Axis patterning is also affected by 
LPP3, as a shortening of the anterior-posterior axis was observed in some of the knockout 
mice (Escalante-Alcalde et al., 2003).  Selective LPP3 deficiency in endothelial cells 
increases vascular permeability and sensitivity to inflammation-induced vascular leak, 
effects that can be blocked by inhibiting LPA production or LPA receptor signaling 
(Panchatcharam et al., 2014). Furthermore, LPP3 is required for maintaining blood vessel 
function and plays a causal role in atherosclerosis as well as being associated with coronary 
artery disease (Schunkert et al., 2011).  Similar to LPP1, LPP3 also plays an important role 
in tumorigenesis (see section 1.3.4). 
1.3.3 LPA receptors and signaling  
Extracellular LPA is known to mediate its effects on the cell through activation of specific 
G-protein coupled receptors (GPCRs).  The GPCRs are 7 transmembrane domain receptors 
that couple to various trimers of G-proteins to mediate intracellular signaling. Although 
Van Corven et al. postulated the presence of LPA-specific GPCRs in 1989, it wasn’t until 
1996 that the first LPA receptor gene was identified (van der Bend et al., 1992; Chun, 
1999; Chun et al., 1999; van Corven et al., 1989; Hecht et al., 1996; Masana et al., 1995; 
Thomson et al., 1994). To date 6 LPA receptors have been identified that have both 
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redundant and unique effects and belong to two distinct families, the endothelial 
differentiation gene (Edg) and purinergic receptor families. 
1.3.3.1 LPA receptor identification 
The Edg family receptors have some common structural features such as lack of a cysteine 
residue in the first extracellular loop found in most GPCRs and they share 50-57% amino 
acid identity in humans (An et al., 1998a; Ishii et al., 2009).  The Edg-2/ LPA1 is a 41 kDa 
(364 a.a) protein cloned and identified as an LPA receptor in humans in 1997 (An et al., 
1997; Chun et al., 1999; Contos and Chun, 1998). In human tissues, LPA1 is widely 
expressed in almost all tissues with high expression in brain, heart, placenta and digestive 
tract and lowest expression in liver and peripheral blood leucocytes (An et al., 1998a). A 
second LPA receptor, LPA2, originally known as Edg-4, was subsequently identified due to 
sequence similarity with Edg-2/ LPA1 (Chun, 1999; Contos and Chun, 1998). The LPA2 is 
less widely expressed in humans, it is detected in testis, pancreas, prostate, thymus, spleen, 
and peripheral blood leukocytes and is almost undetectable in brain, heart, placenta, and 
digestive tract contrary to LPA1 (An et al., 1998a). Similar to LPA1, LPA2 is also expressed 
in various cancer cell types (An et al., 1998a).  The third related gene, Edg-7 or LPA3 has a 
more restricted expression pattern than LPA1 and LPA2, having abundant expression only 
in human testis, prostate, heart and frontal regions of the cerebral cortex (Im et al., 2000) as 
well as pancreas, lung and ovary (Bandoh et al., 1999; Im et al., 2000).  Because signaling 
induced by these receptors was unable to account for all the cellular effects of LPA the 
existence of additional receptors was investigated. (Contos et al., 2002; Hooks et al., 2001). 
 
In 2003, a fourth LPA receptor (LPA4/p2y9/GPR23) was identified that was structurally 
distant from the Edg receptors (Noguchi et al., 2003). This stimulated the identification of 
two additional LPA receptors, LPA5 and LPA6.  These three receptors are more closely 
related to the purinergic receptors (purino-receptor cluster), indicating that they arose from 
different ancestor genes than the Edg family receptors (Ishii et al., 2009; Yanagida et al., 
2013).  The LPA4/p2y9/GPR23 is widely expressed in embryonic tissues including brain 
and stem cells (Lee et al., 2007).  In adults, it is abundant in ovary and is weakly expressed 
in many tissues including pancreas, prostate, spleen, small intestine, colon, skeletal muscle, 
brain, placenta, lung, liver, skin, heart, thymus and bone marrow (Noguchi et al., 2003).  
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The LPA5 (GPR92-93) was an orphan GPCR that was identified as an LPA receptor due to 
its close genetic relation to LPA4 (Kotarsky et al., 2006; Lee et al., 2006). Low levels of 
LPA5 mRNA are expressed in embryonic brain, heart, placenta (Kotarsky et al., 2006) and 
platelets (Amisten et al., 2008), while high levels were found in small intestine (specifically 
in the lymphocyte compartment) and moderate levels in skin, spleen, stomach, thymus, 
lung, liver, dorsal root ganglion cells (Oh et al., 2008) and embryonic stem cells (Lee et al., 
2006). The LPA6 (p2y5), was originally reported in 1996 as an orphan GPCR encoded in an 
intron of the retinoblastoma gene (Herzog et al., 1996).  The LPA6 is ubiquitously 
expressed (Pasternack et al., 2008) with high expression in human umbilical vascular 
endothelial cells (HUVECs) (Yanagida et al., 2009).   Expression of LPA6 was also found 
in a leukemia cell line (Yoon et al., 2006). 
 
1.3.3.2 Signaling pathways of LPARs 
LPA GPCRs mediate effects by coupling to heterotrimeric G-proteins of the Gi, Gq, G12/13, 
or Gs families. The specific G-protein that a receptor will couple to depends not only on the 
receptor sequence but also on cell type, receptor expression levels, and amounts of 
available G-proteins (An et al., 1998b; Bandoh et al., 1999; Im et al., 2000).  LPA1 and 
LPA2 can signal through Gi, Gq and G12/13, while LPA3 only couples to Gq and Gi 
(Fukushima et al., 1998; Ishii et al., 2000). The LPA4 has the broadest coupling specificity 
with a potential to signal through any of the four G-protein families (Lee et al., 2007).  The 
LPA5 only couples to Gq and G12/13, while LPA6 signals through Gi and G12/13 (Lee et al., 
2006; Yanagida et al., 2009). See Figure 6 for an overview of the signaling pathways. 
 
Upon receptor activation, Gα subunits are activated through exchange of GDP for GTP. 
This destabilizes the Gα-Gβγ complex so that the Gα or Gβγ subunit can now interact with 
downstream effectors (Oldham and Hamm, 2008). Gαi-mediated signaling results in 
inhibition of cAMP production, as well as activation of MAP kinases leading to cell 
proliferation and differentiation. Focal adhesion kinase (FAK) and PI3K are also activated 
by Gαi, promoting focal adhesion formation or cell survival and migration, respectively. 
Tyrosine kinase-dependent induction of tyrosine phosphatases can also be promoted by Gαi 
signaling (Chuprun et al., 1997; Gaits et al., 1996). Phospholipase C (PLC) activation is 
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mainly mediated by Gαq, producing two important second messengers, inositol triphosphate 
(IP3) and diacylglycerol (DAG). Mobilization of intracellular Ca2+,by IP3, can result in 
actin depolymerization. Some isozymes of PKC are activated by DAG resulting in 
activation of MAP kinases via Raf-1 (Ghosh et al., 1997), or activation of Src, indirectly 
through protein tyrosine phosphatase alpha, specifically by PKC-δ (Brandt et al., 2003). 
Gα12/13 stimulates RhoGTPase pathways that contribute to SRE-mediated transcription as 
well as mediating cytoskeletal dependent functions such as stress fiber formation and actin 
polymerization.  Gα12/13 also promotes activation of PLD, PI3K, RhoA and Cdc42 (Fromm 
et al., 1997).  Finally, signaling through Gαs results in the production of the second 
messenger cAMP (cyclic adenosine 3’.5’-monophosphate) through activation of adenylyl 
cylclase (AC) (Noguchi et al., 2003; Watts and Neve, 2005). Virtually all cellular responses 
such as proliferation, differentiation, apoptosis, gene transcription, metabolism, secretion, 
cell division and neurotransmission have been found to be affected by cAMP (Cheng et al., 
2008; Robison et al., 1968). Gβγ dimers may also participate in signaling by recruitment of 
PLC (Barr et al., 2000; Sankaran et al., 1998) and association with PI3K (Kurosu et al., 
1997; Maier et al., 1999; Stoyanov et al., 1995). 
  
 
Figure 6 LPAR signaling 
The major LPA signaling pathways, downstream of LPARs 1-6, are illustrated here and 
include signaling through four different G-protein families, Gα12/13, Gαi, Gαq, and Gαs.  
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Signaling through these G-proteins can activate diverse proteins including RhoA, PI3K, 
Ras, PLC and AC.  The major downstream effects of LPA signaling include cytoskeletal 
remodeling, cell migration, stress fiber formation, focal adhesion formation and integrin 
activation. 
 
 
 
1.3.3.3 Crosstalk of LPARs with RTKs 
An additional aspect of LPA receptor signaling is their potential to transactivate RTKs to 
mediate growth factor-like effects.  In this way, numerous GPCRs of the lipid, peptide, 
chemokine, nucleotide, steroid and even orphan receptor families are known to cross-
communicate with RTKs, including VEGFR (Thuringer et al., 2002), PDGFR (Tsai et al., 
2014), EGFR (Gschwind et al., 2002) and IGFR (Köse, 2017; Oligny-Longpré et al., 2012; 
Wang, 2016). The GPCR-mediated EGFR transactivation is the most prominent and well-
studied crosstalk mechanism in various cancer cell lines (Köse, 2017) and has been shown 
to be mediated by a variety of GPCR agonists including LPA, thrombin, S1P, endothelin-1, 
prostaglandin E2 and parathyroid hormone (Cattaneo et al., 2014).  In the case of LPA, 
various studies have identified both ligand-dependent and ligand-independent mechanisms 
of LPA-induced transactivation of various RTKs, such as c-MET (Fischer et al., 2004), 
tropomyosin receptor kinase A (TrkA) (Nan et al., 2016) and EGFR depending on cell type 
and physiological context (Bhola and Grandis, 2008; Cattaneo et al., 2014). Among these, 
EGFR represents the prototypical RTK in the context of LPAR transactivation. For 
example, LPA has been shown to mediate EGFR transactivation via increased ligand 
shedding of the EGFR ligands HB-EGF, amphiregulin (AR) or TGF-alpha. Shedding of 
these ligands was found to be dependent on MMPs or ADAM10, 15 or 17 depending on the 
cell types investigated. Other cell type-dependent factors involved in ligand-dependent 
transactivation were activation of Src kinases and MAPK signaling (Brusevold et al., 2014; 
Gschwind et al., 2002, 2003; Schäfer et al., 2004; Umata et al., 2001; Xu et al., 2007; Yoo 
et al., 2013; Zhao et al., 2006).  Originally, LPA was found to transactivate EGFR through 
a ligand-independent mechanism, as the phosphorylation occured within 5 minutes, 
however the mechanism was not elucidated (Daub et al., 1996).  One mechanism of ligand-
independent transactivation of RTKs involves the generation of ROS, which can directly 
activate kinases via protein-protein interactions or indirectly through inactivation of protein 
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tyrosine phosphatases (PTPs) (Cattaneo et al., 2014; Finkel, 2000).  In this respect, LPA 
has been shown to induce EGFR phosphorylation, in as little as 4 minutes, by increasing 
ROS production (Cunnick et al., 1998; Fischer et al., 2004).  Another ligand-independent 
mechanism involves intracellular tyrosine kinases such as Src, Pyk and Fyn that can 
directly phosphorylate the cytoplasmic domains of RTKs (Cattaneo et al., 2014). The 
prototypical example is Src known to play a prominent role by directly phosphorylating 
EGFR and VEGFR (Cattaneo et al., 2014).  For example, Gi-coupled LPA receptors were 
found to mediate Src-dependent EGFR phosphorylation in COS-7 cells (Luttrell et al., 
1997). Conversely, RTKs have also been shown to transactivate GPCRs providing an 
alternative mechanism for GPCR activation.  Similarly to GPCR transactivation of RTKs, 
RTK-mediated GPCR transactivation can be through production of GPCR ligands or by 
ligand-independent mechanisms involving formation of GPCR-RTK complexes (Delcourt 
et al., 2007). Some examples of RTK ligands shown to transactivate GPCRs are IGF-1, 
Insulin, PDGF, EGF, and NGF (Delcourt et al., 2007). For example, PDGF was found to 
activate S1P1 through ligand synthesis or physical interaction (Hobson et al., 2001; Waters 
et al., 2003), IGF-1 transactivates CXCR4 by formation of a CXCR4-IGF-1R complex 
(Akekawatchai et al., 2005), NGF induces production of S1P to transactivate S1P1 (García-
Sáinz et al., 2010), and insulin receptor, EGFR or PDGFR activity phosphorylates B2-
adrenoceptors increasing their functional activity (Cattaneo et al., 2014; Valiquette et al., 
1995).  In the case of LPA receptors, EGF signaling through EGFR has been found to 
increase the production of LPA in human ovarian cancer cells (Snider et al., 2010), while 
NGF, via TrkA, activates LPARs through physical interactions (Moughal et al., 2004, 
2006). Therefore, various crosstalk mechanisms between RTKs and GPCRs, such as 
LPARs, add to the complexity of receptor signaling and thereby influence biological 
outcomes.  
1.3.3.4 Implication of LPA signaling in physiological and pathological processes  
Signaling by LPA is implicated in diverse biological processes that include tissue 
remodeling, wound healing (Watterson et al., 2007), angiogenesis, platelet aggregation, 
cardiovascular function (Smyth et al., 2008), neurogenesis, myelination, olfaction, 
neuropathic pain, reproduction, adipogenesis (Ye, 2008), and immunomodulation 
(Moolenaar et al., 2004; Noguchi et al., 2009).  The effects of each receptor on these 
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processes have been elucidated by the use of receptor knockout mice. Knockout studies 
have shown that LPA1 is implicated in the initiation of neuropathic pain and is important 
for proliferation of astrocytes.  The LPA1-null mice display 50% lethality, and survivors 
have abnormal phenotypes such as reduced body size, craniofacial dysmorphism and 
reduced brain mass as well as a suckling defect (Contos et al., 2000a).  Therefore, LPA1 
seems to play an important role in the central nervous system.  The LPA2-null mice show 
no obvious phenotypic abnormalities and, therefore, might have redundant functions with 
LPA1 as they both couple to the same G-proteins (Choi et al., 2008).  Female LPA3-null 
mice display delayed embryo implantation, altered embryo spacing, and reduced litter size 
(Ye et al., 2005), suggesting that this receptor is implicated in reproductive functioning.  
The LPA4 knockout mice have no apparent abnormalities, however there is 30% lethality 
due to some blood vessel defects during embryogenesis (Lee et al., 2008; Sumida et al., 
2010).  The LPA5 knockout mice also have no apparent phenotypic defects however they 
do experience decreased pain sensitivity and recover faster from inflammation.  These mice 
were also found to have less social exploration, nocturnal hyperactivity and anxiety, 
suggesting a role in the central nervous system (Callaerts-Vegh et al., 2012). Finally, there 
have been no studies so far on LPA6 knockout mice however this receptor seems to be 
related to hair growth as a mutation in LPA6 was detected in patients with hypotrichosis 
simplex (Pasternack et al., 2008). 
1.3.4 Implications of the ATX/LPA axis in cancer 
Finally, the most relevant role of the LPA/ATX axis for this study is in tumor progression. 
As a potent tumor-promoting molecule, LPA influences many cellular processes implicated 
in tumorigenesis. Supporting this notion is the fact that the enzyme responsible for 
producing the majority of LPA in vivo, ATX, has been shown to be up-regulated in various 
malignancies including breast, lung, colon, ovarian, stomach, thyroid and brain cancer, 
correlating with the invasive potential of these cancer cells (Kehlen et al., 2004; Kishi et al., 
2006; Yang et al., 2002, 1999).  In fact, ATX was found to be one of the top 40 most 
upregulated genes in patients with highly metastatic cancer (Euer et al., 2002) In contrast, 
the LPA degrading enzymes LPP1 and LPP3 have been found to be downregulated in some 
cancer types such as breast, lung and ovarian cancer (Tang et al., 2015). Together, these 
studies suggest a global increase in LPA levels surrounding tumor cells. In fact, this has 
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been documented in ovarian and pancreatic cancer where high levels of LPA are present in 
the ascites from these patients (Westermann et al., 1998; Xu et al., 1998; Yamada et al., 
2004). Furthermore, malignant progression has also been shown to correlate with 
differential expression of the various LPA receptor subtypes (Contos et al., 2000b). 
Increased expression of LPA1 has been observed in bladder cancer and in breast carcinoma 
cells, where it leads to metastatic spread to bone (Boucharaba et al., 2004; Kataoka et al., 
2015), LPA2 is over-expressed in invasive ductal carcinoma (Kitayama et al., 2004), 
ovarian cancer (Erickson et al., 2001) and colorectal cancer (Shida et al., 2004). The 
expression of LPA3 increases the aggressiveness of ovarian carcinoma and is also highly 
expressed in triple-negative breast cancer (breast cancer cells negative for estrogen 
receptors, progesterone receptors and human epidermal growth factor receptor 2) (Sun et 
al., 2015; Yu et al., 2008). Finally, elevated LPA2 and LPA6 expression in hepatocellular 
carcinoma correlates with invasion and recurrence (Enooku et al., 2016). Therefore, the 
increase in LPA production, decrease in LPA degradation, and increased LPA receptor 
levels in various cancer cell types all emphasize the importance of LPA as an extracellular 
signaling molecule in cancer.  
 
Cellular characteristics associated with tumor aggressiveness, including cell proliferation, 
cell survival, cell motility, invasion, angiogenesis, resistance to treatment and metastasis 
have long been known to be augmented by ATX. (Benesch et al., 2018; Leblanc and 
Peyruchaud, 2015; Nam et al., 2000, 2001). For example, ATX-transfected Ras-
transformed NIH3T3 cells were shown to be more invasive, tumorigenic, angiogenic and 
metastatic than mock-transfected controls (Nam et al., 2000, 2001). Research suggests that 
it is the autocrine or paracrine production of LPA via ATX that contributes to these effects 
on cancer cells. It has been demonstrated that several cancer cell lines release significant 
amounts of LPC into the culture medium and the presence of LPC promotes ATX-induced 
increases in chemotaxis and proliferation in multiple cell lines (Umezu-Goto et al., 2002). 
Furthermore, ATX promotes proliferation of A2058, MDA-MB231, CHO-K1 and Edg2-
RH7777 cancer cells, but not RH7777 cells that lack LPA receptors (Brindley, 2004; 
Umezu-Goto et al., 2002).  In contrast, the overexpression of the LPA degrading enzymes 
LPP1 and LPP3 have been shown to decrease proliferation and colony forming ability of 
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ovarian cancer cells while increasing their levels of apoptosis.  Furthermore, ovarian cancer 
cells overexpressing LPP3 had decreased tumor growth in nude mice (Tanyi et al., 2003a).  
In breast and thyroid cancer cells the overexpression of LPP1 decreased cell growth in 3D 
culture and LPA stimulated migration as well as decreasing tumor growth and metastasis 
by up to 80%, compared to overexpression of an inactive LPP1 (Tang et al., 2014).  The 
LPP1 knockout mice were also found to have increased cancer cell seeding implicating 
LPA signaling in the establishment of the pre-metastatic niche (Nakayama et al., 2015). 
Therefore increased production of LPA, by ATX, promotes tumorigenesis while reduced 
levels of LPA, due to the action of LPPs, has a negative effect on tumor progression. 
 
Unsurprisingly, LPA has been shown to modulate many of the same characteristics as 
ATX, affecting cell motility, proliferation and metastasis as well as protecting cancer cells 
from radiation therapy (Benesch et al., 2018). For example, LPA mediates cytoskeletal 
rearrangements via the Rho GTPases Rho and Rac affecting cancer cell motility (Imamura 
et al., 1993; Stam et al., 1998).  This leads to stimulation or inhibition of cell migration or 
invasion depending on the cell type. Proliferation and mitogenic signaling of prostate 
cancer cells can be induced by LPA (Budnik and Mukhopadhyay, 2002).  Also, LPA 
stimulates migration and proliferation of human colon carcinoma cells (DLD1) as well as 
their adhesion to collagen type I and secretion of endothelial growth factor and IL-8, all of 
which can lead to an increased metastasizing potential of DLD1 carcinoma cells (Shida et 
al., 2003).  These effects are mediated by LPA receptors depending on cell type. For 
example, LPA1 signaling has been shown to mediate stimulation of motility of human 
pancreatic cancer cells (Yamada et al., 2004), induction of metastasis by human colon 
carcinoma cells (Shida et al., 2003), spontaneous metastasis of breast cancer cells (David et 
al., 2012) and hepatocellular carcinoma invasion (Park et al., 2011). In addition, LPA2 
promotes mitogenic signaling in human colon cancer cells (Yun et al., 2005), endometrial 
cancer invasion (Hope et al., 2009), and invasion and migration of ovarian cancer cells (So 
et al., 2005).  Finally, LPA3 has been found to increase motility and invasion of pancreatic 
cancer cells (Kato et al., 2012) and LPA5 can increase proliferation and motility of rat lung 
and liver tumor cells (Okabe et al., 2011). 
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Interestingly, overexpression of ATX or LPA1-3 alone in mice was found to induce a 
chronic inflammation contributing to the development of mammary carcinoma as well as 
increased tumor invasion and metastasis of breast cancer cells in these transgenic mice (Liu 
et al., 2009).  In contrast, pharmacological inhibition of ATX and LPA receptors was 
shown to decrease cell migration in vitro and cause tumor regression in mice (Zhang et al., 
2009), further supporting the role of ATX in cancer progression. Several publications 
indicate that ATX and LPA receptors are also implicated in the production of the 
degradative structures, invadopodia (described above section 1.2).  Specifically, ATX 
overexpression was found to increase invadopodia production, which was blocked by LPA4 
knockdown in HT1080 fibrosarcoma cells.  This correlated with a decrease in 3D cell 
invasion and metastasis in vivo upon LPA4 knockdown (Harper et al., 2010). In prostate 
cancer cells, LPA was shown to promote functional invadopodia formation through NF-kB 
and RhoA signaling (Hwang et al., 2016). In melanoma cells, LPA triggered invadopodia 
through Gi coupled receptors and Cdc42 signaling (Kedziora et al., 2016).  Therefore, the 
effects of the LPA signaling axis on cancer cell invasion may be mediated by their control 
of invadopodia biogenesis. 
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1.4 Hypothesis 
Metastasis is the leading cause of cancer patient mortality yet therapeutic targets for the 
treatment of metastatic cancer remain elusive. Recent evidence suggests that invadopodia 
are important mediators of cancer cell metastasis, being essential for blood vessel 
intravasation and extravasation, suggesting that the components and regulators of these 
invasive structures could be used as therapeutic targets for blocking metastasis. The 
hypoxic tumor microenvironment is an important driver of tumor cell invasion and 
metastasis, in part through regulation of invadopodia. The LPA signaling axis, which is 
activated in tumors, has also been implicated in invadopodia production suggesting 
interplay between these two aspects of the tumor microenvironment. However, our 
knowledge of the influence of the hypoxic microenvironment on the LPA signaling axis in 
the context of cancer cell invasion and metastasis is lacking.  
 
Based on the above statements, we formulate the following hypothesis: 
The hypoxic tumor microenvironment promotes cancer cell invasion and metastasis 
through positive regulation of the LPA signaling axis. 
1.4.1 Objectives 
Objective #1 
Determine if hypoxia-mediated effects on invasion and metastasis are dependent on LPA 
receptors 
Objective #2 
Define signaling pathways involved in invadopodia production downstream of LPA 
receptors in hypoxic cells 
Objective #3 
Elucidate the implication of the processes involved in production and degradation of LPA 
in hypoxia-induced invadopodia formation and metastasis  
2. ARTICLE 1 
The Hypoxic Microenvironment of Tumors Promotes Invadopodia Formation and 
Metastasis through Cooperation between LPA1 and EGF Receptors 
 
Auteurs de l’article: Kelly Harper, Roxane R. Lavoie, Martine Charbonneau, Karine 
Brochu-Gaudreau, Claire M. Dubois 
 
Statut de l’article: accepté dans Molecular Cancer Research 
 
Avant-propos: I personally performed the bibliographic research, experimental planning 
and the majority of the experiments.  I also wrote and participated in the correction of the 
manuscript with guidance from my supervisor Dr. Claire Dubois.   
 
Résumé :  
L'hypoxie, une caractéristique commune des tumeurs solides, a été impliquée de manière 
critique dans l'invasion cellulaire et le développement des métastases, mais les mécanismes 
sous-jacents demeurent méconnus. Nos études antérieures avaient démontré que l'axe de 
signalisation du récepteur de l'acide lysophosphatidique, LPA4, médie la production de 
structures subcellulaires invasives, les invadopodes, qui sont connues pour être nécessaires 
à la formation de métastases. Nous démontrons maintenant que LPA1 est le récepteur 
commun et majeur utilisé pour la production d'invadopodes induite par l'hypoxie dans 
diverses lignées cellulaires cancéreuses. L'utilisation généralisée du LPA1 n’est pas due à 
une augmentation de l'expression de LPA1 mais repose plutôt sur une transactivation de 
l’EGFR induite par Src. La phosphorylation du Y845-EGFR, médiée par LPA1 en hypoxie, 
conduit à l'activation de PI3K/Akt, un événement qui augmente la capacité des cellules à 
produire des invadopodes. En outre, la phosphorylation de Y845-EGFR est régulée à la 
hausse dans les zones hypoxiques des tumeurs et une combinaison d’inhibiteurs du EGFR 
et du LPA1 a agit de façon synergique afin de supprimer la production de métastases in 
vivo. Ces résultats mettent en lumière l'axe LPA1-EGFR en tant que  cible potentielle pour 
limiter la progression des métastases chez les patients atteints de cancer. 
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ABSTRACT 
Hypoxia, a common feature of solid tumors, has been critically involved in cell invasion 
and metastasis but the underlying mechanisms remain poorly understood. Previously, it has 
been observed that the lysophosphatidic acid receptor 4 (LPA4) signaling axis mediates 
production of the degradative subcellular structures invadopodia, which are known to be 
required for metastasis. Here, it is demonstrated that LPA1 (LPAR1) is a common and 
major receptor used for hypoxia-induced invadopodia production in various cancer cell 
lines. The widespread use of LPA1 was not due to increased LPA1 expression but rather 
relied on Src-mediated crosstalk with EGFR. Phosphorylation of Y845-EGFR mediated by 
LPA1 under hypoxia led to PI3K/Akt activation, an event that increases the ability of cells 
to produce invadopodia. Moreover, phospho-Y845-EGFR was upregulated in hypoxic 
zones of tumors and a combination of EGFR and LPA1 inhibition synergistically 
suppressed metastasis in an in vivo model in chick embryos.   
 
 
 
IMPLICATIONS 
This study uncovers a LPA1-EGFR signaling axis that is used for cell invasion in hypoxia 
and suggest a potential target to impede cancer metastasis.  
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INTRODUCTION 
Metastasis is the leading cause of mortality in cancer patients. However, effective 
therapies targeting the disseminated disease remain a major challenge in clinical 
management of the disease. Tumor microenvironment is increasingly recognized to play a 
significant role in many of the hallmarks of cancer, notably as an important modulator of 
tumor cell phenotypes driving cell invasion and metastasis (1). A common feature of the 
tumor microenvironment is hypoxia, or low concentrations of oxygen, within solid tumors. 
Tumor hypoxia arises because of inadequate delivery of oxygen as a result of insufficient 
and defective vasculature and high oxygen consumption rate of cancer cells (2). Hypoxic 
tumors are aggressive, resistant to chemotherapy, and prone to recurrence (3). It has been 
recently reported that tumor microenvironment stimuli such as hypoxia and the associated 
acidic pH induce cell invasion and metastasis through activation of sodium-hydrogen 
exchangers, growth factors, metalloproteases or RhoGEFs (4). In these reports, the increase 
in cellular invasion was associated with production of invadopodia, which are specialized 
cell structures required for cancer cell dissemination. 
Invadopodia are actin-rich and proteolytically active subcellular structures 
generated by cancer cells that promote their migration and invasion through tumor stroma 
and the basement membrane of blood vessels during the process of metastasis (5). These 
structures are relevant to the cell invasion process as they have been observed in migrating 
cancer cells undergoing intravasion as well as in tumor cells invading through tissues (6,7). 
More recently, invadopodia have been shown to be essential for cancer cell extravasion and 
metastasis in vivo through genetic analysis and pharmacological inhibition of molecules 
specifically involved in their initiation, maturation or function (8). These studies have 
provided direct in vivo evidence of the functional role of invadopodia in metastasis, making 
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them relevant therapeutic targets to counter pathological cell invasion. Generation of 
invadopodia requires tight coordination between polarized cellular trafficking, signaling 
events and cytoskeletal remodeling. Whereas these events have been extensively studied, 
many of the upstream inducers that drive invadopodia formation and activity remain 
unknown (9). 
An emerging participant in cancer progression is the ATX-LPA receptor signaling 
axis. Lysophosphatidic acid (LPA) is a bioactive lipid produced mainly by Autotaxin 
(ATX) that signals through 6 known LPA G-protein coupled receptors (GPCRs) (LPA1-6). 
These receptors activate various signaling components that include cAMP, PLCβ, PLCε, 
small rhoGTPases, Ras, ERK and PI3K that regulate many pathophysiological processes 
including cancer (10). We have previously reported that LPA4 , through the cAMP-Rap1-
Rac1 axis, was involved in invadopodia production by cancer cells and that this event 
correlated with their metastatic efficiency (11). The ability of LPA to stimulate invadopodia 
production has since been confirmed in prostate and melanoma cells (12,13). Furthermore, 
over-expression of ATX or LPA1-3 has been shown to induce tumorigenesis and metastasis 
in a mouse model (14), whereas their pharmacological inhibition decreased cell migration 
in vitro and caused tumor regression in mice (15). Although these findings suggested the 
critical implication of LPA receptors in tumor progression, the interplay between LPARs 
and hypoxia within the context of cell invasion has not yet been addressed. Here, we report 
that hypoxia promotes cell invasion through a mechanism that involves Src-mediated cross-
communication between the LPA1 receptor and EGFR. Our findings suggest a mechanistic 
rationale for targeting both LPA1 and EGFR to counteract metastasis.  
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MATERIALS & METHODS 
Reagents. 1-oleoyl-sn-glycerol-3-phosphate 18:1 (LPA) sodium salt and LPA receptor 
antagonist (Ki16425) were purchased from Sigma-Aldrich (St. Louis, MO). Inhibitors of 
EGFR (Tyrphostin AG 1478), PLC (U-73122), and PI3K (LY294002) were purchased 
from Biomol International (Plymouth Meeting, PA). Inhibitors of MEK (PD 98059), 
ROCK (Y-27632), Src (PP2) and RAP1 (GGTI-298) were from Calbiochem (EMD 
Chemical Inc, La Jolla, CA). LPA1 receptor antagonist AM095 was from APExBIO 
(Houston, TX). Corning Matrigel Basement Membrane Matrix was from Corning (Bedford, 
MA). The antibody directed against LPA1 was from Abnova (Walnut, CA) and, against 
LPA4, from Novus Biologicals (Littletone, CO). Antibodies directed against EGFR 
(D38B1), pTyr, phospho-EGFR (Y845), phospho-AKT1 (Ser473), pan AKT, Src 32G6 and 
phospho-Src (416) were purchased from Cell Signaling (Danvers, MA). The anti-GRK2 
antibody was from Santa Cruz (Dallas, Texas). The anti-tubulin antibody was from Sigma-
Aldrich and, Texas Red-conjugated phalloidin, DAPI (4’,6-Diamidino-2-Phenylindole), 
and all secondary antibodies were from Invitrogen (Molecular Probes, Eugene, OR).  
Hypoxyprobe kit containing pimonidazole HCl and anti-pimonidazole mouse antibody was 
from Hypoxyprobe (Burlington, MA). 
 
Cell culture and transfections. HT1080 human fibrosarcoma, MDA-MB231 human breast 
cancer and U87 human glioblastoma cells were obtained from the American Type Culture 
Collection (Rockville, MD). All cell lines were routinely tested for mycoplasma using the 
MycoSEQ Mycoplasma Detection Kit (all negative)  (Thermo Fisher Scientific). Cells were 
grown for no more than 25 passages in total for any experiment. Cells were cultured in 
minimal essential medium (MEM) (Wisent, St-Bruno, QC) supplemented with 10% FBS 
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(Gibco BRL, Burlington, ON) and 40 µg/ml of gentamicin (Wisent) in a humidified 95% 
air/5% CO2 incubator at 37ºC. For hypoxic stimulations, cells were cultured in an 
INVIVO2 400 hypoxic chamber (Ruskinn, Sanford, ME) under an atmosphere of 1% O2 
and 5% CO2. In the case of stable transfections with shRNA against LPA1 or LPA4 
(SABiosciences, Frederick, MD), cells were seeded at a density of 1 x 105 cells per well in 
a 6-well culture plate the day before transfection. Transfections were performed using the 
FuGENE reagent (Roche Diagnostics, Mannheim, Germany), according to the 
manufacturer’s protocol. Stable transfectants were obtained by selection with Puromycin 2 
µg/ml (Invivogen, San Diego, CA). In the case of lentiviral transductions, cells were seeded 
at a density of 3 x 105 cells per 10 cm2 Petri dish and infected with 1 ml of viral stock in 2 
ml of optiMEM supplemented with 2 µl Polybrene (10 mg/ml) (EMD Millipore, Etobicoke, 
ON), cell populations were used. Mission lentiviral shRNA targeting EGFR 
(TRCN0000010329), Src (TRCN0000195339), ADAM12 (TRCN0000047033), ADAM17 
(TRCN0000052172), or a scramble sequence were used (Sigma-Aldrich). Viral particles 
were generated by transient transfection of 293T cells using a ViraPower lentiviral 
expression system (Invitrogen Thermo Fisher Scientific, Burlington, ON). 
 
Real-time RT-PCR. Total RNA was isolated using the TRIzol (Invitrogen, Carlsbad, CA) 
protocol, as described (11), and 1 µg of RNA was reverse transcribed to complementary 
DNA (cDNA) using a QuantiTect reverse transcription kit (Qiagen, Mississauga, ON). 
Transcribed cDNA was then analyzed by real-time PCR using a hot start SYBR Green 
qPCR master mix (BiMake, Houston, TX). Primer pairs are described in the supplementary 
Material and Methods section. Quantitative real-time PCR was performed on a Rotor-Gene 
3000 (Corbett Research, Kirkland, QC). The cycling program was as follows: the initial 
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denaturation was performed at 95ºC for 15 min, followed by 40 amplification cycles with 
annealing temperature of 55ºC for 30 s and, final extension at 72ºC for 30 s. For calculation 
of copy numbers, cloned plasmid DNA was used to generate a standard curve for each 
target and samples were normalized with a reference gene (RPLP0) as previously described 
(16). 
 
Western blotting. Cells were lysed in a RIPA buffer (50mM Tris HCL, 150 mM NaCl, 
0.1% Na-deoxycholate, 4mM EDTA, 1% NP40) with protease inhibitors 1/10 (cOmplete 
Mini EDTA-free from Roche Diagnostics (Indianapolis, IN)) and phosphatase inhibitors 
1/10 (10mM NaF, 1mM Na3VO4, 20mM B-glycerophosphate). Supernatant samples were 
recovered by centrifugation (13000 rpm for 30 min at 4ºC) and protein concentrations 
determined using the BCA reagent (Biolynx Inc, Brockville, ON). Immunoblotting was 
performed as previously described (11). In the case of immunoprecipitation experiments, 1 
mg of total protein was immunoprecipitated using an anti-EGFR antibody (dilution, 1:100). 
The membranes were probed overnight with primary antibodies. The secondary antibody 
was a peroxidase-conjugated anti-rabbit or anti-mouse antibody, depending on the source 
of primary antibody used (Amersham, Baie d’Urfé, QC). Immunoblots were revealed using 
the LuminataTM Western HRP Chemiluminescence substrate (Millipore, Etobicoke, ON). 
Band intensities were analyzed using the Quantity One software (Bio-Rad Laboratories, 
Mississauga, ON, Canada). 
 
Invadopodia assay. Coverslips were prepared as described (11), using Oregon-Green488-
conjuagted gelatin (Invitrogen, ON). Thirty thousand cells were seeded on each coverslip 
and allowed to adhere. Following a 10 h or 16 h incubation period under the conditions 
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described in Figure legends, cells were fixed with 2% paraformaldehyde for 10 min at room 
temperature. Nuclei were stained with DAPI and F-actin was stained using Texas-Red-
conjugated phalloidin. Cells were visualized and images were taken using a Zeiss Axioskop 
fluorescence microscope. Cells forming ECM-degrading invadopodia were identified based 
on cells with at least one F-actin-enriched area of matrix degradation (characterized by loss 
of green fluorescence). Three fields of 100 cells (magnification 40X) were counted per 
coverslip to quantify the percentage of cells forming ECM-degrading invadopodia.  
 
RTK phosphorylation array. HT1080 cells were incubated under normoxia or hypoxia for 
30 or 60 min in serum-free medium. Proteins were extracted and analyzed using the human 
PathScan RTK Signaling Antibody Array kit (Cell Signaling Technology), according to the 
manufacturer’s instructions. Fluorescent images were captured using an Odyssey Infrared 
Imaging System and fluorescence intensities semi-quantitated using the ImageJ software. 
 
ELISA assays. HT1080 cells were plated at a density of 1 x 106 cells per 10 cm2 Petri dish. 
On the next day, the medium was removed and replaced with serum-free medium for 
overnight starvation. Cells were then incubated for 8 h in an atmosphere of 21% O2 or 1% 
O2 and supernatants were collected and centrifuged to remove cellular debris and 
concentrated. Ligands for EGFR were detected using Quantikine ELISA kits for human 
EGF, TGF-alpha (R&D Systems) or HB-EGF (Abcam), according to the manufacturer's 
instructions. 
 
Chorioallantoic membrane assays. Fertilized eggs from white leghorn chicken were 
obtained from the Public Health Agency of Canada (Nepean, ON). The project was 
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approved by the Ethics Committee on Animal Research of the University of Sherbrooke 
(Protocol # 054-13) and all experimental procedures involving embryos were conducted in 
accordance with regulations of the Canadian Council on Animal Care. Chorioallantoic 
membrane (CAM) assays were performed as we described (17), with the following 
modifications. Cell suspensions were mixed with the appropriate inhibitors prior to grafting 
on the CAM and the eggs were then returned to the incubator for another 6 days. The cells 
were treated with DMSO (vehicle), AM095, AG1478 or a combination of the two 
inhibitors. At the end of the experiments, livers from the chick embryos were removed and 
immediately snap-frozen in liquid nitrogen and stored at -80°C until DNA extraction. 
Genomic DNA extraction was performed using DNAzol reagent (Invitrogen), according to 
the manufacturer’s instructions. Amplification of Alu repeats by qPCR was performed as 
described (18), using the hot start Taq PCR kit (Qiagen) and relative changes in metastasis 
were then calculated as 2ΔΔCT. 
 
Immunohistochemistry. Immunohistochemistry of tumor hypoxia in tumors grown on 
CAM was performed as we described (17). Tumor sections were double stained for 
pimonidazole, in combination with phospho-Y845-EGFR antibody (1:50). For 
quantification of phospho-Y845-EGFR staining intensity at least 6 representative areas 
from at least 3 separate tumors for each condition were captured using an Axioskop 2 
phase-contrast/epifluorescence microscope (Carl Zeiss Inc., Thornwood, NY).  
Fluorescence intensities were analyzed using the Image Pro software (Media Cybernetics, 
Bethesda, MD), and results are expressed as the sum of labeling intensity (density) relative 
to total area.    
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Statistical analysis. The GraphPad software was used for statistical analysis.  Paired or 
unpaired Student’s t-test were used to assess statistical significance, which was set at a P 
value <0.05. 
RESULTS 
LPA1 is the major LPA receptor used in hypoxia for invadopodia production 
We have previously reported that LPA4 signaling was involved in invadopodia 
production in HT1080 cancer cells cultured under normoxic conditions (11). Since LPARs 
can have cell type and context dependent effects on cell motility and invasion (19), and 
since several GPCRs are known to play a role in hypoxia-mediated signaling (20), we 
sought to investigate which LPAR and downstream signaling were involved in invadopodia 
formation under hypoxic conditions. To address this issue, we first examined the impact of 
LPA4  knockdown on the percentage of cells forming ECM-degrading invadopodia under 
normoxic or hypoxic conditions using various cancer cell lines, namely MDA-MB-231 
breast cancer, U87 glioblastoma and HT1080 fibrosarcoma cells. Unexpectedly, shRNA-
mediated knockdown of LPA4 in MDA-MB-231 or U87 cells had no effect on the 
percentage of cells with invadopodia in hypoxia and had only a partial effect in HT1080 
cells. As previously reported, LPA4 knockdown resulted in complete inhibition of LPA-
induced invadopodia-forming cells in normoxic HT1080 cells (11), whereas it had no effect 
under these conditions in MDA-MB-231 and U87 cells (Fig 1A and Supp Fig1A). Since 
one interpretation of these results is the utilization of LPA receptors other than LPA4, for 
invadopodia production in hypoxia, cells were incubated with the LPAR inhibitor Ki16425, 
which inhibits preferentially LPA1 > LPA3 >> LPA2 (21). Interestingly, low 
concentrations of Ki16425, which are selective for LPA1, were effective at reducing the 
increase in the percentage of cells producing invadopodia under hypoxia in all three cells 
lines. In MDA-MB-231 and U87 cells, Ki16425 treatment also diminished LPA-induced 
invadopodia under normoxic conditions (Fig 1B). These results suggest a common usage of 
LPA1 under hypoxic conditions and a selective usage under normoxia by MDA-MB-231 
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Figure 1 LPA1 is essential for hypoxia-induced cancer cell invasion. 
(A-C) MDA-MB-231, U87 or HT1080 cells were cultured on fluorescently-labeled gelatin 
for 10 h or 16 h, under normoxia (21% O2) or hypoxia (1% O2) in the presence/absence of 
LPA (10 µM). The percentages of cells forming ECM-degrading invadopodia in the case 
of, (A) cells stably transfected with shRNA against LPA4, (B) cells treated with the LPA 
receptor inhibitor Ki16425, or (C) cells stably transfected with shRNA against LPA1 are 
shown (n ≥ 3 independent experiments). (D) Representative immunofluorescence images of 
matrix degradation by scrambled or LPA1 shRNA-transfected HT1080 cells cultured for 10 
h on fluorescently-labeled gelatin in an atmosphere of 21% O2, 21% O2 in the presence of 
LPA, or 1% O2 are shown (magnification 40X). F-actin staining [red] and Oregon 
Green488-conjugated gelatin [green]. Bars represent the mean ± SEM. The asterisks (*) 
correspond to P < 0.05 (*), P < 0.01 (**) and, P < 0.001 (***). 
 
and U87 cells. To confirm the role of LPA1, we silenced its expression using LPA1-
targeted shRNA (Supp Fig1B). Knockdown of LPA1 decreased the percentage of 
invadopodia-forming cells induced by hypoxia in all three cell lines, further underscoring 
the prevailing LPA1 usage under this condition. In addition, LPA1 knockdown also 
decreased the percentage of LPA-induced invadopodia-forming cells in MDA-MB-231 and 
U87 cells (Fig 1C). Immunofluorescence pictures revealed a marked difference in matrix 
degradation between scrambled and LPA1 shRNA transfected HT-1080 cells cultured under 
hypoxic conditions compared to the similar levels of degradation observed in LPA-
stimulated cells under normoxic conditions (Fig 1D). Overall, these results suggested that 
LPA1 is a common and major LPA receptor used for the production of hypoxia-induced 
ECM-degrading invadopodia  in various cancer cell lines. 
 
LPA1 usage in hypoxic HT1080 cells is not related to changes in LPA1 or GRK2 levels 
of expression 
The differential use of LPA receptors under normoxic and hypoxic conditions led us to 
investigate the gene expression profile of LPA receptors in HT1080, MDA-MB-231 and 
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U87 cell lines. Results from qPCR experiments showed that both MDA-MB-231 and U87 
cells expressed predominantly mRNA for the LPA1 receptor, which is consistent with the 
use of this receptor for invadopodia production under both normoxic and hypoxic 
conditions (Fig 2A,B). In contrast, and as previously described (22), HT1080 cells 
expressed mainly LPA4, which correlates with its role in invadopodia formation in 
normoxia. Of interest, these cells displayed low levels of LPA1, despite the major use of 
this receptor in hypoxia (Fig 2C). To further investigate this issue, we examined whether 
modulation of LPA1 expression or activity could explain the main usage of this receptor in 
hypoxic HT1080 cells. Analysis of both mRNA and protein levels showed no significant 
increases in LPA1 expression under hypoxic conditions, despite a significant increase in 
mRNA expression of CAIX, a well-recognized hypoxia-regulated gene (Fig 2D,F,G). Since 
the G-protein regulatory kinase, GRK2, has been shown to be decreased in hypoxic brain 
cells resulting in LPA1 overactivation (23), we next examined whether GRK2 levels were 
modulated in hypoxic HT1080 cells. No significant changes in either mRNA or protein 
expression of GRK2 were observed in HT-1080 cells subjected to hypoxic conditions for 
up to 16 h (Fig 2E,G). Taken together, these results indicated that modulation of LPA1 or 
GRK2 expression did not account for LPA1 usage in hypoxic HT-1080 cells.  
 
LPA1 usage in hypoxic cells involves crosstalk with EGFR 
The GPCRs and LPARs are known to cross-communicate with RTKs to mediate additional 
signaling events and growth factor-like effects (24). Furthermore, hypoxia has been shown 
to increase the expression or activation of various RTKs (25), suggesting the possibility of 
RTK participation in LPA1-induced invadopodia formation in hypoxia. To address this 
possibility, we initially used a phospho-specific RTK antibody array that measures the  
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Figure 2 LPA1 and GRK2 expression is not modulated under hypoxic conditions. 
 (A-C) qPCR analysis of mRNA isolated from (A) MDA-MB-231, (B) U87, or (C) 
HT1080 cells. Graphs show relative expression of LPAR1, LPAR2, LPAR3 and LPAR4 
mRNA in copy number. RPLP0 was used to normalize the data (n = 3 independent 
experiments). (D-F) mRNA expression of (D) LPAR1, (E) GRK2, or (F) CAIX in HT1080 
cells cultured in the presence of 21% O2 or 1% O2 for 4 h, 8 h, or 16 h. RPLP0 was used to 
normalize the data (n = 4 independent experiments). (G) Protein levels of LPA1 and GRK2 
analyzed by Western blotting following incubation of HT1080 cells for 4 h, 8 h, or 16 h 
under hypoxia (1% O2). Tubulin was used as a loading control. One representative blot of 2 
independent experiments is shown. Bars represent the mean ± SEM. The asterisks (*) 
correspond to P < 0.05 (*) and, P < 0.01 (**). ns = not significant. 
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levels of activation of common RTKs and signaling nodes that include MetR, PDGFR, 
VEGFR, IGFR, EGFR and Akt. Results showed that EGFR was a main RTK activated 
under hypoxic conditions in HT1080, MDA-MB-231 and U87 cell lines (Fig 3A,B and 
Supplementary Fig 2A). Immunoprecipitation of EGFR followed by Western blotting using 
anti-phosphotyrosine antibodies revealed that hypoxia or LPA stimulation resulted in a 
rapid phosphorylation of EGFR with maximal effects observed after 1 h and 30 min of 
stimulation, respectively (Fig 3C). In addition, Ki16425 used at a concentration that 
preferentially inhibits LPA1, completely blocked hypoxia-induced EGFR phosphorylation 
(Fig 3D,E), while it had no effect on LPA-induced phosphorylation in normoxia 
(Supplementary Fig2 B), suggesting the participation of LPA1 solely under hypoxic 
conditions in HT1080 cells. Similar inhibition of hypoxia-induced EGFR phosphorylation 
by Ki16425 was observed in MDA-MB-231 and U87 cell lines (Supplementary Fig2 C,D), 
indicating that LPA1-EGFR crosstalk in hypoxic cells is not associated with a particular 
cell type.  
 
The involvement of EGFR in hypoxia-induced invadopodia production downstream of 
LPA1 was next investigated. EGFR knockdown in HT1080 cells was found to significantly 
block the increase in the percentage of cells forming invadopodia under hypoxic conditions 
whereas this procedure did not affect invadopodia induced by LPA under normoxic 
conditions (Fig 4A, Supplementary Fig3). Similar findings were observed in MDA-MB-
231 and U87 cells (Fig 4A). In contrast, in cells where LPA1 had been knocked down by 
shRNA treatment, inhibition of EGFR had no effect on invadopodia production whether 
cells were grown under normoxic or hypoxic conditions or were stimulated with LPA (Fig 
4B). Overall, these results suggested that EGFR was preferentially involved in the ability of 
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cells to produce invadopodia under hypoxic conditions and that this event occurred 
downstream of LPA1. 
 
Figure 3 EGFR is transactivated by LPA1 under hypoxic conditions. 
 (A-B) HT1080 cells were incubated under 21% O2 or 1% O2 for 30 or 60 min and cell 
lysates were subjected to phospho-RTK array analysis. (A) One representative array, 
showing phospho-EGFR and phospho-Akt, of two independent experiments is shown. (B) 
The associated graph shows the mean phosphoprotein fluorescence intensities for each cell 
lysate from two independent experiments. (C-E) HT1080 cell lysates were 
immunoprecipitated using an anti-EGFR antibody and immunoblotted with anti-phospho-
tyrosine (pY) and total EGFR antibodies. (C) One representative blot which shows a time 
course of LPA (10 µM) or hypoxic (1% O2) stimulations. (D) One representative blot 
showing hypoxic stimulation (30 min) in the presence/absence of Ki16425 (1 µM). (E) 
Corresponding graph showing densitometric analysis of p-Y/EGFR ratios of 3 independent 
experiments. Bars represent the mean ± SEM (* P< 0.05). The asterisk (*) corresponds to P 
< 0.05 (*). 
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Figure 4 EGFR is necessary for hypoxia-induced invadopodia formation downstream 
of LPA1. 
(A,B)  Cells were cultured on fluorescently-labeled gelatin for 10 h and the percentages of 
cells forming ECM-degrading invadopodia are shown. (A) HT-1080, MDA-MB-231 or 
U87  cells transduced with scramble or EGFR-targeting shRNA were incubated in 21% O2 
in the presence/absence of LPA (10 µM) or in 1% O2. (B) Cells transfected with scramble 
or LPA1-targeting shRNA were incubated in 21% O2, 1% O2 or 1% O2 in the presence of 
LPA (10 µM) with or without the addition of the EGFR inhibitor AG1478. Bars represent 
the mean ± SEM. The asterisks (*) correspond to P < 0.05 (*), P < 0.01 (**) and, P < 0.001 
(***).  
 
Src is a mediator of LPA1-EGFR crosstalk  
Transactivation of RTKs mediated by GPCRs can involve different mechanisms that 
include increased ligand availability, through protease-mediated shedding of the ligands, or 
direct phosphorylation of the RTK by a downstream kinase (26). To address the first 
possibility, we investigated whether hypoxic HT1080 cells showed increased release of the 
major EGFR ligands involved in GPCR-RTK crosstalk, EGF, HB-EGF and TGF-alpha. 
Results from ELISA assays showed the absence of increases in the release of EGF, HB-
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EGF or TGF-alpha under hypoxic conditions (Fig 5A). Furthermore, shRNA-mediated 
knockdown of ADAM17 or ADAM12, two major proteases involved in the shedding of 
EGFR ligands, did not affect hypoxia-induced EGFR phosphorylation (Fig 5B-D). These 
results indicate that increased ligand availability is unlikely to be the mechanism 
responsible for the rapid increase in EGFR phosphorylation under hypoxia.  
 
Since one of the main kinases known to be involved in phosphorylation-induced 
transactivation of EGFR is Src (26), we next examined the contribution of this kinase to the 
hypoxia-induced LPA1-phosphoEGFR axis. Western blot results showed a clear increase in 
Src Y416 phosphorylation after 45 min of exposure to hypoxia and that upregulated Src 
phosphorylation was reduced to basal levels following inhibition of LPA1 (Fig 5F,G). 
Similarly, shRNA-mediated knockdown of Src, or inhibition of its activity by PP2 strongly 
repressed EGFR phosphorylation induced by hypoxia (Fig 5B,E; Supp Fig 4). These 
findings clearly indicate that Src-mediated phosphorylation of EGFR is the likely 
mechanism of EGFR transactivation by LPA1 in hypoxic cells. 
 
To gain insight into the significance of the Src-mediated EGFR transactivation mechanism 
in the ability of cells to form ECM-degrading invadopodia under hypoxic conditions, Src 
shRNA-transduced cells were tested in invadopodia assays. Cells with Src knockdown 
failed to affect the increase in the percentage of invadopodia forming cells induced by LPA 
under normoxic conditions, which is consistent with our previous results that had identified 
an alternative mechanism downstream of LPA4 (11). In contrast, Src knockdown resulted in 
inhibition in the percentage of hypoxia-induced invadopodia producing cells, in agreement 
with its involvement in EGFR transactivation. As a control, knockdown of ADAM17- or 
 
 
59 
59 
ADAM12 did not affect invadopodia production under hypoxia (Fig 5H), consistent with 
their observed lack of involvement in EGFR phosphorylation (Fig 5B). 
 
 
 
 
Figure 5 Mechanism of transactivation of EGFR by LPA1 under hypoxia. 
 
(A) Detection of HB-EGF, TGFα, and EGF by ELISA was performed on concentrated cell 
supernatants from HT1080 cells incubated for 8 h in the presence of 21% O2 or 1% O2. 
Results are presented in pg/ml (n = 3). ND = non-detectable. (B) Western blot of phospho-
Y845 EGFR and total EGFR in HT1080 cells transduced with scramble, ADAM17, 
ADAM12, or Src-targeted shRNA and incubated under 21% O2 or 1% O2 for 30 min. 
Densitometric analysis of phospho-Y845/EGFR ratio is shown below the blots. One 
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representative blot of 3 independent experiments is shown. (C-E) Quantification of (C) 
ADAM17. (D) ADAM12 and (E) SRC mRNA levels by qPCR using RPLP0 as a reference 
gene (n = 3). (F) HT1080 cell lysates were analyzed by Western blotting using anti-
phospho-Src and Src antibodies. Densitometric analysis of phospho-Src/Src ratio is shown 
below the blots. One representative blot of a time-course of hypoxic (1% O2) stimulations 
is shown. (G) HT1080 cells were incubated for 45 min in 1% O2 with or without Ki16425 
(1 µM). One representative blot is shown. (H) HT1080 cells transfected with scramble, 
ADAM17, ADAM12, or SRC shRNA were cultured on fluorescently-labeled gelatin for 10 
h in 21% O2 or 1% O2 in the presence or absence of LPA (10 µM). The percentage of cells 
forming ECM-degrading invadopodia is shown (n = 3). Bars represent the mean ± SEM. 
The asterisks (*) correspond to P < 0.05 (*) and, P < 0.01 (**) and, P < 0.001 (***).  
 
LPA1-EGFR axis signals through PI3K/Akt to promote hypoxia-induced invadopodia 
production 
We next investigated the involvement of the main LPA1 and EGFR downstream 
signaling pathways in hypoxia-induced invadopodia production using pharmacological 
inhibitors of ROCK (Y-27632), PLC (U-73122), MEK (PD 98059) or PI3K (LY294002). 
Inhibition of Rap1 (GGTI-298), which has previously been reported to be downstream of 
LPA4 for invadopodia production (11), was used as a control. Among the pathways tested, 
only inhibition of MEK or Rap1 signaling significantly decreased the percentage of cells 
forming invadopodia induced by LPA in normoxia or induced by hypoxia. In contrast, 
PI3K inhibition exclusively decreased invadopodia production induced by hypoxia (Fig 
6A). Increasing the concentration of the PI3K inhibitor did not affect LPA-stimulated 
invadopodia-forming cells in normoxia, but efficiently blocked the stimulatory effect of 
hypoxia alone or in the presence of LPA (Fig 6B). As expected, Rap1 inhibition reduced 
the percentage of cells forming invadopodia under both normoxic and hypoxic conditions 
(Fig 6C). Given that cells mostly used LPA1 in hypoxia (Fig 1C), these results suggest that 
HT-1080 cells use PI3K signaling downstream of the LPA1-EGFR axis for invadopodia 
production only under hypoxic conditions. To support this interpretation, we compared the 
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effect of PI3K inhibition in LPA1- or LPA4-knockdown HT1080 cells. Results showed that 
inhibition of the PI3K pathway in hypoxic LPA1-knockdown cells did not affect 
invadopodia production whereas Rap1 inhibition resulted in a strong inhibitory effect (Fig 
6D). Conversely, in LPA4-knockdown cells, PI3K inhibition decreased invadopodia 
production whereas Rap1 had no effect (Fig 6E), which is in line with our previously 
published results (11).  These findings clearly indicate that invadopodia production in 
hypoxic cells requires PI3K signaling downstream LPA1.  
 
A major effector downstream of PI3K, Akt, has been reported to be implicated in 
invadopodia generation as well as production of several matrix metalloproteases important 
for their ability to degrade the extracellular matrix (27,28). To confirm activation of the 
PI3K/Akt pathway under hypoxic conditions, Akt phosphorylation was assessed by 
Western blotting. Results showed that Akt was phosphorylated in response to LPA after 30 
min, whereas a sustained phosphorylation from 1 h up to 6 h was observed following 
hypoxic stimulation  (Fig 6F,G). Furthermore, addition of the LPA1 inhibitor Ki16425 or 
the EGFR inhibitor AG1478 resulted in a reduction of Akt phosphorylation induced by 1 h 
or 6 h of hypoxic stimulation (Fig 6 H,I).  These results suggest that PI3K/Akt activation 
under hypoxia is mediated by LPA1-induced transactivation of EGFR, an event that 
promotes invadopodia production.  
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Figure 6 LPA1 signals through PI3K/AKT to promote hypoxia induced invasion, an 
effect mediated by transactivation of EGFR. 
(A-C) HT1080 cells were cultured on fluorescently-labeled gelatin for 10 h under 21% O2 
or 1% O2 with or without addition of LPA (10 µM) and the following inhibitors of, (A) 
ROCK (Y-27632 2 µM), PLC (U-73122 0.5 µM), MEK (PD 98059 2 µM), Rap1 (GGTI-
298 6 µM) or PI3K (LY294002 0.5 µM) or (B) a dose-response of the cells treated with 
LY294002 or (C) GGTI-298. The percentage of cells forming ECM-degrading invadopodia 
is shown (n ≥ 3 independent experiments). (D-E) GGTI-298 (6 µM) or LY294002 (1 µM) 
were added to cells expressing (D) LPA1-directed shRNA or (E) LPA4-directed shRNA and 
incubated in 1% O2 in the presence of LPA (10 µM), or in 21% O2. The percentage of cells 
forming ECM-degrading invadopodia is shown (n = 4). (F-G) Western blots of cell lysates 
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from HT1080 cells incubated with (F) LPA (10 µM) or in (G) 1% O2 for 0 to 6 h. 
Representative blots of phospho-Akt (p-Akt) and total Akt are shown. (H-I) Western blots 
of p-Akt and total Akt in HT1080 cells incubated under 21% O2 or 1% O2 with addition of 
Ki16425 (1 µM) or AG1478 (2 µM) for (H) 1 h or (I) 6 h. Blots are representative of 3 
independent experiments. Results of densitometric analysis of p-Akt/Akt ratios are shown 
below the blots. Bars represent the mean ± SEM. The asterisks (*) correspond to P < 0.05 
(*), P < 0.01 (**) and, P < 0.001 (***). 
 
A combined inhibition of LPA1 and EGFR reduces metastasis in an in vivo avian 
model  
To assess whether our observations that hypoxia promoted cell invasion through crosstalk 
between LPA1 and EGFR were relevant to cancer metastasis therapy in vivo, we used an ex 
ovo chorioallantoic membrane (CAM) xenograft model in chicken embryos (29). Since 
HT1080 tumors grown in the CAM assay had been previously shown to develop hypoxia 
(17), the CAM model allows us to evaluate the effects of LPAR and EGFR receptor 
inhibition on spontaneous metastasis arising from tumors containing hypoxic areas. First, 
CAM bearing HT1080 tumors (grown for 6 days) were injected with pimonidazole. After  
30 min, the tumors were excised and we determined the presence of phospho-Y845-EGFR 
within hypoxic zones of the tumors. Results showed a significant increase in phospho-
Y845-EGFR staining within pimonidazole-positive regions of the tumors (Fig7A). This 
finding was consistent with increased EGFR phosphorylation that was observed in hypoxic 
cells (Fig 3A-C).  Next, we analyzed the effect of targeting LPA1 alone or in combination 
with EGFR inhibition using the EGFR inhibitor (AG1478) and/or AM095, a potent and 
selective LPA1 inhibitor used for in vivo studies (30). HT1080 cells, in the presence of 
increasing concentrations of AM095 or AG1478, were inoculated in 9-day-old CAMs. A 
time period of 6 days was allowed for tumors to develop, livers were then removed and 
spontaneous metastasis (primate Alu repeats by qPCR) was measured (18). Results showed 
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a dose-dependent decrease in the numbers of metastatic cells found in chick embryo livers 
with maximal effects observed at a concentration of 10 µM of AM095 and 10 µM of 
AG1478 (Fig 7B,C). To define whether these inhibitors can provide therapeutic gain when 
combined, tumors were treated with suboptimal concentrations of AM095 (0.2 µM) and 
AG1478 (0.2 µM). A synergistic effect on metastasis was observed with a combined 
inhibition of EGFR and LPA1 (Fig 7D). We next analyzed the levels of phospho-EGFR in 
hypoxic zones of tumors treated with the above inhibitors.  Maximum EGFR inhibition 
drastically decreased EGFR phosphorylation, as expected.  Similarly the maximum dose of 
AM095 decreased p-EGFR, confirming its role in suppressing hypoxia-induced EGFR 
phosphorylation as observed in in vitro assays (Fig7E).  Finally, suboptimal concentrations 
of both inhibitors induced a strong reduction of EGFR phosphorylate in hypoxic zones of 
tumors, similar to the diminution observed with the highest concentration of EGFR 
inhibitor (Fig 7 F-G) 
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Figure 7 LPA1 and EGFR are implicated in spontaneous metastasis in a 
chorioallantoic membrane. 
(A) Representative immunohistochemistry images of HT1080 xenograft tumors showing 
hypoxic regions (Pimonidazole (Pimo); green) and phospho-EGFR (red) staining. Nuclei 
were stained with DAPI (blue). Scale bars correspond to 100 µm. The associated graph 
shows phospho-EGFR relative labeling intensities in Pimo+ and Pimo-zones of tumors. (B-
G) HT1080 cells (3 x 105) were inoculated in the presence/absence of the LPA1 inhibitor 
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AM095 or the EGFR inhibitor AG1478, to the CAM of chick embryos. Embryonic livers 
were harvested after 6 d of tumor growth for genomic DNA extraction and tumors were 
processed for immunohistochemistry. The ability of HT1080 cells to disseminate in 
embryonic livers was quantitated as the relative amount of metastasis normalized to the 
amount of host DNA. Dose response to, (B) AG1478, (C) AM095 and, (D) a combined 
treatment with AM095 (0.2 µM) and Ag1478 (0.2 µM). (E,F) Relative labeling intensities 
of phospho-EGFR in hypoxic (pimo+) zones of tumors treated with (E) AM095 (10 µM) or 
AG1478 (10 µM) or, (F) a combined treatment with AM095 (0.2 µM) and Ag1478 (0.2 
µM). (G) Representative immunohistochemistry images of HT1080 xenograft tumors 
showing phospho-EGFR staining in hypoxic (Pimo+) zone of tumors treated with AM095 
(0.2 µM) and Ag1478 (0.2 µM). Hypoxic regions (Pimonidazole (Pimo); green) and 
phospho-EGFR (red) staining. Nuclei were stained with DAPI (blue). Scale bars 
correspond to 50 µm. Bars represent the mean ± SEM. The asterisks (*) correspond to P < 
0.05 (*), P < 0.01 (**) and, P < 0.001 (***). 
 
DISCUSSION 
In this study, we uncovered an essential role for LPA1 in hypoxia-induced 
invadopodia production and that this event was dependent on Src-mediated cross-
communication with EGFR. Furthermore, we found that hypoxic cells use PI3K/AKT 
signaling downstream of the LPA1-EGFR axis as a dominant invadopodia-inducing 
signaling node. Tumor xenograft experiments further support the requirement of LPA1 and 
EGFR for in vivo metastasis, and suggest that targeting both receptors could be an effective 
strategy to improve metastasis. 
Hypoxia, a prevalent feature of the tumor microenvironment, is a potent inducer of 
cancer cell aggressiveness, invasion and metastasis. However, the nature of the 
mechanisms involved in these processes remains to be fully understood (3). Although there 
have been a few clues that hypoxia and LPA signaling are intertwined (23,31,32), the 
observations reported here are, to the best of our knowledge, the first study that identifies 
LPA1 as the main receptor involved in invadopodia production triggered by the hypoxic 
microenvironment. The ability to establish the role of a particular LPAR is of importance 
since these receptors can have redundant or opposing effects on cell motility and cell 
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invasion. These cellular properties are cell-type and context-dependent, suggesting that the 
therapeutic use of pan-LPAR antagonists ought to be considered with caution. For example, 
both LPA1 and LPA3 can be positive or negative regulators of cell motility and invasion, 
depending on the cell type involved (19). The LPA receptor LPA4 has also been shown to 
inhibit cell motility and invasion in mouse embryonic fibroblasts while promoting invasion 
and metastasis in human fibrosarcoma cells (11,33). Our findings of the common use of 
LPA1 in a predominant tumor microenvironment highlight the potential benefit of LPA1-
directed therapy to fight cancer metastasis and progression. 
A discrepancy between LPA receptor gene expression levels and usage led us to 
investigate the influence of hypoxia on LPA1 expression and activity. Long-term exposure 
to hypoxia has been shown to increase LPA1 expression in retinal ganglion cells (23), and 
to induce overactivation of LPA1 in fetal brain through downregulation of the G-protein 
regulatory kinase GRK2 (34). To our surprise, exposure of the cells to hypoxia for an 
extended period of time (16 h) did not modulate mRNA or protein expression of LPA1 or 
GRK2. These findings prompted us to explore alternatives for the common use of LPA1 
under hypoxia. We found that the RTK, EGFR, was transactivated by LPA1 leading to 
invadopodia production solely under hypoxia (as compared to normoxia) suggesting that 
receptor crosstalk is a mechanism by which LPA1 promotes invadopodia in this condition.  
LPA1-mediated transactivation of EGFR is in concordance with previous studies 
that identified both ligand-dependent and ligand-independent mechanisms of LPA-induced 
transactivation, depending on cell type and physiological context (35). Under hypoxic 
conditions, we found a ligand-independent mechanism of EGFR transactivation that 
involved Src kinase-mediated phosphorylation of tyrosine-845 (Y845) on EGFR. 
Phosphorylation of this tyrosine residue has been associated with survival, proliferation and 
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malignancy of various cancer cells, including glioma and breast cancer cells, as well as 
being a highly predictive value for prognosis correlating with worse prognosis and poor 
response to chemotherapy (36). In addition, colocalization of p-EGFR and hypoxic markers 
in human tumor biopsies was associated with a critical subpopulation prone to local 
recurrence, metastasis formation or treatment resistance (37). The finding that Y845-EGFR 
is phosphorylated in response to LPA1 activation under hypoxia in vitro and localized in 
hypoxic zones of tumors suggests the possibility that this could be used, in conjuncture 
with hypoxic markers, as predictive tools of the clinical outcome of LPA1- and EGFR-
directed therapy.  
We also uncovered PI3K/Akt signaling as an effector of LPA1 and EGFR crosstalk 
that lead to invadopodia production in hypoxia. Acting through Akt, PI3K has previously 
been implicated in the regulation of invadopodia formation, as well as their ability to 
degrade the extracellular matrix (27). Although our findings showed that PI3K/Akt 
signaling was only involved in hypoxia-induced invadopodia production, we also observed 
phosphorylation of Akt in response to LPA under normoxic conditions. This apparent 
discrepancy may be partly explained by the fact that Akt phosphorylation in normoxic cells 
was transient with a peak effect reached after 30 min of LPA stimulation. In contrast, we 
observed a sustained activation (up to 6 h) in response to hypoxia. Although few 
publications have directly compared the effects of acute versus sustained Akt 
phosphorylation, Goel et al. found differential effects on G1 progression, suggesting 
distinct consequences on biological responses (38). Furthermore, sustained Akt 
phosphorylation has been associated with enhanced tumor survival as well as increased 
cytoskeletal rearrangement and migration (39,40), suggesting that under hypoxic 
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conditions, this event also plays a role in invadopodia formation, as these structures require 
actin remodeling (5). 
The effect of hypoxia on Src-mediated EGFR-LPA1 crosstalk and sustained Akt 
phosphorylation may be due to relocalization of both receptors and Src in specific 
subcellular domains such as lipid rafts, thus facilitating their interactions. Hypoxia has been 
reported to rapidly increase cellular cholesterol levels, thereby influencing the composition, 
number and size of lipid rafts (41). Lipid rafts function as organizing centers for the 
assembly of signaling molecules, their increased rigidity optimizes spatiotemporal 
interactions and compartmentalizes proteins involved in specific signaling tasks (42,43). 
Interestingly, both RTKs and GPCRs can localize to lipid rafts, which provide a platform 
that facilitates interactions between EGFR and GPCRs, therefore enhancing the efficiency 
of transactivation (44). Lipid rafts have also been identified as key plasma membrane 
microdomains for Src-EGFR functional interactions as well as PI3K/Akt activation (42,45). 
It is therefore conceivable that, under hypoxic conditions, the recruitment of LPA1, Src, and 
EGFR in lipid rafts facilitates their interactions and that results in prolonged Akt activation 
and invadopodia formation. This possibility is in keeping with the finding that lipid rafts 
and caveolin-1 are required for invadopodia production in breast cancer cells (46). 
A combination of suboptimal doses of inhibitors revealed a synergistic effect 
between LPA1 and EGFR inhibitors in blocking metastasis. Combination therapy using 
lower doses of inhibitors are of clear clinical interest in order to overcome toxicity and 
resistance, two major issues associated with the use of RTK-targeted therapies (47). It has 
been suggested that resistance to RTK inhibitors is linked to activation or crosstalk with 
receptors that could include IGF-1R, c-MET, and LPARs (EDGRs) (48). More specifically, 
blocking LPA1/3 receptors with Ki16425 has been shown to prevent and delay resistance to 
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the RTK inhibitor Sunitinib® in vivo (49), whereas inhibiting Src or Y845EGFR 
phosphorylation reverses resistance to anti-EGFR monoclonal antibodies (50). These 
results suggest that blocking LPA1-induced transactivation of EGFR could also overcome 
resistance to EGFR inhibitors. In addition, EGF has been shown to increase LPA 
production, suggesting there can be bidirectional crosstalk between LPA and EGF receptors 
(51). Pre-clinical studies that combine the therapeutic potential of LPA1 and EGFR in 
various types of solid tumors should therefore be a valuable research direction.  
In conclusion, our study provides insight into a mechanism of hypoxia-induced cell 
invasion, which implies a major role for LPA1 in activating two major players in 
tumorigenesis: Src and EGFR. Targeting LPA1, alone or in combination with EGFR 
inhibitors, could benefit cancer patients by blocking upstream inducers of invadopodia, a 
key component of the metastatic process. Since metastasis remains the most deadly aspect 
of cancer, efficient interference with this process is of the utmost importance to increase 
cancer patient well-being and survival.  
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Supplementary Materials & Methods 
Real-time RT-PCR. The following primer pairs were selected for LPA1: (forward) 5’-
AATCGAGAGGCACATTACCGG-3’, (reverse) 5’-TGTGGACAGCACACGTCTAG-3’; 
LPA2: (forward) 5’-CATCATGCTTCCCGAGAACG-3’, (reverse) 5’-
GGGCTTACCAAGGATACGCAG-3’, LPA3: (forward) 5’-
TCGCGGCAGTGATCAAAAACAGA-3’, (reverse) 5’-
ATGGCCCAGACAAGCAAAATGAGC-3’;  LPA4: (forward) 5’-
AAAGATCATGTACCCAATCACCTT-3’, (reverse) 5’-
CTTAACAGGGACTCCATTCTGAT-3’; EGFR: (forward) 5’-
CAAGGAAGCCAAGCCAAATG-3’ , (reverse) 5’-CCGTGGTCATGCTCCAATAA-3’ ; 
Src: (forward) 5’-GCTTGTGGGTGATGTTTGAC-3’, (reverse) 5’-
CTGGACTCTTGGCTCTTCTATG-3’ ; ADAM17: (forward) 5’-
CGTGGTGGTGGATGGTAAA-3’ , (reverse) 5’-ATGTGGGCTAGAACCCTAGA-3’ ; 
ADAM12: (forward) 5’-TCTGGACTGGAGGAAGATGAA-3’ , (reverse) 5’-
GATGGTGGTCCCTTGGAAATAA-3’ ; CAIX: (forward) 5’-
CCTCAAGAACCCCAGAATAATGC-3’, (reverse) 5’-CCTCCATAGCGCCAATGACT-
3’; GRK2: (forward) 5’-CTTCCAGCCATACATCGAAGAG-3’, (reverse) 5’-
CCGTGTGAACTTATCGCTCTC-3’;  and housekeeping gene RPLPO: (forward)  5’-
GATTACACCTTCCCACTTGC-3’, (reverse) 5’-CCAAATCCCATATCCTCGTCCG-3’. 
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Supplementary Figures  
 
 
Supplementary Figure 1. qPCR assessment of LPA receptor shRNA-mediated  
knockdown 
MDA-MB-231, U87, or HT1080 cells were transfected with scramble, LPA1 or LPA4 
targeted shRNAs. mRNA levels of (A) LPAR4 or (B) LPAR1 were quantified by qPCR. 
RPLP0 was used as a reference gene (n = 3). Bars represent the mean ± SEM. The asterisks 
(*) correspond to P < 0.01 (**) and, P < 0.001 (***). 
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Supplementary Figure 2. EGFR is transactivated by LPA1 under hypoxic conditions. 
(A) MDA-MB-231 or U87 cells were incubated under 21% O2 or 1% O2 for 30 or 60 min 
and cell lysates were subjected to phospho-RTK array analysis. (A) One representative 
array showing phospho-EGFR is shown with results from densitometric analysis (in fold) 
shown beside the array. (B-D) HT1080, MDA-MB-231 or U87 cell lysates were 
immunoprecipitated using an anti-EGFR antibody and immunoblotted with anti-phospho-
tyrosine (pY) and total EGFR antibodies.  Densitometric analysis of p-EGFR/EGFR ratio 
are shown below the blots.  (B) One representative blot showing LPA (10 µM) stimulation 
in 21% O2 in the presence/absence of Ki16425 (1 µM) in HT1080 cells.  (D-E) One 
representative blot showing hypoxic stimulation (30 min) in the presence/absence of 
Ki16425 (1 µM) in MDA-MB-231 (C) and U87 (D) cells.  
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Supplementary Figure 3. qPCR assessment of shRNA-mediated knockdown of EGFR.  
HT1080 cells were transduced with scramble or EGFR-targeted shRNA mRNA levels of 
EGFR were quantified by qPCR using RPLP0 as a reference gene (n = 3). Bars represent 
the mean ± SEM. The asterisk (**) corresponds to P < 0.01. 
 
 
 
 
Supplementary Figure 4. Src inhibition blocks EGFR phosphorylation in hypoxia. 
Representative immunoblot of HT1080 incubated in 21% O2 or 1% O2 in the presence or 
absence of the Src inhibitor, PP2. Cell lysates were immunoprecipitated using an anti-
EGFR antibody and immunoblotted with anti-phosphotyrosine (pY) and EGFR antibodies. 
Densitometric analysis of p-EGFR/EGFR ratio are shown below the blots. 
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3. CHAPTER 2: HYPOXIA PROMOTES INVASION THROUGH 
REGULATION OF LPA SYNTHESIS AND DEGRADATION ENZYMES 
 
Article 1 presented in this thesis demonstrated that under hypoxia cancer cells rely on LPA1 
signaling for the production of invadopodia and metastasis.  In the Article we uncovered a 
signaling pathway that included transactivation of EGFR by LPA1 exclusively under 
hypoxia, however exactly why this occurs solely in hypoxic cells remains to be determined.  
Signaling by LPA is known to be affected by the amount of LPA available to interact with 
receptors.  Therefore in chapter 2 of this thesis, our goal was to gain a more complete 
understanding of the regulation of LPA signaling by hypoxia in cancer cells by studying the 
effects of hypoxia on the enzymes involved in controlling LPA levels that could modulate 
LPAR signaling. LPA production is mainly regulated by ATX, which promotes tumor 
progression and whose expression is upregulated in various cancers. In contrast, important 
LPA degrading enzymes, the LPPs, are downregulated in cancer cells and play a negative 
role in tumor progression. Yet, the factors involved in shaping the differential expression of 
these LPA regulatory components remain unknown. In the following chapter we first 
investigated the influence of hypoxia on ATX and LPP mRNA and protein expression in 
various cancer cell lines. We further determined their involvement in hypoxia-induced 
invadopodia production using invadopodia assays and shRNA targeting ATX or LPP1/2/3.  
Finally we studied the localization of these LPA-producing and -degrading enzymes in 
hypoxic cells by confocal microscopy. 
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3.1 MATERIALS and METHODS 
3.1.1 Reagents  
1-oleoyl-sn-glycerol-3-phosphate 18:1 (LPA) sodium salt and 1-oleoyl-sn-glycero-3-
phosphocholine 18:1 (LPC) were from Sigma-Aldrich (St. Louis, MO). Plasmid ATX 
cDNA construct was a kind gift from Dr. Tim Clair (Center for Cancer Research, NCI, 
NIH). shRNA against ATX or scramble (ctr) shRNA was from SABiosciences (Frederick, 
MD). Mission lentiviral shRNA targeting LPP1 (TRCN0000010720 and 
TRCN0000002579), LPP2 (TRCN0000002583 and TRCN0000002584), LPP3 
(TRCN0000358710 and TRCN0000358709), or a scramble sequence, were from Sigma-
Aldrich. ATX, LPP1 and LPP3 antibodies were from Abcam (Cambridge, MA). The anti-
tubulin antibody was from Sigma-Aldrich. Texas Red phalloidin, DAPI (4’,6-diamidino-2-
phenylindole), the lipophilic tracer DiD, and all secondary antibodies were from Invitrogen 
(Molecular Probes, Eugene, OR). Fibrillar collagen type I was from R&D Systems 
(Minneapolis, MN). 
3.1.2 Cell culture and transfection 
HT1080 human fibrosarcoma, U87 human glioblastoma, and MDA-MB231 human breast 
cancer cell lines were cultured as described in article 1. In the case of stable transfections, 
with ATX, pcDNA3.1 or shRNA against ATX or scramble sequence, cells were seeded at a 
density of 1 x 105 cells per well in a 6-well culture plate the day before the transfection.  
Transfections were performed with the Fugene reagent from Roche Diagnostics 
(Mannheim, Germany), according to the manufacturer’s protocol.  Stable transfectants were 
obtained by antibiotic selection, G418 600µg/ml (Gibco) for ATX and pcDNA3.1 
transfections and Puromycin 2µg/ml (Invivogen, San Diego, CA) for all shRNA 
transfections. For lentiviral transductions, with LPP1, LPP2, LPP3 or scramble shRNA 
cells were seeded at a density of 3 x 105 cells per 10 cm2 Petri dish and infected with 1 ml 
of viral stock in 2 ml of optiMEM supplemented with 2 µl Polybrene (10 mg/ml) (EMD 
Millipore, Etobicoke, ON). Viral particles were generated by transient transfection of 293T 
cells using a ViraPower lentiviral expression system (Invitrogen Thermo Fisher Scientific, 
Burlington, ON). 
 
 
83 
83 
3.1.3 Real time RT-PCR 
Total RNA was isolated using the TRIzol (Invitrogen, Carlsbad, CA) protocol as previously 
described (Harper et al., 2010) and 1ug of RNA was reverse transcribed to complementary 
DNA (cDNA) using a QuantiTect reverse transcription kit (Qiagen, Mississauga, ON).  
cDNA was then analyzed by real time PCR using a hot start SYBR Green qPCR master 
mix (BiMake, Houston, TX).  The following primer pairs were selected for:  
CAIX: (forward) 5’-CCTCAAGAACCCCAGAATAATGC-3’, 
(reverse) 5’-CCTCCATAGCGCCAATGACT-3’; ATX: (forward)  
5’-TGAAACAGCACCTTCCCAAA-3’, (reverse) 5’-CCAAAGGTTTCCTTGCAACA-3’; 
LPP1: (forward) 5’-GTCGAGGGAATGCAGAAAGA-3’, (reverse)  
5’- CCTTCATCCTGGCTTGAAGATA-3’;  
LPP2: (foward) 5’- CCTACCGTCCAGATACCATCA-3’,  
(reverse) 5’- GTTGAAGTCCGAGCGAGAATAG-3’;  
LPP3: (forward) 5’- CAAATCAGAAGGAGCCAGAGAA-3’,  
(reverse) 5’- CAGCAAGAGCAACTCCTACAA-3’; and housekeeping gene RPLP0: 
(forward)  5’-GATTACACCTTCCCACTTGC-3’, (reverse)  
5’-CCAAATCCCATATCCTCGTCCG-3’. Quantitative Real-Time PCR was performed on 
a Rotor-Gene 3000 (Corbett Research, Kirkland, QC, Canada).  The cycling program was 
as follows:  initial denaturation at 95ºC for 15 min, 35 amplification cycles with annealing 
Tº of 59ºC for 30 s and final extension at 72ºC for 30 s. Results were calculated as 2ΔΔCT. 
3.1.4 Western blotting  
Western blotting was performed as described in article 1. 
3.1.5 Invadopodia assay 
Coverslips were prepared as previously described (Harper et al., 2010), using Oregon-
Green488-conjugated gelatin (Invitrogen, ON).  Thirty thousand cells were seeded on each 
coverslip and allowed to adhere.   Following various incubation times as described within 
the figure legends, cells were fixed with 2% paraformaldehyde for 10 min at room 
temperature. Nuclei were stained with DAPI and F-actin was stained using Texas-Red-
conjugated phalloidin. Cells were visualized by fluorescence microscopy using a Zeiss 
Axioskop fluorescence microscope. Cells forming ECM-degrading invadopodia were 
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identified based on cells with at least one F-actin-enriched area of matrix degradation 
(characterized by loss of green fluorescence). Three fields of 100 cells (magnification 40X) 
were counted per coverslip to quantify the percentage of cells forming ECM-degrading 
invadopodia. To quantify the areas of degradation, pictures of fluorescent gelatin were 
acquired and captured into ImagePro imaging software (MediaCybernetics) and 
degradation areas were calculated in pixels for a total of at least 20 cells per coverslip. 
3.1.6 Immunofluorescence 
Cells were grown on non-fluorescent gelatin coated coverslips and fixed with 2% 
paraformaldehyde in PBS for 10 min at room temperature. Where indicated cells were 
permeabilized with 0.05% saponine (Sigma-Aldrich) in PBS for 20 min and blocked with 
2% BSA in PBS for 30 min.  Then, cells were incubated with the appropriate primary 
antibodies, for 2h, and secondary antibodies, for 1h or fluorescent phalloidin, for 45 min, as 
indicated within the Figure Legends.  Images were taken with a FV1000 scanning confocal 
microscope (Olympus, Tokyo, Japan) coupled to an inverted microscope using a 63x oil 
immersion objective. For calculation of the number of invadopodia per cell, cells were 
incubated with anti-cortactin antibody and Texas Red phalloidin.  Colocalization of actin 
and cortactin was visualized using an Axioskop 2 phase-contrast/epifluorescence 
microscope and 20 cells were counted per condition (Carl Zeiss, Inc., Thornwood, NY).  
3.1.7 3D invasion assay  
Collagen type I 3D matrix was prepared as follows: Aliquots (50 µL) of Agarose 
containing 10% FBS were deposited in a 96 well culture plate.  Aliquots (50 µL) of fibrillar 
collagen type I (R&D Systems, Minneapolis, MN) were then prepared following 
manufacturer’s instructions and layered on top of the Agarose.  Cells (2x104/100µl in 
serum-free MEM) were deposited on top of the collagen gel and incubated for 24 h.  The 
cells were then labeled with CellTraceTM calcein green AM (Invitrogen) 1h prior to the 
end of incubation. Cells were then washed with PBS and fixed with 3% glutaraldehyde for 
30 minutes followed by confocal microscopy analysis using a FV1000 Olympus confocal 
microscope.  Collagen matrix pellets were scanned along the Z-axis.  Cells that had invaded 
the collagen were imaged and quantitated at each 5µm layer within the gel. 
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3.2 RESULTS 
3.2.1 Hypoxia induces ATX and represses LPP expression 
Previously, we established that hypoxic cells use LPA1 signaling to promote invadopodia 
production and metastasis.  HT1080 cells, in particular, were found to use the LPA1-Src-
EGFR signaling path for invasion only under hypoxic conditions (see Article1). To gain a 
more complete understanding of the LPA signaling axis under hypoxia, we investigated 
whether hypoxia also has an effect on enzymes controlling LPA levels that could modulate 
LPAR signaling. As previous work from our laboratory has shown that both hypoxia and 
ATX can increase invadopodia production (Harper et al., 2010; Lucien et al., 2011), and 
ATX was found overexpressed in many cancer cell lines (Kehlen et al., 2004; Kishi et al., 
2006; Yang et al., 2002, 1999), we investigated whether hypoxia could modulate ATX 
expression levels to drive invadopodia production. To address this question, we first 
investigated the hypoxic regulation of the LPA producing enzyme, ATX in three diverse 
cancer cell lines, HT1080 fibrosarcoma, U87 glioblastoma, and MDA-MB231 breast 
cancer.  A significant increase in ATX (ENPP2) mRNA expression was observed following 
8 or 16 hours of hypoxic stimulation in HT1080 cells.  This was correlated with an increase 
in ATX protein levels at 16 hours (Fig 1 A-B).  In the other cell lines tested, preliminary 
results indicated no significant modulation in ATX expression (Fig 1 C-D).  
 
LPA degrading enzymes also play an important role in controlling LPA levels. Lipid 
phosphate phosphatases (LPPs), which are major LPA-degrading enzymes, have been 
found downregulated in various cancers (Tang et al., 2015).  Therefore, we investigated 
whether hypoxia is a contributing factor to the decreased expression of LPPs observed in 
tumor cells. A small but significant inhibition of LPP1 (PLPP1) expression upon hypoxic 
stimulation was observed in the U87 and MDA-MB231 cell lines at 4h or 16h with no 
significant modulation in HT1080 at all time points tested (Fig 2 A-C).  In contrast, LPP2 
mRNA expression was not significantly inhibited in any of the cell lines tested, but rather 
had a tendency to be increased in hypoxic conditions, particularly in HT1080 and MDA-
MB231 cells (Fig 2 D-F). Interestingly, hypoxia had a more pronounced effect on LPP3, 
significantly decreasing the mRNA expression levels of LPP3 by up to 40%, in all cell lines 
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tested (Fig 2 G-I).  Together these results demonstrate that hypoxia increases the expression 
of the LPA-producing enzyme ATX and decreases the expression of LPA degrading 
enzymes LPP1 and LPP3, two events that could potentially lead to higher overall levels of 
LPA.  
  
 
Figure 1 ATX expression is modulated in hypoxia 
(A, B) HT0180 cells were incubated under normoxic (21%O2) or hypoxic (1%O2) 
conditions. (A) mRNA expression of ENPP2 (Autotaxin) was evaluated by qPCR 
following 4, 8, or 16 hours of stimulation. RPLPO was used to normalize the data. N=5 (B) 
ATX protein levels were analyzed by western blotting after 16 hours of stimulation, with 
alpha-tubulin as a loading control. One representative blot is shown. (C-D) Cells were 
incubated under normoxic (21%O2) or hypoxic (1%O2) conditions for 4, 8 or 16 hours.  
mRNA expression of ENPP2 (Autotaxin) was evaluated by qPCR in (C) U87 cells, or (D) 
MDA-MB231 cells. RPLPO was used to normalize the data. N=2. Bars represent the mean 
± SEM (* P< 0.05). 
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Figure 2 Lipid phosphate phosphatase expression is modulated in hypoxia 
 (A-I) Cells were incubated under normoxic (21%O2) or Hypoxic (1%O2) conditions for 4, 
8 or 16 hours.  mRNA expression of (A-C) PLPP1 (LPP1), (D-F) PLPP2 (LPP2) or (G-I) 
PLPP3 (LPP3) was evaluated by qPCR in (A,D,G) HT1080, (B,E,H) U87, or (C,F,I) 
MDA-MB231 cells. RPLPO was used to normalize the data. N=3 or more. Bars represent 
the mean ± SEM (* P< 0.05, ** P< 0.01). 
 
 
3.2.2 Activity of the LPA producing enzyme ATX is required for hypoxia-induced 
invadopodia production  
Since ATX expression was increased in hypoxia, we next investigated its involvement in 
hypoxia-induced invadopodia production.  To this aim, we first compared the effects of 
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overexpression and hypoxic stimulation induced an increase in the percentage of cells 
forming ECM-degrading invadopodia (Fig 3A).  The effect of ATX overexpression was 
superior to hypoxia on the percent of cells forming invadopodia at both time points. Both 
stimuli also increased the number of invadopodia formed per cell and the area of 
degradation per cell (Fig 3B,C).  While ATX overexpression induced slightly more 
invadopodia per cell, hypoxia on the other hand had a more important effect on the area of 
degradation per cell. These results indicate that ATX may have a role in invadopodia 
formation, while hypoxia may play a more important role in ECM degradation. Next, using 
ATX-targeted shRNA, we observed that ATX inhibition abolished invadopodia production 
induced by hypoxia suggesting an important role for ATX in hypoxia-induced invadopodia 
production (Fig 3D).  Furthermore, under hypoxic conditions the addition of the product 
(LPA), but not the substrate (LPC) of ATX restored invadopodia production in ATX 
knockdown cells to the same level as in control cells (Fig 3E).  These results demonstrate 
that exogenous LPA can override ATX inhibition, suggesting that the effects of ATX on 
hypoxia-induced invadopodia production are due to its ability to produce LPA.   
3.2.3 Lipid phosphate phosphatases modulate invadopodia production 
Since LPP1 and LPP3 expression levels were reduced in hypoxic cells, we sought to 
determine whether inhibiting their expression in normoxic cells could recapitulate some 
effects of hypoxia on invadopodia production.  Results showed that LPP1 and LPP3 
knockdown, by targeted shRNA, induced significant increases in the percentage of cells 
forming ECM-degrading invadopodia (Fig 4A).  In contrast, LPP2-targeted shRNA had no 
effect on invadopodia production (Fig 4A), which is consistent with the lack of inhibition 
of LPP2 gene expression in hypoxia (Fig 2).  These results suggest that LPP1 and LPP3 
have an inhibitory role in invadopodia production, most likely through their ability to 
degrade LPA. 
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Figure 3 ATX is essential for hypoxia-mediated invadopodia production 
 (A) HT1080 cells or cells overexpressing ATX (ATX O/E) were cultured for 4h or 10h on 
fluorescently labeled gelatin in normoxia (21%O2) or hypoxia (1%O2).  The percentage of 
cells forming ECM-degrading invadopodia is shown. N=5.  (B) HT1080 cells or cells 
overexpressing ATX (ATX O/E) were cultured on non-fluorescent gelatin for 4h in 
normoxia (21%O2) or hypoxia (1%O2).  Actin and cortactin were labeled by 
immunofluorescence and the number of invadopodia per cell was counted based on 
actin/cortactin colocalization. N=3. (C) HT1080 cells or cells overexpressing ATX (ATX 
O/E) were cultured for 10h on fluorescently labeled gelatin in normoxia (21%O2) or 
hypoxia (1%O2).  Quantification of ECM degradation area per cell is shown. N=3. (D-E) 
Cells transfected with scramble (Ctr) or ATX targeted shRNA were cultured for 10h on 
fluorescently labeled gelatin. The percentage of cells forming ECM-degrading invadopodia 
is shown for cells cultured in (D) normoxia (21%O2) or hypoxia (1%O2), or (E) normoxia 
(21%O2), hypoxia (1%O2), hypoxia with LPC (1%O2 + LPC), or hypoxia with LPA (1%O2 
+ LPA). N=3. Bars represent the mean ± SEM (* P< 0.05, ** P< 0.01, *** P< 0.001). 
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Figure 4 LPP1 and LPP3 contribute to invadopodia production  
(A) HT1080 cells transduced with scramble (ctr), LPP1, LPP2, or LPP3 shRNA were 
incubated for 10h on fluorescently labeled gelatin in normoxia (21%O2).  The percentage of 
cells forming ECM-degrading invadopodia is shown. Results from two sets of shRNA for 
each of LPP1, LPP2, and LPP3 were combined. N=3. Bars represent the mean ± SEM (*** 
P< 0.001). 
 
3.2.4 Hypoxia affects the spatial localization of ATX and LPPs 
Results demonstrated that ATX knockdown exerted strong inhibitory effects on 
invadopodia production induced by hypoxia (Fig 3D), however, ATX expression was not 
affected in most cells lines tested with a somewhat late, 8-16h, induction in HT0180 cells 
(Fig 1 A-D).  As discussed in the introduction, secreted ATX is known to bind to integrins 
or heparin sulfates on the cell surface, which may result in localized production of LPA 
close to LPA receptors (Fulkerson et al., 2011; Houben et al., 2013). Therefore, we sought 
to determine whether hypoxia modulates the cellular localization of ATX.  First, HT1080 
cells were permeabilized and stained for ATX and actin. Strong ATX staining, at what 
appears to be the leading edge of cells, was observed in hypoxia, compared to a more 
diffuse staining under normoxic conditions (Fig 5A).  Furthermore, ATX was localized at 
or near the cell surface in these hypoxic cells, as seen in the z-axis view (Fig 5A). Because 
secreted ATX is recruited to the cell-surface, we also performed ATX staining in non-
permeabilized cells.  Co-staining of the cells with the lipophilic marker DiD and ATX 
showed localized ATX staining at the cell surface.  In hypoxic cells, a prominent cell-
surface staining was orientated towards the leading edge, while in normoxic cells less 
pronounced cell-surface staining of ATX was observed (Fig 5B). These results indicate that 
there is either an increased secretion of ATX and/or increased recruitment of ATX by cell-
surface proteins in hypoxia.   
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Figure 5 ATX localization is altered in hypoxic cells 
(A-B) Representative immunofluorescence images of HT1080 cells cultured on non-
fluorescent gelatin for 4h in normoxia (21%O2) or hypoxia (1%O2) are shown. (A) 
Representative images of cells permeabilized and stained for ATX (green) or F-actin (red). 
Nuclei were stained with DAPI (blue). Magnification 60X. (B) Representative images 
showing ATX (green) and DiD (red) staining in non-permeabilized cells. Nuclei were 
stained with DAPI (blue). Magnification 60X.   
 
Given the changes in ATX localization observed in Figure 5, it was of interest to 
investigate if hypoxia also modulates the localization of the LPA degrading enzymes, LPP1 
and LPP3. Furthermore, since there was no significant decrease in LPP1 expression in 
hypoxic HT1080 cells, but there was a significant increase in invadopodia production in 
LPP1 knockdown HT1080 cells, an alternative mechanism of LPP1 regulation would seem 
likely.  Indeed, double immunofluorescence staining of LPP1 and ATX, or LPP3 and ATX, 
in non-permeabilized cells shows overlapping staining in normoxic cells, while hypoxic 
cells display staining for each protein in distinct cellular localizations.   In hypoxia, ATX 
staining is concentrated towards the leading edge, as in Figure 5, while LPP1, or LPP3, 
staining is located at the trailing edge with no apparent overlap with ATX (Fig 6A-B). 
Furthermore, results from LPP3 and ATX co-staining show clearly less LPP3 staining in 
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hypoxic cells than normoxic cells (Fig 6B). These results suggest an altered localization of 
LPP1 and LPP3 in hypoxia as well as a decrease in LPP3 expression. This decrease in 
LPP3 staining observed in hypoxic cells could be due to the observed reduction in its 
expression levels in hypoxia (Fig 2).   
 
Figure 6 LPP1 and LPP3 localization is altered in hypoxic cells 
(A-B) Representative immunofluorescence images of HT1080 cells cultured on non-
fluorescent gelatin for 4h in normoxia (21%O2) or hypoxia (1%O2) are shown. (A) Cells 
were stained for LPP1 (green) and ATX (red). Nuclei were stained with DAPI (blue). 
Magnification 60X. (B) Representative images of cells stained for LPP3 (green) and ATX 
(red). Nuclei were stained with DAPI (blue). Magnification 60X. 
 
3.2.5 ATX promotes cancer cell migration and invasion 
Immunofluorescence results showing ATX localization at the leading edge of cells, distinct 
from the location of LPP1 and LPP3 expression in hypoxic cells, suggests a function in cell 
migration. To investigate the possible role of ATX in hypoxia-induced cell migration we 
used a more physiological 3-dimentional (3D) invasion assay in type I collagen matrices. 
These assays require formation of ECM-remodeling cell protrusions, cell elongation, and 
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stable cell orientation for directionally persistent cell migration in order for cells to invade 
deeply into the collagen matrix (Thievessen et al., 2015). Control shRNA cells seeded on 
top of 3D collagen gels were found to migrate deeper into the matrix when incubated in 
hypoxic conditions (Fig 7A-B).  In contrast, cells transfected with shRNA targeting ATX 
did not exhibit this increased invasive migration in response to hypoxia (Fig 7A-B). These 
results indicate that ATX is necessary for hypoxia-mediated increases in directionally 
persistent cell migration.  
 
Figure 7 ATX is necessary for hypoxia-induced 3D invasion and migration 
 (A-B) Cells transfected with scramble (Ctr) or ATX targeted shRNA were incubated on 
type I collagen in 3D invasion assays in normoxia (21% O2) or hypoxia (1% O2) for 24h. 
(A) The relative intensity of cell staining according to depth of invasion is shown. (B) The 
maximal depth of invasion is shown for each condition. N=2-3. Bars represent the mean ± 
SEM. 
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4. DISCUSSION 
Tumor metastasis is the leading cause of cancer patient mortality, however due to the 
complexity of the processes involved there are currently no specific metastasis inhibitors in 
clinical use. The hypoxic tumor microenvironment is an important driver of tumor 
progression and the metastatic phenotype, therefore a better understanding of the 
mechanisms involved in hypoxia-induced invasion is warranted. In this thesis, we have 
identified hypoxia as a master regulator of the LPA signaling axis. In the first part (chapter 
1) of this thesis, we discovered a mechanism of LPA1-Src-EGFR crosstalk under hypoxic 
conditions that mediates hypoxia-induced invadopodia production and metastasis through 
PI3K/Akt signaling. Our results also revealed the therapeutic potential of a combination of 
LPA1 and EGFR inhibition on tumor metastasis.  Furthermore, in chapter 2 of this thesis, 
hypoxia was found to modulate the expression and localization of the LPA producing 
(ATX) and degrading (LPP1, LPP3) enzymes, thereby identifying another mechanism by 
which hypoxia could modulate LPA signaling. The upregulation of ATX or downregulation 
of LPP1 or LPP3 were all found to promote invadopodia production, supporting the 
essential role of LPA signaling in this process.  
4.1 Discussion of Article  
Mounting evidence suggests a crucial role of the LPA/LPAR axis in cancer cell invasion 
and promising studies are underway to investigate the therapeutic potential of LPAR 
antagonists in pathologies such as idiopathic pulmonary fibrosis (Kihara et al., 2015). Pan-
LPAR antagonists are likely to have cross-reactivity with other GPCRs as well as systemic 
side effects. It is therefore imperative to identify the specific LPA receptors involved under 
aggressive microenvironment conditions, such as hypoxia, in order to develop proper 
targeted therapies for cancer cell invasion and metastasis. The findings, presented in the 
manuscript section of this thesis, raise the interesting possibility that LPA1 usage can be a 
hallmark of hypoxia-induced invadopodia production and point to a potential benefit of 
LPA1-directed therapy to counteract cancer cell invasion. The LPA signaling axis, 
including LPA receptors, are promising clinical targets to treat chronic inflammatory 
conditions, fibrosis, and cancer (Benesch et al., 2018). Various phase I and phase II clinical 
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trials are currently underway to investigate the efficacy of various inhibitors in blocking 
pulmonary fibrosis, systemic sclerosis, and lesions caused by traumatic brain injury 
(Benesch et al., 2018; Desroy et al., 2017).  Due to the many similarities between 
inflammation and fibrosis, and cancer associated pathways, these LPA signaling inhibitors 
have the potential to be useful for cancer therapy as well.  However currently there are no 
approved cancer therapies that target the LPA signaling axis.  Our identification of the 
essential role of LPA1 in hypoxia-induced invadopodia production and metastasis suggest 
that some LPA1 antagonists, such as BMS-986020 (NCT01766817) that is being tested in 
clinical phase II by Bristol-Myers-Squibb, could be useful for cancer therapy.  In addition 
to cancer cell invasion and metastasis, LPA signaling also plays an important role in tumor-
driving inflammation (Benesch et al., 2018).  Therefore, an LPA1 antagonist may have even 
more beneficial effects in the clinic by blocking both inflammation and cell invasion.  
 
The most likely use of such inhibitors will be in combination with other approved therapies 
in order to increase efficacy and potentially overcome toxicity, by reducing the amounts of 
other drugs used. Due to the complex signaling networks involved in tumor progression, 
which interact through crosstalk and feedback loops, single therapeutic agents often have 
limited efficacy (Yap et al., 2013). Recently, combination therapy of two targeted drugs has 
been shown to be more beneficial than mono-therapies (Bayat Mokhtari et al., 2017; Yap et 
al., 2013). For example, a combination of VEGF and EGFR inhibitors showed improved 
efficacy over individual inhibitors for the treatment of renal cell carcinoma (Hainsworth et 
al., 2005), combined BRAF and MEK inhibition had a synergistic effect in melanoma 
(Flaherty et al., 2012), and combined suppression of Rictor and EGFR resulted in complete 
tumor regression in an orthotopic glioblastoma mouse model (Verreault et al., 2013). In 
agreement with the benefits of combination therapy, our results suggest that LPA1 
inhibition acts synergistically with EGFR inhibition to block metastasis. Inhibitors of 
EGFR are often not well tolerated, mostly due to gastrointestinal and cutaneous toxicity, 
and occasionally more severe side effects such as pulmonary or hepatic toxicity (Harari, 
2004; Hidalgo et al., 2001). Furthermore, despite positive early responses most patients 
eventually develop acquired resistance to EGFR inhibitors, which been linked to activation 
or crosstalk from another receptor (Rosenzweig, 2012; Steeg and Theodorescu, 2008). 
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Therefore LPA1-EGFR combination therapy could be a useful strategy to reduce EGFR 
inhibitor side effects and overcome resistance, by reducing the required dose of EGFR 
inhibitor and disrupting a crosstalk mechanism. Due to the heterogeneous nature of human 
tumors it will be important to determine if a patients tumor will respond to EGFR and 
LPA1 inhibition in order for such a combination therapy to be useful.  It would therefore be 
of interest to test for expression of these receptors in tumor biopsies, or even use the CAM 
model and directly test the inhibitors on the patient tumor samples implanted on the CAM.  
 
The identification of LPA1-EGFR crosstalk under hypoxic conditions, that promotes 
invadopodia biogenesis and metastasis, identifies this crosstalk as a potential target to block 
the effects of the hypoxic microenvironment on invasion and metastasis. Therefore, a better 
understanding of how LPA1-EGFR crosstalk is promoted under hypoxia could help to 
better target this phenomenon. While we uncovered a ligand-independent, Src-mediated 
mechanism of transactivation, exactly why this occurs solely in hypoxic cells remains to be 
determined. Various possibilities will be examined below. 
 
One possible explanation for the LPA1-EGFR crosstalk observed in hypoxic conditions 
could be the generation of ROS. As mentioned in the introduction, ROS have been 
implicated in GPCR-RTK crosstalk with one mechanism involving inactivation of PTPs 
resulting in increased tyrosine phosphorylation levels (Cattaneo et al., 2014; Finkel, 2000).  
For example, EGFR transactivation by a GPCR, FPRL1, was mediated by increased ROS 
generation that modulates Src kinase activity (Cattaneo et al., 2011).  Phosphorylation of 
EGFR induced by LPA was also found to require ROS (Cunnick et al., 1998). Increased 
production of ROS in hypoxia has been extensively documented (Tafani et al., 2016). For 
example, hypoxia was shown to increase ROS via activation of NADPH oxidase in 
pulmonary smooth muscle cells (Rathore et al., 2008). Hypoxia was also shown to generate 
hydrogen peroxide in pulmonary artery endothelial cells (Porter et al., 2014). In addition, 
hypoxia was shown to increase ROS generation, involved in activation of HIF pathways, in 
A549 lung cancer cells (Goyal et al., 2004). In concordance with these studies, we have 
found an increase in ROS production induced by hypoxia in the HT1080 cells line, an 
effect that was dependent on LPA1 activation (Discussion Figure 1, Annex 1).  
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Interestingly, Diaz et al. detected ROS at sites of invadopodia formation and found that 
ROS generation was necessary for invadopodia formation (Diaz et al., 2009).  It is therefore 
possible that, under hypoxia, local production of ROS would enhance invadopodia 
production by increasing tyrosine phosphorylation of TKs, such as Src or EGFR, which are 
involved LPA1-EGFR crosstalk. To verify the involvement of ROS in this process we 
could determine the effect of ROS inhibition on the LPA1-EGFR crosstalk mechanism and 
invadopodia production, using antioxidants such as NAC (N-acetyl-L-cysteine) or specific 
shRNA targeting essential components of the NADPH complex such as p22PHOX.   
 
Another potential explanation for the LPA1-EGFR crosstalk in hypoxia is a change in 
receptor localization under this condition. Relocalization of the receptors and signaling 
components to specific microdomains, such as lipid rafts, where they would be in close 
proximity could presumably facilitate their crosstalk. Lipid raft formation can be controlled 
by hypoxia and GPCRs, EGFR, Src and Akt can all be relocalized to lipid rafts (Danza et 
al., 2013; Irwin et al., 2011; Jensen et al., 2013; Liu et al., 2014; Simons and Toomre, 
2000). Therefore, increased lipid raft formation in hypoxia might promote the interaction of 
LPA1, EGFR and Src leading to their cross communication. To determine if lipid rafts are 
involved in LPA1-mediated transactivation of EGFR, we can use a variety of techniques. 
First, we can assess whether LPA1 and EGFR are localized in lipid rafts by biochemical raft 
isolation using ultracentrifugation.  Lipid raft fractions can then be identified by the 
absence of transferrin receptors and the presence of flotillin and GM1, a lipid raft-specific 
ganglioside (Macdonald and Pike, 2005; Wolf et al., 1998). Localization of LPA1 and 
EGFR in the lipid raft fractions can then be evaluated by Western blotting. Confocal 
microscopy analysis using super-resolution stimulated emission depletion (STED) 
microscopy could also be used to visualize the colocalization of LPA1 and EGFR in lipid 
rafts following lipid raft staining with labeled cholera toxin subunit B, which binds to GM1 
(Wolf et al., 1998), and staining of LPA1 and EGFR. We can also determine if LPA1 and 
EGFR colocalize with caveolin, which identifies a subset of lipid rafts (Zheng et al., 2011). 
We can further use techniques to disrupt lipid rafts, such as methyl-beta cyclodextrin 
(MβCD) induced depletion of cholesterol (Mahammad and Parmryd, 2015) and determine 
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the effects on EGFR transactivation, interaction of LPA1 and EGFR by 
coimmunoprecipitation, and invadopodia formation.  
 
Altered receptor trafficking in hypoxia might also mediate crosstalk. Abnormal trafficking 
is involved in malignant transformation and endocytosis-associated proteins are often 
deregulated in cancer (Mosesson et al., 2008). Some of the mechanisms involved in 
defective trafficking and unbalanced recycling are influenced by hypoxia in the tumor 
microenvironment (Wang and Ohh, 2010). For example, hypoxia has been found to 
globally inhibit endocytosis, via a caveolin-1 dependent mechanism. However certain 
proteins were found to have enhanced internalization under hypoxic conditions, including 
several RTKs such as EGFR, DDR1, IGFR1 and ROR2, and several integrins such as 
ITGA1, 2, or 3 and ITGB1 and 5 (Bourseau-Guilmain et al., 2016). This suggests that 
hypoxia has protein-specific effects on trafficking. For example, hypoxia was found to 
mediate delivery of integrin containing vesicles to the leading edge of invasive cancer cells 
(Yoon et al., 2005). In another study, hypoxia was found to delay endocytosis resulting in 
reduced EGFR degradation and prolonged EGFR signaling using a mechanism involving 
downregulation of the protein rabaptin-5 (Wang et al., 2009). In the manuscript presented 
herein, we discovered a ligand-independent mechanism of LPA1 transactivation of EGFR 
via Src kinase-mediated phosphorylation of EGFR on Y845. Phosphorylation of this 
residue was previously found to result in endosomal distribution of EGFR. In the study by 
Medts et al. activated Src phosphorylated EGFR on Y845 and triggered EGFR endocytosis 
via clathrin-coated vesicles. Importantly, the Src-EGFR interaction was sufficient to trigger 
EGFR activation without the requirement of an extracellular ligand (Medts et al., 2010). 
Internalization of EGFR in response to Src activation also resulted in sequestration of 
EGFR in perinuclear/recycling endosomes that avoid lysosomal degradation (Medts et al., 
2010).  This is reminiscent of the effect of hypoxia on EGFR internalization, which also 
delayed EGFR degradation. In addition, Src seems to play an important role in trafficking 
of other receptors, as some proteins involved in GPCR endocytosis and trafficking are Src 
substrates, for example, dynamin, a large GTPase involved in fusion of clathrin-coated 
vesicles. Phosphorylation of dynamin mediated by Src is required for internalization of 
GPCRs such as B2-adrenergic and M1 muscarinic receptors (Luttrell and Luttrell, 2004). 
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Therefore, Src activity could control LPA1 trafficking as well. Altogether, this suggests that 
altered trafficking in hypoxia could bring LPA1 and EGFR together in endosomes where 
EGFR is known to signal from (Di Guglielmo et al., 1994; Murphy et al., 2009).  
Furthermore, the crosstalk mechanism involving Src kinase may play a role in the altered 
trafficking.     
 
Preliminary results from investigation into LPA1 and EGFR localization show that they are 
found colocalized at specific microdomains in the cell including what appear to be 
membrane ruffles and large vesicles inside the cells (Discussion Figure 2, Annex 1). This 
could be due to internalization via macropinocytosis, an alternative form of endocytosis. 
Macropinocytosis is an actin-driven process whereby a membrane protrusion forms a large 
vesicle that is subsequently internalized into the cell (Michalopoulou et al., 2016). 
Macropinocytosis has also been shown to be dependent on lipid rafts (Conner and Schmid, 
2003; Liu et al., 2002; Nichols and Lippincott-Schwartz, 2001), and therefore could be 
responsible for internalizing the components found in lipid rafts that were implicated in our 
study, such as LPA1, EGFR, Src and Akt. Another observation suggesting that the vesicles 
detected in our preliminary study are macropinosomes is the fact that they are found close 
to membrane ruffles, which is consistent with studies indicating that macropinosomes 
originate from ruffles (Michalopoulou et al., 2016). Interestingly, Rac1 and Cdc42 are 
major regulators of macropinocytosis along with Arp2/3 and PI3K (Dumontier et al., 2000; 
Hoeller et al., 2013).  All of these are also implicated in invadopodia formation, and PI3K 
was the major signaling pathway leading to LPA1-regulated invadopodia in hypoxia (Eddy 
et al., 2017). Macropinocytosis also shares another link with invadopodia as both depend 
on CARMIL2, an actin capping protein regulator, for their formation and the loss of this 
protein inhibits macropinocytosis and impairs cell migration (Lanier et al., 2015, 2016). 
Therefore, macropinocytosis may contribute to the formation of invadopodia and these two 
events could work together to increase cellular invasion.  
 
Macropinocytosis is a nutrient-scavenging pathway that allows the cell to recuperate 
nutrients via uptake of extracellular proteins (Recouvreux and Commisso, 2017). Hypoxic 
tumors are deprived of nutrients and hypoxic cells have been shown to support growth by 
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scavenging lipids (Kamphorst et al., 2013; Recouvreux and Commisso, 2017). Therefore, 
we might suspect that hypoxia could induce macropinocytosis to internalize lipids to 
support their metabolic needs. However, regulation of macropinocytosis by hypoxia is not 
clear at this time as there was only one study that found that low pH could modulate 
macropinocytosis in a cell-dependent manner (Gündel et al., 2017). However, there is a 
very interesting link between Src, EGFR signaling and macropinocytosis. Firstly, Src can 
induce macropinocytosis (Mettlen et al., 2006; Veithen et al., 1996) and EGFR is known to 
be internalized via macropinocytosis (Orth et al., 2006).  In a study by Donepudi et al., Src 
and activated EGFR were found to be colocalized and traffic together in large endocytic 
vesicles identified as macropinosomes (Donepudi and Resh, 2008). Under this condition, 
EGFR activation was found to be prolonged in a Src-kinase dependent manner, presumably 
because EGFR in macropinosomes could evade degradation. In fact, macropinosomes  
were found to remain distinct from lysosomes (Donepudi and Resh, 2008), and as discussed 
above, EGFR is able to signal from intracellular vesicles (Murphy et al., 2009; Wang et al., 
2002). Macropinocytosis has been shown to be regulated by GPCRs in podocytes (Chung 
et al., 2015). Therefore, the mechanism of crosstalk that we identified, involving Src kinase 
activation of EGFR, could be driving the production of invadopodia observed in hypoxia 
due to increased EGFR internalization and activation in macropinocytic vesicles. To 
investigate the involvement of macropinocytosis we can use inhibitors to block the 
formation of macropinosomes and 70kDa fluorescent dextran as a probe to detect and 
quantify them.  
 
Scaffolding proteins play an important role in assembling multi-protein signaling 
complexes to facilitate their concerted interactions and functions. It is therefore plausible 
that a scaffolding protein could also be involved in LPA1-EGFR crosstalk.  An interesting 
candidate for this is NHERF1/EBP50 (Na+/H+ Exchanger Regulatory Factor/ERM Binding 
Protein 50) which is a PDZ-domain containing scaffolding protein that recruits a variety of 
transmembrane proteins, including RTKs and GPCRs, into functional complexes (Saponaro 
et al., 2014; Weinman et al., 2006). Interestingly, NHERF1 was also found to interact with 
an LPA receptor, LPA2 (Oh et al., 2004) and has important effects on EGFR trafficking and 
function (Bellizzi et al., 2015; Lazar et al., 2004). By bringing together multiple proteins 
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NHERF1 plays a role in cell signaling, cytoskeletal remodeling and receptor trafficking 
(Oh et al., 2017).   Many cancers overexpress NHERF1 in association with poor prognosis 
(Saponaro et al., 2014). In a study by Cardone et al. the hypoxic tumor microenvironment 
was found to regulate the expression and localization of NHERF1.  Briefly, they observed 
an upregulation of NHERF1 expression and a redistribution of NHERF1 to leading edge 
pseudopodia in hypoxic cells (Cardone et al., 2007). Recently, LPA was also found to 
stimulate NHERF1 translocation to the plasma membrane, specifically to protrusive 
structures, in ovarian cancer cells.  In this study, NHERF1 was also found to be essential 
for LPA-induced cell migration. Unfortunately, this study did not examine the involvement 
of LPA receptors (Oh et al., 2017).  Therefore, NHERF1 is an important scaffolding protein 
that can be relocalized to protrusive structures under hypoxic conditions, and that can 
potentially interact with both EGFR and LPA1 in order to bring them together at specific 
microdomains in hypoxia. NHERF1 may therefore facilitate LPA1-EGFR crosstalk in 
hypoxic cells.  It would be interesting to knockout NHERF1 expression and measure the 
effects on LPA1-EGFR crosstalk as well as visualizing their subcellular localization by 
confocal microscopy and ultimately the outcome of invadopodia production.  
 
Finally, the PI3K/Akt pathway was found to mediate invadopodia production downstream 
of LPA1-EGFR crosstalk. The involvement of Akt is in concurrence with other studies, 
which have shown that Akt may promote invadopodia through several potential 
mechanisms. For example, Akt can activate Rac1, which could lead to the recruitment of 
cortactin, which is essential for the formation of invadopodia precursor structures (Han et 
al., 1998; Head et al., 2003; Henderson et al., 2015). The degradative capacity of 
invadopodia can also be augmented by Akt through increased secretion of MMP9, an 
important protease involved in ECM degradation (Cho et al., 2008).  Additionally, the 
PI3K/Akt pathway may be an interesting target for cancer therapy, especially in light of the 
recent research into PI3K isoform specific inhibitors.  Clinical trials with pan-PI3K 
inhibitors were found to have disappointing results possibly due to their lack of specificity 
(Rodon et al., 2013).  This is not surprising, as different PI3K isoforms are known to have 
divergent biological effects, as illustrated by the different phenotype of knockout mice 
(Thorpe et al., 2015).  Subsequently, PI3K inhibitors selective for p110α, p110β, p110δ, or 
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p110γ were developed and are currently being tested in phase I and phase II clinical trials 
(Chaussade et al., 2007; Thorpe et al., 2015).  Therefore, PI3K isoforms could potentially 
provide additional selective targets to inhibit metastasis. It would be of interest to 
investigate which specific isoform is implicated downstream of LPA1-EGFR crosstalk in 
hypoxia to mediate invadopodia production and metastasis. To this aim, we could test the 
different isoform selective inhibitors in invadopodia assays and in vivo metastasis studies. 
We can also measure the relative levels of each isoforms, and determine if they are 
modulated by hypoxia. Results from these experiments should give us an indication of 
which one is dominant in mediating signaling. After determining the isoform/s involved we 
may want to test them in conjunction with the inhibitors of EGFR and/or LPA1 to 
determine if we can achieve a synergistic effect in blocking invadopodia and metastasis.  
 
4.2 Discussion of Chapter 2  
Signaling by LPA is known to be affected by the amount of LPA available to interact with 
receptors. Increased levels of LPA have been found in the ascites from ovarian and 
pancreatic cancer patients compared to control groups (Westermann et al., 1998; Xiao et 
al., 2001; Xu et al., 1998; Yamada et al., 2004). Interestingly, ovarian ascites fluid is 
hypoxic suggesting that hypoxia could be responsible for the observed increase in LPA 
levels (Kim et al., 2006). The potential role of hypoxia is supported by the demonstration of 
increased LPA levels in a chronic-hypoxia pulmonary hypertension rat model (Shlyonsky 
et al., 2014). Shlyonsky et al. observed an increase in LPA serum content as well as 
increased LPA staining in the lungs of rats exposed to hypoxia. This was accompanied by 
an increase in ATX mRNA levels in the lung tissues of hypoxic rats (Shlyonsky et al., 
2014). Elevated levels of LPA have also been measured in patients with ischemic 
cerebrovascular disease (Li et al., 2008).  Therefore, conditions of hypoxia, or low oxygen 
concentration, seem to increase LPA levels in non-malignant pathologies, potentially 
through upregulation of ATX. 
 
In the second chapter of this thesis, our goal was to gain a more complete understanding of 
the regulation of LPA signaling by hypoxia in cancer cells by studying the effects of 
hypoxia on the enzymes involved in controlling LPA levels. LPA production is mainly 
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regulated by ATX, which promotes tumor progression and whose expression is upregulated 
in various cancers (Benesch et al., 2014a; Kehlen et al., 2004; Kishi et al., 2006; Yang et 
al., 2002, 1999). In contrast, important LPA degrading enzymes, the LPPs, are 
downregulated in cancer cells and play a negative role in tumor progression (Tang et al., 
2015; Tanyi et al., 2003a, 2003b). Yet, the factors involved in shaping the differential 
expression of these LPA regulatory components remain unknown.  Since hypoxia is 
associated with both increased LPA levels and tumor progression (Hockel et al., 1996; 
Shlyonsky et al., 2014), we investigated the impact of the hypoxic microenvironment on 
ATX and LPP expression. We observed an increase in ATX expression in hypoxic HT1080 
cells, which correlates with the increased LPAR signaling in these cells discovered in 
Article 1. This finding identifies hypoxia as a novel inducer of ATX in cancer cells that 
could be responsible for ATX upregulation in fibrosarcomas. In contrast, ATX expression 
was not modulated in U87 or MDA-MB-231 cells exposed to the same hypoxic condition.  
The lack of significant increase of ATX expression in the U87 cell line may be explained 
by the fact that ATX is known to be already overexpressed in glioblastomas (Kishi et al., 
2006).  Breast cancer stromal cells as well as the mammary fat pad have been identified as 
major sources of ATX for breast tumor cells (Benesch et al., 2014b; Popnikolov et al., 
2012). This may provide an explanation for the lack of increased ATX expression observed 
in hypoxia-stimulated MDA-MB-231 breast cancer cells. Certainly, protein levels of ATX 
both in cell lysates and supernatants, since ATX is a secreted protein, will need to be 
measured in the U87 and MDA-MB-231. There is a discrepancy between mRNA and 
protein abundance for many genes, as differential expression of mRNA has been found to 
explain at most 40% of the variation in protein expression (Tian et al., 2004; Wang, 2008). 
Therefore, we could observe an increase in ATX protein expression despite little change in 
ATX mRNA expression in these cell lines.  
 
Results demonstrated that LPP1 and LPP3 expression is also modulated by hypoxia. 
Hypoxia significantly decreased LPP3 mRNA levels in all cell lines tested. Expression of 
LPP1 was similarly decreased, albeit to a lesser extent, with significant down modulation 
observed only in the MDA-MB-231 and U87 cell lines. These results suggest that although 
U87 cells express high levels of ATX, the reduced expression of LPA degrading enzymes 
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in hypoxia could be necessary to sustain high levels of LPA, since LPA is normally rapidly 
degraded by these enzymes (Brindley et al., 2002). Breast cancer MDA-MB-231 cells do 
not appear to increase ATX levels; therefore, the reduced expression of LPA degrading 
enzymes in hypoxia could be the main mechanism involved in the regulation of LPA levels 
under hypoxic conditions in these cells (Li et al., 2008; Shlyonsky et al., 2014).  Result also 
highlight the fact that it will be important to look at both ATX and LPP expression levels 
when investigating autocrine production of LPA levels in cell lines or pathological 
contexts.  In contrast to LPP1 and LPP3, LPP2 expression was not decreased. This is 
consistent with previous studies indicating that LPP1 and LPP3 are downregulated in some 
cancers (Tang et al., 2015) and their overexpression inhibits cell proliferation and migration 
as well as tumor growth and metastasis (Tang et al., 2014; Tanyi et al., 2003a). On the 
other hand, LPP2 has increased expression in cancer and opposing effects to LPP1 and 
LPP3, as it induces cell cycle progression (Morris et al., 2006). Interestingly, when we look 
at the specificity of these different LPPs, LPP1 and LPP3 degrade mostly LPA while LPP2 
prefers PA as a substrate, suggesting an important role for LPP1 and LPP3, but not LPP2, 
in controlling LPA-mediated signaling (Brindley and Waggoner, 1998). We have therefore 
identified hypoxia as a novel modulator of LPP1 and LPP3 expression, uncovering an 
important microenvironment factor that may contribute to their low expression in tumors.  
Again, these results will need to be validated by western blotting of protein levels to 
confirm that the decreased mRNA levels correlate with lower protein expression.  Overall, 
the increase in ATX expression and/or decrease in LPP1 and LPP3 expression in hypoxic 
cells may contribute to increased LPA levels in the tumor microenvironment (Westermann 
et al., 1998; Xiao et al., 2001; Xu et al., 1998; Yamada et al., 2004).  
 
Hypoxia is known to modulate gene expression, through various transcriptions factors, 
primary among them is HIF1. Therefore, it will be of interest to determine if the 
modulation of ATX, LPP1 and LPP3 expression under hypoxia is dependent on HIF1 or 
other transcription factors known to be modulated by hypoxia.  The expression of ATX can 
be modulated by a variety of transcription factors including AP1, SP and NFkB (Farina et 
al., 2012; Wu et al., 2010) that can also be activated under hypoxic conditions (Achison and 
Hupp, 2003; Beitner-Johnson and Millhorn, 1998; Koong et al., 1994; Millhorn et al., 
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1997). In contrast, very little is known concerning LPP1 and LPP3 gene regulation; so far, 
the only transcription factor associated with increased LPP1 expression is p73, a p53-
related transcription factor (Ishida et al., 2007).  In this study by Ishida et al., several p53 
responsive element-like sequences were identified in the promotor of LPP1 indicating that 
p53 may also play a role in regulation of LPP1 expression. However, no modulators of low 
LPP expression have been discovered so far.  It would therefore be of interest to determine 
the involvement of HIF1 and other transcription factors in hypoxia-induced down 
modulation of LPP1 or LPP3. This could be assessed by various means including the use of 
pharmacological inhibitors of the transcription factors or knockout of their expression with 
shRNA.  
 
Following the identification of increased ATX and decreased LPP1 and LPP3 levels in 
hypoxic cells it will be important to determine if these modulations have an effect on the 
global LPA production by these cells. For this, we could measure LPA levels by mass 
spectrometry, as described by Wijesinghe et al. (Wijesinghe et al., 2011).  This method can 
also identify specific LPA species to determine which ones might be preferentially 
produced in hypoxia.  Different LPA species may have differing biological activities and 
can preferentially activate specific LPA receptors. For example, LPA3 prefers unsaturated 
LPA species and LPA1-3 prefer acyl to alkyl LPA (Bandoh et al., 1999; Okusa et al., 2003; 
Tigyi, 2010; Yanagida and Ishii, 2011).  It would also be of interest to verify if changes in 
total LPA levels or production of specific species of LPA depends on the activities of ATX 
or LPP1 or LPP3.  For this we can knockdown their expression with shRNA or overexpress 
these enzymes and analyze LPA levels. The identification of specific species of LPA 
produced in hypoxia could provide additional clues as to how hypoxia mediates its effects, 
for example does hypoxia increase the production of an LPA species that preferentially 
activates LPA1, potentially explaining the importance of this receptor in hypoxia?  
 
Since ATX expression was increased in hypoxic HT1080 cells and ATX is known to 
promote cell invasion (Liu et al., 2009), the involvement of ATX in hypoxia-induced 
invadopodia production was investigated. We first determined that both ATX 
overexpression and hypoxic stimulation were strong inducers of invadopodia, increasing 
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the percentage of cells forming invadopodia, the number of invadopodia formed per cell, 
and the area of degradation. These results correlate with previous studies that showed 
increased invadopodia production in hypoxic cells or cells overexpressing ATX (Harper et 
al., 2010; Lucien et al., 2011). Interestingly, overexpression of ATX was found to induce a 
much higher percentage of cells forming invadopodia than hypoxic stimulation, suggesting 
ATX may play an important role in the initiation of invadopodia formation.  Hypoxic cells 
on the other hand were more aggressive at degrading the matrix compared to ATX 
overexpressing cells. This is most likely due to the effect of hypoxia on factors distinct 
from ATX, which increase the degradative capacity of the cells. For example, hypoxia can 
increase the expression of many matrix-degrading proteases such as MT1-MMP, MMP-2 
and MMP-9 (Hanna et al., 2013; Semenza, 2012).  Furthermore, the acidic extracellular pH 
associated with hypoxic conditions can also drive matrix degradation by augmenting the 
secretion and activation of these proteases (Rozhin et al., 1994; Stock and Schwab, 2009). 
Therefore, it would be of interest to determine what specific aspects of invadopodia 
formation and function are affected by ATX overexpression versus hypoxic stimulation to 
fully delineate their roles in invadopodia biogenesis. 
 
Our results also identify ATX as a novel and essential mediator of hypoxia-induced 
invadopodia, as ATX knockdown completely blocked this event. Furthermore, LPA, but 
not LPC, was able to efficiently rescue ATX shRNA-mediated knockdown of invadopodia 
in hypoxic conditions, indicating that the effects of ATX are most likely due to its 
production of LPA and downstream signaling through LPARs. These results are consistent 
with our previously published results in normoxic conditions, and studies with ATX 
knockout mice, indicating that LPA production and GPCR signaling were responsible for 
ATX effects (Harper et al., 2010; van Meeteren et al., 2006). Furthermore, this finding 
provides additional evidence that LPA signaling plays a role in hypoxia-induced 
invadopodia, complementing the findings from Article 1. Perhaps part of the explanation 
for increased LPA1 signaling in hypoxia was due to increased activity of ATX in hypoxia. 
The ATX/LPA axis may therefore be a major factor in hypoxia-induced invasion and 
metastasis.  
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As LPP1 and LPP3 have negative effects on cancer progression and metastasis (Tang et al., 
2014, 2015) and were downregulated in hypoxic conditions, we investigated the result of 
inhibiting their expression on invadopodia production. Knockdown of the LPA-degrading 
enzymes, LPP1 and LPP3, resulted in an increase in invadopodia production, an effect 
similar to overexpression of the LPA-producing enzyme, ATX.  These results are in 
concordance with the decreased expression of LPP3 observed in hypoxic HT1080 cells in 
this study, as well as decreased LPP1 and LPP3 found in breast, lung, and ovarian cancers 
(Tang et al., 2015). This is the first time that LPPs have been shown to negatively affect 
invadopodia production therefore providing a potential mechanism by which they mediate 
their negative effects on cancer metastasis (Tang et al., 2014). To further our study on the 
implication of LPPs in hypoxia-induced invadopodia production overexpression of LPP1 or 
LPP3 in hypoxic conditions will be an asset. It will also be important to verify that the 
effects of LPPs are due to their ability to degrade of LPA specifically and not to non-
catalytic effects (Tang et al., 2015). One way to verify the involvement of LPP1 or LPP3 
LPA-degrading activity is to use a non-hydrolysable analogue of LPA that can therefore not 
be degraded by these LPPs (Brindley et al., 2002).  Addition of a non-hydrolysable LPA 
analogue should reverse the effects of LPP overexpression on invadopodia production if 
their effects are due to their catalytic activity.  Another approach would be to express a 
catalytically inactive form of LPP1 or LPP3 (Tang et al., 2014) and measure the effects on 
invadopodia and LPA production. 
 
In addition to changes in gene expression, hypoxia may also mediate effects by altering the 
trafficking and subcellular localization of proteins (Bourseau-Guilmain et al., 2016). 
Therefore we studied the subcellular localization of ATX, LPP1 and LPP3 under hypoxic 
conditions. Firstly, we observed a striking concentration of ATX staining at the leading 
edge of hypoxic cells, compared to less, and more diffuse ATX staining in normoxia. ATX 
staining was localized to the exterior cell surface as non-permeabilized cells also displayed 
strong ATX staining. This is interesting, since ATX has been shown to bind to β1 and β3 
integrins, localizing ATX to the surface of platelets or mammalian cells such as 
lymphocytes (Fulkerson et al., 2011; Hausmann et al., 2011; Kanda et al., 2008). 
Furthermore, β1 integrins are dynamically relocalized to the leading edge of polarized 
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migrating cells, suggesting they could be involved in recruiting ATX to this area (Shafaq-
Zadah et al., 2016). In addition, hypoxia enhances integrin expression, including β1, to 
promote metastasis (Ju et al., 2017), and β1 integrins are required for the formation of 
mature degradation-competent invadopodia, as discussed in the introduction (Huck et al., 
2010; Lahlou and Muller, 2011). Therefore, increased β1 expression in hypoxia may recruit 
ATX to the cell surface where the enzyme can augment local LPA concentrations in the 
vicinity of LPA receptors. Furthermore, binding of ATX to β1 integrins could potentially 
localize ATX to sites of invadopodia formation where ATX could produce LPA and 
activate LPAR signaling directly at invadopodia sites.  We intend to further investigate the 
localization of ATX at invadopodia by colocalization with invadopodia markers such as 
cortactin or Tks5 and areas of matrix degradation. To further investigate the role of integrin 
binding in ATX localization under hypoxia we could construct ATX mutants lacking 
integrin-binding sites. These mutants would also be useful to determine the effect of altered 
ATX binding on invadopodia production or other biological effects.  
 
Interestingly, if ATX does interact with integrins this could potentially link it to the 
possible NHERF-LPA1-EGFR complex described in section 4.1 of this discussion (Bellizzi 
et al., 2015; Saponaro et al., 2014).  In a study by Antelmi et al. phosphorylated ezrin, a 
cytoskeletal linker protein, was found to bind to both NHERF1 and β1 integrins at sites of 
functionally active invadopodia (Antelmi et al., 2013; Vaheri et al., 1997). Interestingly this 
NHERF-1-ezrin-β1 complex also contained EGFR (Antelmi et al., 2013). Therefore if 
NHERF-1 forms a complex with LPA1 and EGFR and β1 integrins recruit ATX, all of 
these proteins could be brought together in a functional complex by NHERF-1/β1 joint 
interaction with ezrin. This is an intriguing possibility to further pursue, as localized 
production of LPA, by ATX bound to integrins, in close proximity to LPA1 would favor 
LPA1 signaling.  Furthermore if LPA1 is already in a complex with EGFR, mediated by 
NHERF1, crosstalk would be promoted as well. Therefore it could be of interest to 
investigate LPA1 and EGFR localization in relation to ATX in hypoxic cells and determine 
if the NHERF1 scaffolding protein or integrins play a role in bringing these proteins 
together.  
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There are other mechanisms that could also be implicated in ATX recruitment to the cell 
surface. The ATXα isoform was shown to bind heparan sulfate proteoglycans at the cell 
surface, which could also localize ATX to this cell compartment (Houben et al., 2013; 
Perrakis and Moolenaar, 2014).  To investigate the involvement of this mechanism in ATX 
cell-surface localization we can use heparinase to cleave proteoglycans, thereby preventing 
ATX binding to them. Another alternative possibility is the delivery of ATX via exosomes.  
Recently exosomes were found to bind ATX and act as a delivery mechanism. Briefly, 
secreted ATX can bind the surface of cell-secreted exosomes, where it remains active and 
carries LPA. Exosome-bound ATX can then bind to cells through integrins and deliver the 
LPA for signaling (Jethwa et al., 2016). Exosomes can promote tumor progression and 
metastasis (Whiteside, 2016), and have key roles in various steps of invadopodia biogenesis 
(Hoshino et al., 2013b). In fact, invadopodia have been identified as important docking and 
secretion sites for exosomes (Hoshino et al., 2013b). Furthermore hypoxia can induce 
exosome secretion to promote invasive behavior of cancer cells (Ramteke et al., 2015). 
Therefore an intriguing possibility for future study is whether hypoxia releases exosomes 
containing ATX that promote invadopodia production. 
 
Co-staining of ATX and LPP1 or LPP3 revealed a subcellular spatial segregation of these 
enzymes under hypoxic conditions. Staining of ATX was localized to the leading edge, 
while LPP1 or LPP3 staining was localized towards the trailing edge, of hypoxic cells, and 
distinct from ATX staining. Furthermore, we observed less staining of LPP3 in hypoxia, 
which could potentially be due to the downregulation of LPP3 expression in hypoxia. 
Quantification of LPPs and ATX staining intensities in different regions of the cells 
(leading edge versus trailing edge) should add further support to these observations. Our 
finding of ATX localization at the leading edge of cells distinct from the location of LPP1 
and LPP3 expression in hypoxic cells suggests a function in cell migration. This 
compartmentalization of ATX and LPP1 or LPP3 under hypoxia might lead to uncontrolled 
LPA production towards the leading edge of the cell promoting migration by activating 
LPA receptors (Zhang et al., 2009).  
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To support this possibility, we investigated the role of ATX in hypoxia-induced cell 
migration using a more physiological 3-dimentional (3D) collagen invasion assay, which 
requires formation of ECM-remodeling cell protrusions, cell elongation, and stable cell 
orientation for directionally persistent cell migration in order to invade deeply into this 
substrate (Thievessen et al., 2015). Indeed, we observed that cell migration induced by 
hypoxia was efficiently blocked by ATX shRNA, suggesting an important role for ATX in 
this process. This is in concordance with other publications identifying important roles for 
LPA and ATX in cell migration, but is the first time ATX was shown to mediate hypoxia-
induced cell migration (van Meeteren et al., 2006; Zhang et al., 2009).  It would be of 
interest to investigate the involvement of spatial segregation between ATX and LPP1/LPP3 
in directionally persistent cell migration in 3D cell migration assays.  One possibility is to 
utilize GFP- and RFP-tagged ATX and LPPs in order to visualize their localization in cells 
migrating through a 3D collagen matrix, ideally we would use CRISPR/Cas9 technology to 
tag endogenous proteins, avoiding the need for overexpression  (Leonetti et al., 2016). To 
complement this study, we may also knockdown ATX expression and label either cell 
membranes and/or the actin cytoskeleton, before incubation in the 3D assay, to analyze 
changes in cell shape or actin-based protrusions in ATX deficient cells.  
 
There is another intriguing possibility as to how hypoxia may affect ATX, LPP1 and LPP3 
activity that involves changes in pH.  As discussed in the introduction, one of the major 
effects of hypoxia in the tumor microenvironment is a reverse acid-outside pH gradient 
(Cassavaugh and Lounsbury, 2011; Chiche et al., 2010). Hypoxia increases the activity of 
the sodium hydrogen exchanger, NHE-1, a principal regulator of cellular pH, to increase 
the extrusion of protons (Casey et al., 2010; Lucien et al., 2011). The exchanger, NHE-1, is 
preferentially localized to the leading edge of migrating cells where it results in localized 
extracellular acidification (Ludwig et al., 2013; Stock et al., 2007). Localized acidification 
produced by NHE-1 at invadopodia microdomains is also essential for hypoxia-induced 
invadopodia (Busco et al., 2010; Lucien et al., 2011).  Therefore, distinct pH nanodomains 
at the leading edge or invadopodia may result in differential activation of pH-dependent 
proteins at these sites.  
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As ATX is a secreted protein and LPP1 and LPP3 are membrane proteins with their 
catalytic sites facing the extracellular space, in order to degrade extracellular LPA, they 
would all be exposed to changes in the extracellular pH under hypoxia.  One of the ways 
that pH affects proteins is by altering the protonation state of histidine residues, that act as 
pH sensors due to the fact that their pKa is close to physiological pH (Webb et al., 2011).  
Various histidine-containing proteins have been found to experience altered protein-protein 
interactions or activity following changes in pH (Dillon et al., 2012; Kelly et al., 2002; Kim 
et al., 2010; Mueller et al., 2008; Webb et al., 2011; Zhang et al., 2013). At low pH 
histidine is protonated and positively charged, while at high pH it is unprotonated and 
negatively charged.  Most interestingly ATX, LPP1 and LPP3 all contain histidine residues 
that are important for their catalytic activity. Several important histidine residues are found 
within ATX, H316, H360 and H475, which are metal-binding residues (Gijsbers et al., 
2003; Koh et al., 2003), and H226 and H434 involved in substrate interactions, all of which 
were found to be essential for ATX catalytic activity and biological effects. Mutation of 
any of these histidine residues to glutamine, which mimics the non-protonable form of 
histidine, attenuated the activity of ATX towards LPC and reduced cell migration in 
response to ATX (Koh et al., 2009). The extracellular catalytic sites of LPP1 and LPP3 also 
contain conserved histidine residues. As mentioned in the introduction the conserved 
histidine in C3 acts as a nucleophile, and therefore must be in its unprotonated state to form 
the phospho-histidine intermediate (Bischoff and Schlüter, 2012; Sigal et al., 2005). This 
information suggests that the acidic extracellular pH found in hypoxic conditions may very 
well increase the activity of ATX specifically at the leading edge or invadopodia. Whether 
these changes would simultaneously inhibit LPP1 and LPP3 activity would likely depend 
on their localization at acidic subcellular sites of the cells or other cell compartments.  
 
To investigate whether this is the case we can envision a variety of experiments.  First we 
can alter the extracellular pH and measure the amount of LPA produced, in this way we can 
determine if hypoxia-mediated changes in LPA levels are dependent on pH.  For this we 
can use pH neutralizers such as NH4Cl or chloroquine, or add medium adjusted to a 
specific pH to the cells.  We can also measure the effects of pH modulation specifically on 
ATX activity using ATX activity assays that are sold commercially or on LPP activity with 
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non-commercial assays for LPP activity (Han and Carman, 2004). To investigate more 
specifically the role of each histidine residue we can perform mutagenesis experiments for 
ATX, LPP1, and LPP3.  The histidine residues can be substitued by arginine, to mimic the 
protonated state and therefore acidic conditions, representing hypoxic conditions, or by 
glutamine, to mimic the non-protonated state and therefore more alkaline conditions.   With 
these mutants we can again assess LPA levels as well as biological effects such as 
invadopodia production or cell migration to determine if these histidine residues are 
playing an essential role in the functioning of the enzymes. To determine if NHE-1-
mediated changes in pH and associated formation of distinct pH nanodomains can affect 
LPP or ATX activity in hypoxia we can use shRNA targeting NHE-1 and measure the 
outcomes previously described. Interestingly, NHE-1 may itself be affected by LPA 
signaling creating a potential positive feedback loop. Signaling by LPA has been shown to 
contribute to the phosphorylation of NHE-1 in its cytoplasmic tail via Rock and p90Rsk, 
resulting in increased cell migration (Wallert et al., 2015). Studies of the reciprocal effects 
of LPA signaling and NHE-1 activity in hypoxia will be interesting to pursue as we 
previously found hypoxia to increase NHE-1 activity through p90Rsk-mediated 
phosphorylation of its cytoplasmic tail (Lucien et al., 2011).  
 
Finally, the identification of ATX and LPP involvement in invadopodia production and 
their regulation by hypoxia makes them relevant targets to block the LPA signaling axis 
and therefore reduce cancer cell invasion. Interestingly, there has been much research into 
the development of ATX inhibitors, particularly following the identification of its crystal 
structure, which aided the design of rationale inhibitors (Benesch et al., 2014a). Similar to 
LPA receptors, ATX inhibitors have been developed and are currently in clinical trials for 
pulmonary fibrosis (Benesch et al., 2018). Although in light of our observations of 
localized plasma-membrane expression of ATX in hypoxic cells, blocking ATX-cell 
interactions might be a more selective approach to inhibit the specific effects of hypoxia on 
ATX-induced invasion.  This approach has the potential to generate fewer side effects than 
global ATX inhibition.  As for the LPPs, increasing their reduced expression levels in 
hypoxic cancer cells could be a novel target for cancer therapy (Benesch et al., 2016).  
Increasing low LPP1/3 expression through gene overexpression has been shown to limit 
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tumor progression (Benesch et al., 2018) and interestingly, tetracyclines can increase the 
expression of LPPs through stabilization of the protein (Tang et al., 2016). Therefore, 
tetracyclines or other potential inducers of LPP gene, or protein, expression or, stabilization 
could be used to inhibit LPA signaling. Clearly, more information on the mechanism of 
LPPs inhibition by hypoxia could provide novel targets for the control of LPP expression 
levels.  The results of our study indicate that ATX or LPPs could be targeted as anti-
metastasis therapies, due to their implication in invadopodia production, which is essential 
for cancer cell invasion and metastasis.  
 
4.3 Conclusions and Perspectives  
Metastasis is the main cause of cancer patient mortality making it vital to elucidate novel 
ways to block the metastatic cascade. Invadopodia make ideal targets to block the 
metastatic process due to their essential role in cancer cell intravasation and extravasation.  
Our work suggests that hypoxia is a master regulator of the LPA signaling axis for 
invadopodia production, highlighting the importance of taking into account the influence of 
the tumor microenvironment when investigating cell invasion processes.  The LPA 
signaling axis is revealed in this thesis to be a relevant target to overcome hypoxia-induced 
increases in cell invasion and metastasis, therefore therapies targeting this axis could be 
beneficial to counteract the detrimental effects of tumor hypoxia on cancer patient survival. 
The use of LPA1 inhibitors, already in clinical trials for fibrosis, in conjunction with EGFR 
inhibitors, currently used in the clinic for cancer patients, is a promising avenue of 
therapeutic targeting.  Eventual development of ways to interfere with ATX recruitment to 
the cell surface in hypoxia and also ways to increase LPP expression may provide new 
therapeutic targets and warrant investigation.  Currently, there are no approved cancer 
therapies that target LPA signaling therefore this provides an exciting opportunity for 
developing novel strategies that could improve upon current cancer therapies. 
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ANNEXES 
Annex 1: Discussion Figures 
 
 
Figure 1 Increased ROS production in hypoxia is dependent on LPA1  
HT1080 cells transfected with scramble (Ctr) or LPA1 shRNA were incubated in normoxia 
(21% O2) or hypoxia (1% O2) for 60 minutes.  The fold change in ROS production is 
shown, measured using CellROXtm Green Reagent. Bars represent the mean ± SEM (* P< 
0.05, ** P< 0.01). 
  
 
Figure 2 LPA1 and EGFR are colocalized in hypoxic HT1080 cells 
Representative image of LPA1-GFP (green) transfected HT1080 cells cultured on non-
fluorescent gelatin for 4h in hypoxia (1% O2). Cells were permeabilized and stained for 
EGFR (red), and nuclei were stained with DAPI (blue). Magnification 60X. 
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